<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-11-24 09:17:26 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. G. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine, Nature Network Boston</td>
          <td>85</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>133</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, Joan Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db216fc3d5be7dbd3db4a74639b3258d970f9b5a" target='_blank'>
              Reinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade
              </a>
            </td>
          <td>
            Paulien Kaptein, Nadine Slingerland, A. M. van der Leun, Eline Runderkamp, Roos A. Wagensveld, S. Michael Chin, Janniek R. Mors, M. Machuca-Ostos, Timm M. Reissig, K. Moynihan, I. Djuretic, Y. A. Yeung, T. Schumacher, D. Thommen
          </td>
          <td>2025-09-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0843f3f7a821365903c898413d075bbe00b55445" target='_blank'>
              CD4 memory T cells orchestrate therapy-responsive immune niches in colorectal cancer liver metastases
              </a>
            </td>
          <td>
            M. Mayoux, Gioana Litscher, Fabius Wiesmann, Marijne Vermeer, Pau Jorba-Adolff, Elena Guido Vinzoni, Nicolas Nunez, Colin Sparano, V. Vetter, Ekaterina Friebel, Tobias Wertheimer, Xenia Ficht, Samira Burr, Ariana Karimi, Stanislav Dergun, Jonas Schmid, Sinduya Krishnarajah, F. Mair, Andreas Moor, Burkard Becher, B. Sobottka, Sònia Tugues
          </td>
          <td>2025-11-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dfcb0c515a1fef2e5bd8d06a28f07486ae95bcfb" target='_blank'>
              Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions
              </a>
            </td>
          <td>
            E. Mccaffrey, A. Delmastro, Bindu Singh, Annu Devi, Nadia A Golden, S. Khader, Michael Angelo, Deepak Kaushal, S. Mehra
          </td>
          <td>2025-10-04</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="Abstract Background Neoadjuvant chemoimmunotherapy (NACI) shows promise for locally advanced cervical cancer (LACC), but drug-tolerant persister (DTP) cells and immunosuppressive microenvironmental adaptations limit clinical efficacy. The underlying determinants governing heterogeneous responses to NACI regimens remain poorly understood, particularly regarding how dynamic tumor-immune interactions shape therapeutic outcomes. Methods We characterized microenvironmental dynamics in patients with LACC by integrating single-cell RNA sequencing (RNA-seq), single-cell VDJ sequencing (n=10, five paired pre-NACI/post-NACI samples) and spatial transcriptomics (ChiCTR2300072535). Pathological response was assessed using major pathological response criteria. The findings were validated in an independent NACI cohort (n=23 with RNA-seq), multiplex immunohistochemistry (mIHC) analysis of six surgically resected specimens, as well as functional in vitro and murine models. Results MPR patients exhibited cytotoxic revival via oligoclonal expansion of tumor-reactive CD8+T cell clones and CCR5-mediated myeloid-T cell crosstalk. Conversely, non-MPR tumors exhibited endoplasmic reticulum (ER) stress-adapted DTP cells with elevated ER stress signaling, accompanied by a deficiency in tumor-specific T-cell clone expansion and an accumulation of transforming growth factor beta receptor 2 (TGFBR2) + myeloid DTP niches. Mechanistically, ER stress signaling via the inositol‑requiring enzyme 1 alpha (IRE1α) / X‑box binding protein 1 (XBP1) axis induces growth differentiation factor 15 (GDF15) production in DTP cells, contributing to treatment‑resistant microdomains. Pharmacological IRE1α inhibition synergized with chemoimmunotherapy to eradicate DTP populations in murine models. Conclusions This study provides critical insights that NACI resistance stems from adaptive ER stress signaling in DTP cells and spatially organized immunosuppressive networks. Targeting the IRE1α/XBP1-GDF15 axis represents an actionable strategy to reprogram microenvironmental ecology and improve immunotherapy outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e84ac5ffc12204bf8550cc95429e880520006cd3" target='_blank'>
              Oligoclonal tumor-specific CD8 T-cell revival and IRE1α/XBP1-GDF15-mediated immunosuppressive niches determine neoadjuvant chemoimmunotherapy efficacy in cervical cancer
              </a>
            </td>
          <td>
            Guang-xu Cao, Yuhan Wang, Huimin Zeng, Yong Zhi, Yi Guo, Mengting Xu, Yetian Ruan, Ying Wang, Yuhang Xiao, Jianqiao Lu, Ka Yu Tse, Jinli Gao, Qingfeng Zhang, Chenfei Wang, Zhiqiang Han, Fang Li
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Background Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable responses in B-cell acute lymphoblastic leukemia (B-ALL). However, the contribution of the tumor microenvironment to the therapeutic response after CAR T-cell treatment remains incompletely understood. Methods We performed single-cell RNA sequencing and spectral flow cytometry-based analyses of bone marrow-resident immune cells from B-ALL patients before and after CAR T-cell treatment. Results We observed profound changes in the microenvironment in response to CAR T-cell-mediated inflammation, including an increase in myeloid cells. Significant induction of the interferon response, hypoxia, and TGF-β signaling was accompanied by expansion of myeloid-derived suppressor cells (MDSCs) and endogenous exhausted CD8+ T cells. PD-1 expression in endogenous T cells post-treatment was associated with a lack of durable response in the cohort of patients analyzed. Further, we revealed that HIF-1α, VEGF, and TGFBR2 are key players in the intercellular communication between CAR T cells and the immune niche, potentially driving widespread T-cell dysfunction. Infusion of anti-CD19 CAR T cells led to increased accumulation of human MDSCs, exacerbation of a hypoxic environment and T-cell exhaustion in hematopoietic stem/progenitor cell-humanized mice bearing a human tumor. Conclusions In conclusion, CAR T-cell-mediated myeloid activation is associated with pathways of immune dysregulation that may antagonize the effects of therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e17ba18b5c3d494ffd54cbb6fc378f9f236571c2" target='_blank'>
              Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance
              </a>
            </td>
          <td>
            Marianna Ponzo, Lorenzo Drufuca, C. Buracchi, Marco M. Sindoni, Silvia Nucera, C. Bugarin, Ramona Bason, G. Rossetti, R. Bonnal, Cristian Meli, B. Rambaldi, F. Lussana, Silvia Ferrari, Alex Moretti, G. Dastoli, Giulia Risca, C. Pellegrino, M. Manz, Stefania Galimberti, A. Rambaldi, G. Gaipa, A. Biondi, Massimiliano Pagani, Chiara F Magnani
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/747fc844bb9d12e0be71b22fc094a876f2fb6866" target='_blank'>
              Disease-specific fibroblast-myeloid interactions in rheumatoid arthritis synovium
              </a>
            </td>
          <td>
            A. Khmelevskaya, Katerina Apostolopoulou, Camino Calvo Cebrian, Ege Ezen, Melpomeni Toitou, Phatthamon Laphanuwat, Masoumeh Mirrahimi, Celina Geiss, Marija Lugar, Asimina Kakale, Silja V. Malkewitz, Andrea Laimbacher, Dimitris Konstantopoulos, V. Rinotas, M. Armaka, M. Houtman, Eva Meier, K. Bürki, Justine Leclerc, H. Mohammadian, Christof Seiler, Eva Camarillo-Retamosa, Chantal Pauli, A. Ramming, Ursula Fearon, Katharina Zachariassen, Thomas Rauer, A. Ciurea, Muriel Elhai, R. Micheroli, Caroline Ospelt
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/150e482713115efc1b44d4529edb3279c0d13350" target='_blank'>
              Childhood brain tumours instruct cranial haematopoiesis and immunotolerance
              </a>
            </td>
          <td>
            Elizabeth Cooper, David A. Posner, C. Lee, Linda Hu, Sigourney Bonner, Jessica T. Taylor, Oscar Baldwin, Rocio Jimenez-Guerrero, Katherine E. Masih, Katherine Wickham Rahrmann, Jason Eigenbrood, Gina Ngo, Luca Porcu, Valar Nila Roamio Franklin, Clive S. D’Santos, Richard Mair, T. Santarius, Claudia Craven, I. Jalloh, Júlia Moreno Vicente, Timotheus Y. F. Halim, Li Wang, Arnold R. Kreigstien, F. Swartling, Javed Khan, M. Clatworthy, Richard J. Gilbertson
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Myelodysplastic syndrome (MDS) is characterized by bone marrow failure, clonal evolution and leukemic progression, but the pathophysiologic processes driving these events remain incompletely understood. Here, by establishing a comprehensive single-cell transcriptional taxonomy of human MDS, we reveal that inflammatory remodeling of bone marrow stromal niches is a common early feature, irrespective of the genetic driver landscape. We identify an activated CD8-T-cell subset as a source of stromal inflammation via TNF-receptor signaling, which prompts the inflammatory rewiring and loss of repopulating ability of residual normal hematopoietic stem/progenitor cells (HSPC). Mutant HSPCs display relative resistance to this inflammatory stress and reside predominantly in a transcriptional ‘high output’ state, providing a biological framework to their competitive advantage in an inflammatory microenvironment. Consistent with this, stromal inflammation associates with leukemic progression and reduced survival. Our data thus support a model of immune-stromal inflammatory signaling driving tissue failure and clonal evolution in the hematopoietic system. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, we provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human MDS. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, authors provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human myelodysplastic syndrome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d21dc014f548d4524dba3eed50e502490dcae8e" target='_blank'>
              An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome
              </a>
            </td>
          <td>
            Lanpeng Chen, Yujie Bian, Eline Pronk, Claire van Dijk, Tim V.D. van Tienhoven, R. Hoogenboezem, E. Bindels, Dennis Bosch, Sadaf Fazeli, A. D. de Graaf, Theresia M. Westers, M. Kholmatov, Judith B. Zaugg, Pedro L. Moura, Eva Hellström-Lindberg, A. A. van de Loosdrecht, J. Jansen, M. Sanders, M. H. Raaijmakers
          </td>
          <td>2025-11-18</td>
          <td>Nature Communications</td>
          <td>1</td>
          <td>48</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, Na-Young Kim, Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitor (ICI) therapies present a pillar of modern cancer therapy but can cause neurological immune-related adverse events (n-irAEs), of which up to 35% are severe or even fatal. However, the detailed immunological mechanisms and risk factors underlying n-irAEs remain largely unknown. Here, we leveraged single-cell genomics to dissect immune cell type, state, and clonal heterogeneity associated with n-irAEs. Methods We performed coupled single-cell RNA sequencing and T cell receptor (TCR) profiling on peripheral blood cells of 17 patients with cancer receiving ICI therapy, including 8 patients with acute neurotoxicity. This approach enabled integrated analyses of immune cell states and T cell clonality linked to ICI-induced n-irAEs. Results We profiled 186 435 immune cells and conducted pseudotime analyses, revealing that patients with n-irAEs, compared with controls, present with clonally expanded CD4+ cytotoxic T lymphocytes (CD4+ CTLs) with an n-irAE-specific effector gene expression profile. These T cells predominantly belong to a select set of expanded clonal families and express genes linked to antigen-induced activation, cell lysis, and neuroinflammation. Moreover, they highly express CXCR3 (FC=2.03 compared with control CD4+ CTLs, with a false discovery rate=7.7×10⁻⁴), encoding the chemokine receptor of CXCL10, previously nominated as a biomarker for severe ICI therapy-induced n-irAEs with concomitant multiple organ system toxicity. Conclusions Overall, our study highlights the expansion and activation of CD4+ CTLs in ICI-induced neurotoxicity, proposing these cells as potential targets for developing new biomarkers and therapeutic strategies to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8a4f4e0b8916eaa4261cd264db53571afd725a2f" target='_blank'>
              Clonally expanded effector CD4+ cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy
              </a>
            </td>
          <td>
            Ambre Giguelay, Patrick Maschmeyer, L. Müller-Jensen, Christian Schinke, Smilla K. Maierhof, Natasha Nambiar, Manpreet Meyer, Petra Huehnchen, Wolfgang Boehmerle, Matthias Endres, Samuel Knauss, L. S. Ludwig
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7fde1e93aca554dff30d3a72e531050b06480632" target='_blank'>
              Bioengineered human tonsil organoids as an immuno-engineering platform for evaluating immune functions
              </a>
            </td>
          <td>
            Intan Rosalina Suhito, Donovan Eu Kum Chuen, Hong Sheng Cheng, Nguan Soon Tan, Zhe Zhang Ryan Lew, Kai Sen Tan, Justin Jang Hann Chu, Giselle G.K. Ng, Yvonne C.F. Su, G. Smith, Chee Wah Tan, Andy Tay
          </td>
          <td>2025-10-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Colorectal cancer (CRC) is a highly immunosuppressive malignancy characterized by limited therapeutic options and a poor prognosis. Within the CRC tumor immune microenvironment (TIME), tumor-associated macrophages (TAMs) represent the predominant immune cell population. This study aimed to characterize the specific macrophage subsets contributing to CRC progression and resistance to immunotherapy. Single-cell RNA sequencing (scRNA-seq) was used to identify the key macrophage marker genes. The clinical significance of death-associated protein kinase 1 (DAPK1), was evaluated in clinical CRC cohorts using immunohistochemistry, immunofluorescence, Kaplan-Meier plots and Cox Proportional Hazards Models. Cytometry by time-of-flight, RNA-seq, flow cytometry and an in vitro co-culture system were performed to explore the functional role of macrophage-derived DAPK1 in the TIME. Subcutaneous tumor models and splenic-liver metastasis models were constructed to assess the potential of DAPK1 inhibition to enhance immune checkpoint blockade (ICB) efficacy. scRNA-seq analysis revealed predominant DAPK1 expression in intratumoral macrophages of CRC TIME. Elevated macrophage-specific DAPK1 level was significantly associated with worse prognosis. DAPK1+TAMs exhibited immunosuppressive properties and inhibit CD8+T cells cytotoxicity. Pharmacological inhibition of DAPK1 enhanced the efficacy of anti-PD-1 therapy in murine models. DAPK1+TAMs infiltration was an independent risk factor for overall survival in patients with CRC. These DAPK1+TAMs exhibit an immunosuppressive phenotype and promote the establishment of the TIME with immune evasion. Targeting DAPK1 may represent a potential strategy for synergizing immunotherapy in CRC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d25841457c8b6bc5218514a8ce08f04c9f270986" target='_blank'>
              DAPK1-positve macrophages facilitate immunosuppressive microenvironment and determine immunotherapy efficacy in colorectal cancer
              </a>
            </td>
          <td>
            Jiang Chang, Yuxu Niu, Shizhao Zhou, Ziqi Zhang, Weiying Zhu, Junchang Zhu, Haoran Xiu, Ke Shang, Q. Feng, Ye Wei
          </td>
          <td>2025-11-04</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood. Methods To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses. Results We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models. Conclusion Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b3ad6676052a006d7f44e56422f87b86b5aaedd5" target='_blank'>
              Oncolytic virus-induced IL-1β+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
              </a>
            </td>
          <td>
            Fan Li, Jingru Chen, Yuanke Li, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang, Jufeng Yu, Zhen Zhao, Li Deng, Shiyu Liu, Yajuan Wan, Zhigang Zhao, Song‐Tao Xu, Jiangmei Li, Youjia Cao, Hongkai Zhang
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Melanoma plasticity drives immune evasion and therapy resistance through dynamic cell-state transitions beyond genetic alterations. Epigenetic remodeling critically influences such processes, yet its role in reshaping the tumor ecosystem under therapeutic pressure remains unresolved. Here, we profiled longitudinal biopsies from melanoma patients treated in the phase Ib NIBIT-M4 epi-immunotherapy clinical trial (NCT02608437), testing the combination of a DNMT1 inhibitor with anti-CTLA4 using single-cell multiome and high-resolution spatial transcriptomics. Integrated analyses resolved seven malignant meta-programs, including a rare Wnt/β-catenin–driven melanocytic state and a de-differentiated neural crest–like state enriched in non-responders. Spatial modeling revealed that homotypic clustering stabilizes resistant programs, with neural crest–like cells forming compact, centrally localized niches, whereas Wnt/β-catenin subpopulations displayed a bimodal architecture, either cohesive clusters sustained by adhesion or dispersed, transcriptionally plastic cells. Responders exhibited progressive enrichment of an antigen presentation/interferon program and coordinated remodeling of the tumor microenvironment with T and B cell expansion, whereas tumors from non-responder patients maintained stable composition of neural crest–like clusters. Epigenetic therapy reactivated transposable elements, providing both regulatory signals that prime innate immunity within microenvironment and generating antigens that drive immunoediting and immunogenicity of Antigen presentation/interferon cell states in responders. Finally, NFATC2 emerged as a master regulator of neural crests–like transcriptional phenotypes and promoter of resistance to therapeutic interventions in melanoma patients. NFATC2 perturbation was able to shift tumor cells towards more differentiated and immunogenic states. These findings reveal how epigenetic-based immunotherapy reshapes melanoma ecosystems, provide mechanistic insights into how multiple transcriptional programs promote tumor plasticity and resistance to both combinatorial therapies and immune checkpoint blockade, identify spatial clustering as a principle stabilizing resistant niches, and highlight β-catenin and NFATC2 as actionable vulnerabilities to overcome resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9320984fb7ca80afa8b2d49d724dd86390a378" target='_blank'>
              Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy
              </a>
            </td>
          <td>
            Erika Ciervo, Francesco Ceccarelli, A. D. Di Giacomo, Piera Grisolia, A. Covre, Z. M. Besharat, Antonio De Falco, F. Caruso, Luigi Laezza, Luigi Ferraro, Gloria Mas Martin, M. F. Lofiego, Tommaso Sani, E. Ferretti, Yan Guo, Sean B. Holden, R. Mortarini, A. Anichini, M. Maio, T. Noviello, M. Ceccarelli
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a872ad111f545dec2c3ad6375d1f4e56d1e106cf" target='_blank'>
              Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune Surveillance
              </a>
            </td>
          <td>
            Thomas Fabre, Eleanore Hendrickson, Katherine McGourty, Paola M. Marcovecchio, James McMahon, Sara Patti, KaiLi Cage, Stephen Searles, Christella Widjaja, Christopher Stairiker, Kathryn Bound, Roxanne Martino, Edward Pyszczynski, Ying Zhang, Graham Thomas, Samuel A. Stoner, Keith A. Ching, Fang Jin, Christopher P. Dillon, Thomas A. Wynn, Richard L. Gieseck, Alexander M. S. Barron
          </td>
          <td>2025-09-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background LKB1 (STK11)-deficient tumors exhibit an immunosuppressive microenvironment that limits the efficacy of immunotherapies such as anti-programmed cell death protein 1 (PD-1) antibodies. However, the underlying mechanisms driving immune evasion remain unclear. Dendritic cells (DCs), especially conventional DC 1 (cDC1), play a crucial role in antigen presentation and CD8+ T-cell activation, yet their dysfunction in LKB1-deficient tumors has not been well characterized. Methods Tumor-intrinsic LKB1 deficiency was modeled by subcutaneous inoculation of CRISPR/Cas9-engineered Stk11-knockout tumor cell lines into syngeneic mice. DC infiltration and function were assessed through a series of flow cytometry-based in vivo and in vitro assays, including analyses of infiltration, migration, antigen uptake, maturation, and CD8+ T-cell priming. Naïve CD8+ T-cell activation by cDC1s was evaluated via adoptive transfer of CD45.1+ OT-I T cells. Secretome proteomics and functional rescue experiments identified anterior gradient 2 (AGR2) as a key immunosuppressive mediator, and arginase 1 (ARG1) was validated as its functional interactor through liquid chromatography-tandem mass spectrometry (LC-MS/MS), co-immunoprecipitation, and imaging flow cytometry. Upstream regulation of AGR2 was investigated by AMPKα/FOXA1 silencing and chromatin immunoprecipitation (ChIP) quantitative PCR, revealing a tumor-intrinsic AMPKα–FOXA1–AGR2 axis driving DC dysfunction. Results LKB1-deficient tumors exhibited significantly reduced cDC1 infiltration, and cDC1s were functionally impaired in antigen uptake, migration, and naïve CD8+ T-cell priming. AGR2, a secreted protein transcriptionally upregulated via the tumor-intrinsic AMPKα–FOXA1 pathway, was identified as a key mediator of DC dysfunction. Mechanistically, AGR2 interacted with ARG1, stabilizing its expression and promoting ARG1 accumulation in DCs. Restoring DC infiltration and activity through FLT3L-driven expansion and tumor-antigen–specific DC supplementation significantly enhanced the efficacy of anti-PD-1 treatment in LKB1-deficient lung adenocarcinoma models. Conclusion Our study identifies profound DC dysfunction—characterized by impaired antigen uptake, migration, and naïve CD8+ T-cell priming—as a key mechanism of immune evasion in LKB1-deficient tumors. This dysfunction is driven by tumor-secreted AGR2, which stabilizes ARG1 in DCs and suppresses CD8+ T-cell activation. Targeting the AMPKα–FOXA1–AGR2–ARG1 axis or restoring DC competence offers a promising strategy to enhance immunotherapy efficacy in LKB1-deficient subtype.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e07849093d53dea4843df9f47992371aef80f74" target='_blank'>
              Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer
              </a>
            </td>
          <td>
            Yuxin Yao, Yuejun Luo, Zhanyu Wang, Enzhi Yin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoya Tang, Nan Sun, Jie He
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4-CD8-TCRαβ T cells that interact with CXCL16 expressing non-classical monocytes. Leukemia cell intrinsic transcriptional rewiring in these patients is associated with activation of Rap1 signaling. Inhibiting Rap1 signaling results in increased sensitivity to the BCL2/BCL-XL inhibitor navitoclax. Our study provides insights into the immune microenvironment of pediatric hematologic malignancies, forming the basis for identifying potential (immuno) therapeutic targets and risk stratification for treatment. Understanding of the immune microenvironment in pediatric acute T cell lymphoblastic leukemia is limited. By analyzing single-cell transcriptome, surface protein expression and immune repertoire data, the authors here identify non-malignant CD4-CD8- TCRαβ T cells that are present in a subset of patients with Rap1 signaling in leukemia cells and are associated with adverse clinical outcome in patients with low minimal residual disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb527a6740e54a5aab04ff54dc24e5f1755e30d3" target='_blank'>
              Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia
              </a>
            </td>
          <td>
            Caroline R. M. Wiggers, Eugene Y Cho, Merve Ozdemir, Gbolahan Bamgbose, Justin Hegel, Julia Frede, Frederike Warlitz, Tayla B. Heavican-Foral, Ioana Pop, R. Shraim, P. Pölönen, Victoria B. Koch, Thai Hoa Tran, C. Mullighan, D. Teachey, Jacob R. Bledsoe, Yana Pikman, Marian H. Harris, Andrew E. Place, Lewis B. Silverman, Jens G. Lohr, Birgit Knoechel
          </td>
          <td>2025-11-21</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>107</td>
        </tr>

        <tr id="Uropathogenic Escherichia coli (UPEC) typically trigger rapid and robust innate immune responses in the bladder. In order to identify the key facets of the host response that influence pathogen clearance and tissue damage, single-cell RNA sequencing was used to investigate the transcriptomic changes of immune cells in mouse bladder after UPEC infection. Single-cell analysis revealed significant elevated CD137L expression in macrophages and dendritic cells in bladder after UPEC infection. CD137L defines a macrophage population in bladder that is important for the host response to UPEC infection. Deletion of CD137L in macrophages resulted in severe bacterial burden and bladder inflammation during the acute stage of UPEC infection. Further study demonstrated that the crucial role of CD137L+ macrophages in protecting against UPEC infection might be mediated by Tregs, which express high levels of CD137 (the receptor for CD137L). Deletion of CD137L+ macrophages decreased Treg cells and led to a reduction in inhibitory factors such as CTLA-4 and PD-1 on Tregs. Deletion of Tregs using Foxp3DTR mice also aggravated inflammatory reactions, bacterial load, and urothelial destruction during the acute phase of UPEC infection. Similarly, the deletion of CD137 in Tregs resulted in a decrease in these inhibitory factors on Tregs, causing more severe bladder inflammation during UPEC infection. These results illuminate the immune landscape of the bladder infected by UPEC and highlight the crucial role of CD137L+ macrophages during UPEC infection in bladder. CD137L+ macrophages might prevent excessive inflammatory response during the host response to UPEC infection by regulating Tregs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7954121d279c90d1325ddfc45384733f19ba8846" target='_blank'>
              Single-cell analysis reveals an important role of CD137L+ macrophages in the host response to uropathogenic Escherichia coli infection in the bladder
              </a>
            </td>
          <td>
            Yaxiao Liu, Zizhuo Yang, Yinrui Xiang, Guangzhou Cheng, Lipeng Chen, Shuai Wang, Maolin Zang, Nan Zhou, Xiaoyi Zhang, Rui Chen, Benkang Shi, Yan Li
          </td>
          <td>2025-10-01</td>
          <td>PLOS Pathogens</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="T follicular regulatory cells (Tfr) play a pivotal role in maintaining immune self-tolerance and prevention of autoantibody induction. However, the stages of Tfr formation have still not been clarified. Here, we found that 30 to 50% of circulating Tfr in human blood have a naïve-like phenotype (preTfr, CD45RA+CD45RO−Foxp3+CXCR5+). PreTfr are expandable in vitro while retaining suppressive capacity. They are transcriptionally similar to naïve Tregs (nTregs) ex vivo, but after stimulation, they gain increased expression of Tfr-related suppressive molecules such as IL-1RA, suggesting that they are primed for full differentiation into mature Tfr. Further, we demonstrate that preTfr but not nTreg are significantly reduced in the blood of patients with COVID-19 and patients with sepsis and that this loss is correlated with increased anti–interferon-γ antibodies and activated atypical B cells. Together, these data suggest that Tfr are disrupted at the earliest stage of their formation during severe disease and may be an important therapeutic target in future vaccine developments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56c2e2e7fe87e9ba317c343bbbacab121050c33c" target='_blank'>
              Human precursor T follicular regulatory cells are primed for differentiation into mature Tfr and disrupted during severe infections
              </a>
            </td>
          <td>
            J. Tulyeu, J. Søndergaard, David G Priest, Takeshi Ebihara, Hisatake Matsumoto, Mara A. Llamas-Covarrubias, Masaki Imai, Shinichi Esaki, Shinichi Iwasaki, A. Morita, S. Yamazaki, Shimon Sakaguchi, James B. Wing
          </td>
          <td>2025-09-26</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="Tissue-resident memory T (TRM) cells are increasingly recognized as crucial components of tumor immunosurveillance and potential targets in cancer immunotherapy. However, studying TRM cells within the tumor microenvironment (TME) has been challenging due to limitations in existing tumor models. Traditional cell lines injected subcutaneously fail to replicate the biological cues of dermal and epidermal tumors, and many genetically engineered mouse models (GEMMs) lack a specific tumor antigen for tracking immune responses. Here, we use an autochthonous Braf/PTEN model of melanoma, modified to express OVA as a tumor-specific model antigen, to show that CD103+ TRM-like cells orchestrate the initial antitumor immune response and this response is antagonized by infiltration of regulatory T (Treg) cells. Longitudinal spatial profiling (cyclic immunofluorescence) and flow cytometry analysis of Braf/PTEN/OVA mice show that TRM-like cells rapidly fill a stable niche in the tumor. These TRM-like cells are phenotypically and transcriptionally distinct from other T cells, expressing low levels of PD-1 and Tim-3, but uniquely expressed CD101 and GzmB. Depletion of Treg cells led to augmentation of the OVA-specific antitumor immune response involving activation of TRM-like CD8+ TILs, substantial CD8+ and CD4+ T cell infiltration, and a decrease in tumor growth. Depletion of CD8+ T cells prior to Treg depletion blunted T cell recruitment to the tumor. These data show that immune escape is mediated by the ability of Tregs to suppress early antitumor responses and T cell recruitment by TRM-like cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b829e516ebd849b779eb9a27bfa0536b868f851" target='_blank'>
              Regulatory T cells inhibit CD8 + T RM -like cells during the early stages of tumor immune escape
              </a>
            </td>
          <td>
            Jason B. Williams, Shishir M. Pant, Alexander L. Kley, B. Rajmalani, Clarence Yapp, Jiang Zhang, Kyle Deans, E. Rotrosen, Angelika Sales, Peter K. Soger, Thomas S. Kupper
          </td>
          <td>2025-10-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5268b5f8f5e67d2ca0369f9fa75cc7835efa85a7" target='_blank'>
              Anti-CD206 CAR T Cell Treatment Restores Fibrosis-Induced Loss of Dermal White Adipose Tissue
              </a>
            </td>
          <td>
            Chanhyuk Park, Asmaa O. Mohamed, Helen C. Jarnagin, Rajan Bhandari, Jason Gunn, Joana M. Murad-Mabaera, Noelle N Kosarek, Fred W. Kolling, Owen M. Wilkins, Yina H. Huang, Michael Whitfield, Patricia A. Pioli
          </td>
          <td>2025-10-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b846de35114daacf2b8cb62d0ddc0dc54e1e9471" target='_blank'>
              Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy
              </a>
            </td>
          <td>
            Lior Goldberg, Eric R Haas, Jiaqi Wu, Bryan Garcia, Ryan Urak, Vibhuti Vyas, Ruby Espinosa, Tamara Munoz, Shirley Bierkatz, K. Pathak, Nathaniel P. Hansen, P. Pirrotte, Jyotsana Singhal, J. Figarola, Ricardo Zerda Noriega, Zhuo Li, Dasol Wi, Erin Tanaka, Ramon I. Klein Geltink, Min-Hsuan Chen, Xiwei Wu, J. Wagner, Jinny A Paul, Mary C. Clark, Dat Ngo, Ibrahim Aldoss, Stephen J. Forman, Xiuli Wang
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98a4e027d57002b46ccf88e1aa10930bce31da48" target='_blank'>
              Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma
              </a>
            </td>
          <td>
            Isabelle Bergiers, M. C. Köse, Sheri Skerget, Milan Malfait, N. Fourneau, Jenna-Claire Ellis, Greet Vanhoof, Tina Smets, Bie Verbist, Dries De Maeyer, Jeroen Van Houdt, Koen Van der Borght, Raluca Verona, Bradley Heidrich, William Kurth, Michel Delforge, Nathalie Meuleman, Jan Van Droogenbroeck, P. Vlummens, Christoph J Heuck, Yves Beguin, Nizar J. Bahlis, T. Casneuf, J. Caers
          </td>
          <td>2025-10-01</td>
          <td>PLOS Genetics</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Tumor-infiltrating lymphocytes (TILs) are a promising autologous cell therapy to treat solid tumors. TILs are manufactured by expanding and reinfusing tumor-reactive T cells from tumor biopsies. Efficacy of TIL therapies has been limited by the heterogeneity of expanded TIL products and the high prevalence of dysfunctional exhausted CD8+ T cells (TEX). While a subset of CD8+ TILs co-expressing CD103 and CD39 are enriched for tumor-reactive TILs across multiple cancer types, these cells are often in the TEX state with low proliferative potential. To identify regulators of human TIL proliferation, we screened an open reading frame library encoding for all human transcription factors (TFs). RELB emerged as the dominant driver of human TIL expansion with a skew towards CD8+ cells. TCR diversity was maintained after multiple days of in vitro expansion driven by RELB. Transcriptome profiling of multiple RELB-expressing TIL subtypes revealed a shift towards a memory/costimulatory-like phenotype. Using a HER2-targeting CAR and tumor co-culture model, RELB conferred improved persistence after multiple tumor challenges in vitro and improved solid tumor control in mouse xenografts in vivo. Finally, co-culture of RELB-overexpressing TILs with patient-matched tumor organoids showed an increase in TIL product polyfunctionality, tumor reactivity, and tumor killing. Collectively these results support promoting RELB expression as a strategy for broadly enabling TIL therapy for treating solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0439a6de8243c20d60a46c125842a0d34a0ceda" target='_blank'>
              RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy
              </a>
            </td>
          <td>
            Christian D. McRoberts Amador, Rachel E. Conover, Michael C. Brown, Liliana S. Lyniv, P. Noldner, Ying Zhou, Aretha R. Gao, Sean R. McCutcheon, S. Antonia, Charles A. Gersbach
          </td>
          <td>2025-10-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs), targeting checkpoint receptors such as programmed cell death protein 1 (PD-1), are associated with increased risk of cardiovascular events, but the underlying mechanisms remain poorly understood. Here we show that PD-1+ T cells from murine atherosclerotic aortas mainly display a progenitor exhausted phenotype (PD-1intSlamf6+Tim3−), produce IFNγ in vivo, exhibit signs of recent proliferation and maintain polyfunctionality. PD-1 blockade induced marked changes in plaque immune phenotype, with increased PD-1high T cell accumulation, IFNγ production, formation of lymphocyte foci and neutrophil recruitment. Depletion of PD-1high T cells prior to PD-1 blockade did not impede T cell recruitment, suggesting a role for progenitor exhausted PD-1int T cells in ICI-driven T cell plaque accumulation. Human circulating PD-1+ T cells produced IFNγ and were associated with subclinical coronary atherosclerosis. Our studies highlight IFNγ-producing PD-1+ T cells as a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving ICI. Mulholland et al. identify progenitor exhausted T cells, expressing intermediate levels of PD-1 (PD-1int), as a prominent source of pro-inflammatory cytokines in the murine atherosclerotic aorta and potential cellular targets driving checkpoint inhibition-elicited pro-atherosclerotic immune responses. They further demonstrate elevated levels of circulating PD-1-expressing T cells in individuals with subclinical cardiovascular disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5a29caf4329bc4f3e79ec49abf0bdad10c56e11d" target='_blank'>
              Progenitor exhausted PD-1+ T cells are cellular targets of immune checkpoint inhibition in atherosclerosis
              </a>
            </td>
          <td>
            Megan Mulholland, Anthi Chalou, Samuel H A Andersson, M. Depuydt, Yinda Yu, Shiying Lin, Klara Tallbäck, Astrid Ericsson, G. Jakobsson, J. de Mol, Dmytro Kryvokhyzha, A. Lichtman, A. Foks, A. Schiopu, Harry Björkbacka, B. Slütter, Anton Gisterå, D. Engelbertsen
          </td>
          <td>2025-10-01</td>
          <td>Nature Cardiovascular Research</td>
          <td>0</td>
          <td>65</td>
        </tr>

        <tr id="Massive immune cell infiltration and persistent inflammation in the central nervous system (CNS) are key hallmarks of multiple sclerosis. Here, we report a myeloid-derived suppressor cell (MDSC)–based therapeutic strategy, named CNS Immune Targeting Enabled by MDSCs (CITED), which uses surface-decorated MDSCs carrying rapamycin nanoparticles (NPs) for targeted multimodal immune reprogramming in CNS. We show that NP decoration enhances MDSC immunomodulatory function, facilitates their trafficking to inflamed CNS regions, and increases NP accumulation within CNS. In an experimental autoimmune encephalomyelitis model, CITED exhibited robust therapeutic efficacy, resulting in reduced disease progression, improved motor function, and diminished myelin damage. Mechanistic studies reveal that CITED exerts its therapeutic effects by targeted reprogramming of both innate and adaptive immune responses in CNS. Specifically, CITED inhibits immune cell infiltration, rebalances CD4 T cell phenotypes, and promotes the polarization of myeloid cells toward anti-inflammatory phenotypes. Collectively, CITED could provide a broadly effective approach for targeted immune restoration in multiple sclerosis and potentially other autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8f24c23e0ed496fd13e4cd70e0bb4daac42d668" target='_blank'>
              Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis
              </a>
            </td>
          <td>
            Endong Zhang, H. Algarni, Luyu Zhang, Chih-Jia Chao, Shan He, Aditi Upadhye, Qing Bao, Dahee Jung, Shubhi Srivastava, Edidiong Michael Udofa, Philana Phan, Dejan S. Nikolic, Steve Seung-Young Lee, Jalees Rehman, Zongmin Zhao
          </td>
          <td>2025-10-15</td>
          <td>Science Advances</td>
          <td>1</td>
          <td>5</td>
        </tr>

        <tr id="Background Immune checkpoint therapies targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been met with limited clinical responses in the treatment of patients of varying cancer types. Current US Food and Drug Administration (FDA)-approved therapies function to prevent PD-1 binding to PD-L1, thereby preventing T-cell suppression. However, these therapies fail to prevent PD-L1 intrinsic signaling and recycling, which can render these treatments ineffective. Moreover, most research primarily focuses on how these antibodies affect tumor cells and their interactions with T cells. Myeloid cells, which also express PD-L1 and influence T-cell responses, are integral to the efficacy of these therapies. However, strategies that can target these cells to boost antitumor responses have not been effective. Methods Our group has developed a new anti-PD-L1 antibody (H1A), which disrupts PD-L1 recycling and redirects it towards degradation. Due to the loss of available PD-L1 protein, H1A effectively prevents PD-L1 intrinsic signaling. Using in vivo humanized PD-1/PD-L1 mouse tumor models, we evaluated the therapeutic efficacy of H1A against current FDA-approved PD-L1 blocking antibodies. Using human-derived immune cell in vitro assays, we pinpoint the biological consequences of H1A-induced PD-L1 degradation in myeloid cells. Results H1A demonstrated improved tumor control and established immunological memory responses in vivo in the treatment of tumors with moderate immunogenicity that are less responsive to current immunotherapies. This was supported by enhanced activation of myeloid cells (major histocompatibility complex (MHC)-II and CD80) and frequencies of effector T-cell populations found intratumorally. Human myeloid cells treated with H1A were also observed to have increased activation (MHC-II and CD80) and cytokine secretion. Similar to our in vivo findings, human peripheral blood lymphocyte cultures demonstrated increased frequencies of effector T-cell populations and greater tumor cell killing. Conclusions This work highlights the importance of targeting PD-L1 recycling and intrinsic signaling, specifically in myeloid cells, to boost antitumor responses. Our studies suggest that H1A can provide a solution to the lack of responses seen with current therapeutics, while also revealing previously unknown intrinsic functions of PD-L1 in myeloid cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/df562168cc189f5673c420360b67b646df275229" target='_blank'>
              Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion
              </a>
            </td>
          <td>
            Michelle A Hsu, Xin Liu, Whitney Barham, Kevin D. Pavelko, S. Harrington, Crystal Lin, Jacob B Hirdler, Zhiming Mao, Wenjing Zhang, Emilia R Dellacecca, Dallin S Ashton, Nicholas D. Sun, Jessica N Lancaster, Fabrice Lucien, Haidong Dong
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with limited curative options for advanced disease. Natural Killer (NK) cells are critical innate immune effectors, but their anti-tumor function is severely compromised by the immunosuppressive tumor immune microenvironment (TIME), particularly through transforming growth factor-beta (TGF-β). This study investigates the pivotal role of TGF-β signaling in modulating NK cell phenotypes and functions within the HCC TIME. Methods to comprehensively assess TGF-β pathway activation and its impact on NK cells, tumor-infiltrating lymphocytes (TILs) and liver-infiltrating lymphocytes (LILs) were isolated from HCC patients undergoing curative resection. Phenotypic and functional analyses were performed, along with functional restoration experiments targeting TGF-β signaling. Results Tumor-infiltrating NK cells (TINKs) exhibited significant activation of both canonical (SMAD-dependent) and non-canonical (TAK1/p38 MAPK) TGF-β signaling, with a predominance of the non-canonical pathway. This activation was associated with the emergence of an ILC1-like NK subset (CD103+/CD49a+), which was nearly absent in non-tumor liver tissue. These ILC1-like cells maintained strong cytokine production and expressed high levels of inhibitory receptors (PD-1, TIM-3, TIGIT), whereas conventional NK cells (cNKs; CD103−/CD49a−/CD9−) were functionally impaired. Notably, blocking TGF-β receptor binding and SMAD3 activation restored cNK functionality. Discussion our findings suggest that while non-canonical TGF-β signaling drives phenotypic reprogramming and contributes to NK cell dysfunction, canonical SMAD-dependent signaling remains a key therapeutic target for functional restoration. These results highlight the dual role of TGF-β in immune modulation and suggest that targeted pathway inhibition could enhance innate anti-tumor responses, opening new avenues for combination therapies in HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d50b55fb9cfe5da9b9edf682ff5af672c4fe236" target='_blank'>
              TGF-β-driven NK Cells plasticity in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Valentina Reverberi, Anna Montali, Andrea Vecchi, M. Rossi, A. Pelagatti, S. Doselli, B. Farina, Andrea Olivani, G. Economopoulos, Raffaele Dalla Valle, D. Laccabue, F. Ferraglia, A. Penna, P. Fisicaro, C. Boni, G. Missale
          </td>
          <td>2025-11-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="Epigenetic scarring of terminally dysfunctional (TDysf) CD8+ T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8+ T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8+ T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program. In contrast, prolonged stimulation for 2–3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGF-β1 signals, enabling survival of chronically stimulated CD8+ T cells for over 3 weeks. These conditions induced a state of terminal dysfunction, marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses verified the development of terminal exhaustion-specific signatures in TDysf cells. Adoptive transfer of TDysf cells revealed their inability to recall effector functions or proliferate after acute lymphocytic choriomeningitis virus rechallenge. This tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of therapeutic targets for cancer or chronic infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc4dbe9ec01dc079f493706a4c9a1123f839c591" target='_blank'>
              Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro
              </a>
            </td>
          <td>
            Amira Yousif, Abbey A. Saadey, Ava Lowin, Asmaa M. Yousif, Ankita Saini, Madeline R. Allison, Kelley Ptak, Eugene M Oltz, Hazem E. Ghoneim
          </td>
          <td>2025-10-08</td>
          <td>JCI Insight</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/739a87fd565af12d2e067e28eb04d43a769bbc0a" target='_blank'>
              Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis
              </a>
            </td>
          <td>
            Tomson Kosasih, Tatsuya Morishima, Sohyeon Lee, Jungyeon Yoon, Kanako Wakahashi, Pilhan Kim, Aiko Sada, Hitoshi Takizawa
          </td>
          <td>2025-10-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c63743e84578638f8c9499455b868d94cba45959" target='_blank'>
              Splenic granulopoiesis and S100A9 drive resistance to checkpoint inhibitors conferred by liver metastases
              </a>
            </td>
          <td>
            R. Lee, S. Hooper, L. Pallett, Mariana Diniz, Tate McKinnon Snell, Zoe Ramsden, Nicolas Rabas, Stefan Boeing, Oliver Kennedy, Charlotte Buttercase, Gloryanne Aidoo-Micah, Gareth Price, Sarah C. Macfarlane, Sasha Bailey, Jessica Davies, Anandita Mathur, Ginevra Pistocchi, Alexandrine Carminati, Avinash Gupta, Patricio Serra, Brian Davidson, Joerg-Matthias Pollok, V. Papayannopoulos, I. Malanchi, Paul Lorigan, M. Maini, E. Sahai
          </td>
          <td>2025-10-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>67</td>
        </tr>

        <tr id="Background Bispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting tumor-specific antigens such as interleukin 13 receptor alpha 2 (IL13RA2) and epidermal growth factor receptor variant III (EGFRvIII) have been developed for glioblastoma (GBM). However, there is limited mechanistic understanding of the action of BTE since prior studies were mostly conducted in immunocompromised animal models. To close this gap, the function of BTEs was assessed in the immunosuppressive tumor microenvironment (TME) of orthotopic and genetically engineered mouse models (GEMM) with intact immune systems. Methods A BTE that bridges CD3 epsilon on murine T cells to IL13RA2-positive GBM cells was developed, and the therapeutic mechanism was investigated in immunocompetent mouse models of GBM. Multicolor flow cytometry, single-cell RNA sequencing (scRNA-seq), multiplex immunofluorescence, and multiparametric MRI across multiple preclinical models of GBM were used to evaluate the mechanism of action and response. Results BTE-mediated interactions between murine T cells and GBM cells triggered T cell activation and antigen-dependent killing of GBM cells. BTE treatment significantly extended the survival of mice bearing IL13RA2-expressing orthotopic glioma and de novo forming GBM in the GEMM. Quantified parametric MRI validated the survival data, showing a reduction in glioma volume and decreased glioma viability. Flow cytometric and scRNA-seq analyses of the TME revealed robust increases in activated and memory T cells and decreases in immunosuppressive myeloid cells within the brains of mice following BTE treatment. Conclusions Our data demonstrate that the survival benefits of BTEs in preclinical models of glioma are due to the ability to engage the host immune system in direct killing, induction of immunological memory, and modulation of the TME. These findings provide a deeper insight into the mechanism of BTE actions in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3d8175d96b7c6cd7d7b5ae734fb75666b210772" target='_blank'>
              Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
              </a>
            </td>
          <td>
            M. Zannikou, J. Duffy, Daniel Procissi, H. Najem, R. Levine, A. Thakur, D. Hambardzumyan, Catalina Lee-Chang, Lara Leoni, C. Horbinski, D. Simberg, Bin Zhang, A. Heimberger, J. Miska, Irina V. Balyasnikova
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b26845defb7abdc1bf1c1d65b82acb78bc096a5c" target='_blank'>
              Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer
              </a>
            </td>
          <td>
            Chaitanya N. Parikh, Kelly D. DeMarco, Griffin I. Kane, Nikita Bhalerao, Ronnie W. Dinnell, Boyang Ma, Hadiya K. Giwa, Zhen Zhao, Lin Zhou, Katherine C. Murphy, Loretah Chibaya, Haruka Mori, Youwei Qiao, Brian Lewis, Wen Xue, Jason R. Pitarresi, Prabhani U. Atukorale, M. Ruscetti
          </td>
          <td>2025-10-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Background Osteosarcoma (OS) lung metastases remain a significant therapeutic challenge. Innate immune activation is a promising therapeutic approach. Innate immune agonists can modulate the tumor immune microenvironment and improve therapeutic response. Methods Using an experimental syngeneic OS lung metastasis BALB/c mouse model with K7M3-luc OS cells, we evaluated the antitumor effects of yeast-derived particulate β-glucan in prevention and therapeutic settings. We then assessed whether the CD40 agonist (CD40a) in combination with β-glucan increased therapeutic response in two different immune-competent mouse models of OS lung tumor burden. Results In the pretreatment settings, mice treated with β-glucan prior to OS cell infusion developed significantly fewer lung tumor burdens and had increased survival. Pretreatment with β-glucan prevented tumor cell seeding in the lungs. In tumor-bearing mice, β-glucan treatment significantly suppressed tumor growth and prolonged overall survival. β-glucan treatment increased activated pro-inflammatory M1-like macrophages and natural killer (NK) cells secreting interferon-γ and granzyme B in the lungs. Depletion studies showed that the antitumor effect of β-glucan was dependent on macrophages and NK cells. Additionally, β-glucan treatment also induced myelopoiesis in the bone marrow. The therapeutic benefit of β-glucan was further augmented when combined with CD40a. Combination therapy significantly increased the infiltration of activated macrophages, including tumor necrosis factor-α secreting macrophages, and NK cells into the lungs compared with monotherapy. Bulk RNA sequencing of lung tissue revealed that the combination treatment group exhibited enhanced activation of antitumor innate immune pathways. Conclusions Collectively, our findings demonstrate the antitumor activity of β-glucan against OS lung tumor burden, that combining β-glucan and CD40a increases therapeutic activity, and that this activity is mediated by activation of innate immunity (macrophages and NK cells).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/503c5b9f99e8551d1b2df720ef9a54f9dbadc0d5" target='_blank'>
              Inhibition of osteosarcoma lung metastases by β-glucan and CD40 agonist is mediated by activation of macrophages and NK cells
              </a>
            </td>
          <td>
            Pradeep Shrestha, Rejeena Shrestha, E. Kleinerman
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="B lymphocytes exhibit a multifaceted and context-dependent role in tumor biology, acting as both promoters and suppressors of malignancy through dynamic interactions within the tumor microenvironment (TME). This review synthesizes current evidence on the dual functions of B cells in tumor immunity, highlighting their capacity to orchestrate antitumor responses via antigen presentation, antibody-dependent cytotoxicity, and tertiary lymphoid structure (TLS)-mediated T cell activation, while paradoxically driving immunosuppression through regulatory B cells (Bregs), pro-angiogenic signaling, and immune checkpoint modulation. Key mechanisms include TLS formation, which enhances cytotoxic T cell priming and correlates with improved immunotherapy outcomes, and Breg-mediated secretion of IL-10/TGF-β, which fosters T cell exhaustion and myeloid-derived suppressor cell recruitment. Tumor-type specificity is evident: TLS-rich malignancies like melanoma and Non-Small Cell Lung Cancer (NSCLC) show B cell-driven immune activation, whereas pancreatic and hepatocellular carcinomas demonstrate B cell functional plasticity influenced by metabolic and epigenetic reprogramming. Therapeutically, B cell-targeted strategies—including CD20 antibodies, CAR-T cells, and B cell epitope vaccines—demonstrate efficacy in hematologic and solid tumors, yet face challenges due to subset heterogeneity and sex-specific response disparities. Emerging approaches combine immune checkpoint inhibitors (ICBs) with TLS-inducing agents or exploit B cell-derived biomarkers for personalized therapy. Future directions emphasize deciphering B cell metabolic-niche crosstalk, optimizing combinatorial regimens, and leveraging spatial multiomics to resolve functional heterogeneity. By bridging mechanistic insights with clinical translation, this work underscores B cells as pivotal regulators of tumor immunity and advocates for precision strategies to harness their antitumor potential while mitigating pro-tumor plasticity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ebd579b54f9dae49f949806c09388f29afa2ecc8" target='_blank'>
              The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications
              </a>
            </td>
          <td>
            Zhuangwei Lv, Ruohao Yang, Kai Zhang, Ruihan Wang, Xiaoyu Shi, Jinhua Wu, Lulu Liu, J. Jiao
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Immune checkpoint inhibitors have traditionally been understood to exert their effects primarily within the tumor microenvironment, particularly targeting CD8 + T cells. However, recent studies have highlighted a pivotal role of tumor-draining lymph nodes in mediating responses to immune checkpoint inhibitor therapy. This study aimed to elucidate the specific mechanisms by which tumor-draining lymph nodes respond to immune checkpoint inhibitor therapy and regulate the tumor microenvironment in human colorectal cancer. We performed single-cell RNA sequencing and T cell receptor sequencing on tumor-draining lymph nodes and tumor tissues from patients with colorectal cancer. Through in-depth analysis of the single-cell data, we established the connection between TDLNs and tumor, and explored the impact of immune checkpoint inhibitor therapy on the immune microenvironment of tumor-draining lymph nodes. In addition, we conducted animal experiments to validate these findings. Our findings revealed that immune checkpoint inhibitor treatment induced the expansion of tumor-specific CD8 + effector memory T cells within tumor-draining lymph nodes, which may serve as a source for the progenitor-exhausted CD8 + T cells in the tumor microenvironment. Moreover, conventional dendritic cells type 1 and macrophages within tumor-draining lymph nodes facilitated this process. We also observed that immune checkpoint inhibitor therapy promoted the expansion of tumor-specific CD4 + follicular helper T cells in tumor-draining lymph nodes, which may explain the increase of CD4 + follicular helper T cells in the tumor microenvironment after immune checkpoint inhibitor therapy. These hypotheses were corroborated through experiments in mice. Our findings delineate the critical regulatory function of tumor-draining lymph nodes in modulating the tumor microenvironment during Immune checkpoint inhibitor therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b9de1a203560b665a61560f8094ade12f18f1b7" target='_blank'>
              Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling
              </a>
            </td>
          <td>
            Jinzhu Zhang, Jian Ma, Yaru Niu, Jialiang Liu, Zhexue Wang, Jinyu Guo, Yongsheng Meng, Ruifang Sun, Zhen Zhang, Haiyi Liu, Juan Xu, L. Zan, Xu Guan, Xishan Wang
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related mortality worldwide, with its progression shaped not only by tumor-intrinsic factors but also by a complex and immunosuppressive tumor microenvironment (TME). Within this niche, diverse immune populations—including CD8+ cytotoxic T cells, CD4+ helper T cell subsets (Th1, Th17, Tregs), B cells, natural killer (NK) cells, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs)—collectively regulate immune surveillance and tumor escape. While effector lymphocytes mediate antitumor responses, their function is often attenuated by TAM- and MDSC-driven immunosuppression via cytokines (IL-10, TGF-β), metabolic disruption, and immune checkpoint expression. High densities of M2-polarized TAMs and MDSCs correlate with poor prognosis and resistance to therapy. Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have improved outcomes in lung cancer, yet therapeutic efficacy remains limited by the immunosuppressive TME. This review outlines the functional roles of key immune cell subsets in lung cancer and highlights emerging strategies to reprogram the TME and enhance immunotherapeutic responsiveness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec07b573d2c713f5c6d11528b863b0a4240be315" target='_blank'>
              Reprogramming the immune microenvironment in lung cancer
              </a>
            </td>
          <td>
            Kai Chen, Linqi Luo, Yong Li, Ge Yang
          </td>
          <td>2025-09-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="CNS infection by HIV-1 contributes to neuroinflammation, cognitive impairments, and the establishment of viral reservoirs. Although HIV-1 is known to enter the brain early in infection via “Trojan horse” leukocytes, including infected monocytes and CD4⁺ T cells, the specific cellular phenotypes facilitating this process during acute infection remain incompletely characterized. This study aims to characterize the roles of brain lymphocytes during acute infection and primary CD4 + T cell phenotypes seeding the SIV to the CNS. scRNA-seq was performed on brain and blood cells of three acutely SIV-infected rhesus macaques. The transcriptomic data were analyzed using bioinformatics approaches and validated through in vitro co-culture assays and re-analysis of a publicly available scRNA-seq dataset. scRNA-seq of brain and blood immune cells from acutely SIV-infected rhesus macaques revealed an expansion of proliferating CD4⁺ cytotoxic T lymphocytes (CTLs) in the blood, characterized by high CD4, CCR5, and adhesion molecule expression, indicating strong potential for CNS infiltration. In the brain, CD4⁺ CTLs, tissue-resident memory cells, and a unique Myeloid–T cell cluster were enriched for SIV⁺ cells. Integration of brain and blood data revealed transcriptomic maturation of CD4⁺ CTLs upon brain entry. To validate the biological relevance of the Myeloid–T cluster, we used a macrophage–T cell co-culture system, which reproduced similar dual-marker expression and identified chemokines (e.g., CCL3, CCL4) as potential markers of T cell–myeloid cell interaction. Our findings suggest that CD4⁺ cytotoxic-like T cells represent a key lymphocyte subset responsible for initiating SIV entry into the brain and triggering neuroinflammatory processes. Furthermore, interactions between infiltrating lymphocytes and brain-resident myeloid cells, potentially through chemokine signaling, may facilitate viral propagation within the CNS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72fbfac68579326979ef04a1dc07549f993cb4aa" target='_blank'>
              T cell-mediated SIV dissemination into the CNS: a single-cell transcriptomic analysis
              </a>
            </td>
          <td>
            Xiaoke Xu, Meng Niu, Benjamin G. Lamberty, Kathleen M. Emanuel, L. D. Estrella, Howard S. Fox
          </td>
          <td>2025-10-08</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Abstract Background Numerous studies have demonstrated the promising efficacy of granulocyte colony‐stimulating factor (G‐CSF) in the treatment of couples with unexplained recurrent pregnancy loss (URPL) during early pregnancy. While neutrophils are recognised as the main effectors mediating immunoregulation, their G‐CSF‐mobilised phenotype and mechanisms regulating maternal–fetal immunity remain unclear. Methods Single‐cell RNA sequencing (scRNA‐seq) and single‐cell T‐cell receptor sequencing (scTCR‐seq) were conducted to uncover the immune reconstitution dynamics of peripheral blood under G‐CSF stimulation. Integrative analysis of transcriptomic‐proteomic profiles with functional validation revealed a unique immunomodulatory neutrophil population. Further, we used spatial transcriptomics, flow cytometry and immunohistochemistry to explore the spatial distribution characteristics of this population at the maternal–fetal interface, and validated its therapeutic efficacy in animal models. Results G‐CSF‐mobilised peripheral blood (G‐PB) displayed immune hyporesponsiveness. Unique neutrophils expressing high levels of CD177 and the S100A gene family expanded substantially in response to G‐CSF. These neutrophils exhibited a comparatively immature morphology and impaired T‐cell responses via contact‐dependent arginase 1 release, as well as upregulation of T‐cell immune checkpoints. A reduction of CD177+S100Ahi neutrophils was observed in both peripheral blood and decidua of URPL patients relative to healthy pregnant women. Functional validation in abortion‐prone murine models confirmed that exogenous supplementation of G‐CSF or adoptive transfer of CD177+S100Ahi neutrophils could successfully improve the pregnancy outcomes. Conclusion G‐CSF played a crucial regulatory role in improving pregnancy outcomes by selectively expanding CD177⁺S100Ahi neutrophils with polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs) properties, providing a solid theoretical foundation for the treatment of patients with URPL using G‐CSF. Key points G‐CSF induces peripheral blood immune hyporesponsiveness in patients with UPRL. First to characterize G‐CSF mobilised CD177+S100Ahi neutrophils displayed PMN‐MDSCs properties. Both CD177+S100Ahi‐LDNs and CD177+S100Ahi‐NDNs induce T cell hyporesponsiveness through coordinated activation of the ARG1/L‐Arg metabolic axis and synergistic upregulation of immune checkpoint molecules. CD177+S100Ahi neutrophils are diminished in the peripheral blood and decidua of patients with UPRL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6e8e769871352922cc92c745bad2ac8d159aa41" target='_blank'>
              Granulocyte colony‐stimulating factor induced T‐cell hyporesponsiveness via modulation of CD177+S100Ahi neutrophils in unexplained recurrent pregnancy loss
              </a>
            </td>
          <td>
            Ping-Fen Li, Xue Zhang, Peng-Sheng Zheng
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>1</td>
          <td>3</td>
        </tr>

        <tr id="The co-inhibitory receptor TIGIT suppresses excessive immune responses in autoimmune conditions while also restraining antitumor immunity. In viral infections, TIGIT alone does not affect viral control but has been shown to limit tissue pathology. However, the underlying mechanisms are incompletely understood. Here we found TIGIT+ T cells to express not only an immunoregulatory gene signature but also a tissue repair gene signature. Specifically, after viral infection, TIGIT directly drives expression of the tissue growth factor amphiregulin (Areg), which is strongly reduced in the absence of TIGIT. We identified regulatory T (Treg) cells, but not CD8+ T cells, as the critical T cell subset mediating these tissue-protective effects. In Treg cells, TIGIT engagement after T cell antigen receptor stimulation induces the transcription factor Blimp-1, which then promotes Areg production and tissue repair. Thus, we uncovered a nonclassical function of the co-inhibitory receptor TIGIT, wherein it not only limits immune pathology by suppressing the immune response but also actively fosters tissue regeneration by inducing the tissue growth factor Areg in T cells. Joller and colleagues show that the co-inhibitory receptor TIGIT induces the expression of the tissue growth factor amphiregulin (Areg) in regulatory T cells and contributes to tissue repair in response to viral infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0b61dd16412c6f14fc56828dfe7806631ed84034" target='_blank'>
              The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells
              </a>
            </td>
          <td>
            C. Panetti, Rahel Daetwyler, A. Moncsek, Nikolaos Patikas, A. Agrafiotis, Adelynn Tang, F. Andreata, Valeria Fumagalli, Jean de Lima, Lifen Wen, Carolyn G King, Ajithkumar Vasanthakumar, Matteo Iannacone, Axel Kallies, A. Yermanos, M. Hemberg, Nicole Joller
          </td>
          <td>2025-10-15</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>31</td>
        </tr>

        <tr id="Effective anti-tumor immunity critically depends on functional CD8+ T cells, yet in almost all solid tumors, these cells become dysfunctional, exhausted, or spatially excluded. This breakdown of immune surveillance arises not only from cell-intrinsic T cell exhaustion but also from multimodal communication among tumor, stromal, and immune cells within the tumor microenvironment (TME). This communication is mediated not only through direct receptor-ligand interactions but also through a suite of indirect mechanisms, such as metabolic competition, secretion of immunosuppressive metabolites and cytokines, extracellular vesicle exchange, and even mitochondrial transfer via tunneling nanotubes or membrane transfer through T cell trogocytosis. Together, these suppressive interactions impair CD8+ T cell metabolism, effector function, and persistence, thereby enabling tumor immune evasion. In this review, we summarize current understanding of how multimodal cell-cell communication, including immune checkpoints, metabolic reprogramming, and stromal crosstalk, cooperatively drive CD8+ T cell dysfunction. We also highlight emerging therapeutic strategies aimed at rewiring these suppressive networks, with emphasis on translational potential. A deeper understanding of the spatial, molecular, and metabolic context of CD8+ T cell suppression offers new avenues to enhance the efficacy of cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5ae6993d7bfa10b0ab3f27994a45882bb6514da" target='_blank'>
              Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion
              </a>
            </td>
          <td>
            Liping Chen, Qianping Huang, Peipei Zhou
          </td>
          <td>2025-11-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract Neutrophils and monocytes are persistently elevated in sickle cell anemia (SCA), yet the intrinsic mechanisms driving pathological myelopoiesis and inflammation remain poorly defined. Through single-cell RNA sequencing and functional assays, we demonstrate that hematopoietic stem and multipotent progenitor cells (HSPCs) in SCA are transcriptionally reprogrammed toward myeloid differentiation. This process is orchestrated by aberrant activation of type I interferon (IFN-I) signaling, which promotes premature myeloid commitment of hematopoietic stem cells. SCA progenitors further exhibit unexpected responsiveness to granulocyte colony-stimulating factor (G-CSF) through upregulation of CSF3R, resulting in skewed myelopoiesis toward the monocytic lineage. Importantly, hydroxyurea treatment attenuates IFN-I signaling in neutrophils, consistent with its therapeutic role in reducing excessive inflammation and granulopoiesis. Collectively, these findings uncover IFN-I–driven remodeling of hematopoiesis as a fundamental mechanism of leukocytosis and chronic inflammation in SCA, and establish a tractable therapeutic axis to mitigate innate immunity activation in this disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/381b70218da54c4009f797520df51073a0a3a2d8" target='_blank'>
              IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-skewed Hematopoiesis in Sickle Cell Anemia
              </a>
            </td>
          <td>
            Marion Serra, Marine Aglave, Mohammad Salma, Steven Akkaya, Patricia Hermand, Carine Lefevre, Romain Duval, Jade Merrer, Fallou Leye, Joelle Magne, Isabelle Plo, Lionel Blanc, Eric Soler, S. Azouzi, Bérengère Koehl
          </td>
          <td>2025-10-07</td>
          <td>Research Square</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/394995c0fcb10ae0448160919d2f62f9453d3170" target='_blank'>
              Comprehensive single-cell analysis reveals mast cells’ roles in cancer immunity
              </a>
            </td>
          <td>
            Hao Qian, Wenbo Wang, Jiaomeng Pan, Ming Zhao, Li Gao, Jia Zeng, Hang Gong, Guangyan Zhangyuan, Zi Li, Mao Zhang, Xia Shen, Yuanchi Weng, Xiaxing Deng, Yingying Huang
          </td>
          <td>2025-10-10</td>
          <td>Oncogene</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Colorectal cancer (CRC) remains one of the most lethal malignancies worldwide, with outcomes shaped not only by genetic alterations but also by the complexity of the tumor microenvironment (TME). The TME encompasses stromal and endothelial cells, extracellular matrix components, gut microbiota, and a diverse array of immune cells that dynamically interact to influence tumor initiation, progression, and therapeutic response. This review delineates the immunological landscape of CRC, highlighting the dual functions of innate immune cells—including tumor-associated macrophages, natural killer cells, dendritic cells, neutrophils, and mast cells—and adaptive immune players such as cytotoxic T lymphocytes, helper T-cell subsets, and B/plasma cells. These cellular interactions contribute to the heterogeneity between immunologically “hot” microsatellite instability-high (MSI-H) tumors, which are highly responsive to immunotherapy, and “cold” microsatellite-stable (MSS) tumors, which remain resistant. Key mechanisms of immune evasion, such as cancer immunoediting, checkpoint signaling, and exosome-mediated communication, are examined alongside prognostic tools like the Immunoscore that serve as biomarkers of immune infiltration. Emerging immunotherapeutic strategies, including checkpoint blockade, macrophage reprogramming, natural killer cell agonists, and microbiome modulation, are discussed with emphasis on both their promise and limitations in CRC management. By integrating current insights into immune–tumor interactions, the review underscores opportunities for developing personalized, TME-targeted interventions to improve CRC outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1877a469ae4ff5d08c11f55218aceb0c7af5a6c3" target='_blank'>
              Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities
              </a>
            </td>
          <td>
            Adile Buse Andac-Aktas, Gizem Calibasi-Kocal
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Molecular Biosciences</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract Background Oncolytic virus M1 (OVM), a naturally occurring alphavirus, has demonstrated potent antitumor activity in various solid tumor models by inducing immunogenic cell death and activating CD8+ T cells. However, its in vivo efficacy varies widely, and resistance mechanisms remain poorly understood. Tumor-associated macrophages (TAMs), key immunosuppressive cells within the tumor microenvironment, may limit OVM therapeutic potential. Methods We investigated the role of TAMs in OVM resistance using multiple syngeneic mouse tumor models (MC38 colorectal cancer, KPC1199 pancreatic cancer, RM1 prostate cancer, and B16F10 melanoma). TAMs were depleted using clodronate liposomes or CSF1R (Colony Stimulating Factor 1 Receptor) antibodies. Flow cytometry, mass cytometry, quantitative reverse transcription-PCR, and transcriptomic sequencing were employed to assess TAMs infiltration, viral load, and immune responses. CD8+ T cells were selectively depleted to determine their functional relevance. Results TAMs infiltration was positively correlated with resistance to OVM across tumor models. Depletion of TAMs increased intratumoral viral load and promoted accumulation of GZMB+ CD8+ T cells. RNA sequencing analysis revealed upregulation of antiviral and T-cell immune pathways in TAMs-depleted tumors. Importantly, the therapeutic benefit of TAMs depletion was abrogated on CD8+ T-cell depletion, confirming their essential role in mediating OVM efficacy. In both OVM non-responsive and responsive tumors, TAMs depletion enhanced OVM-mediated tumor suppression and survival. Conclusions TAMs, particularly M1-like subsets, play a critical role in mediating resistance to OVM therapy by reducing viral persistence and suppressing CD8+ T-cell responses. Targeting TAMs significantly improves the antitumor efficacy of OVM in solid tumors. These findings support the development of TAMs-targeted combination strategies to optimize oncolytic virotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/753ddef784ec7db8d4ec432d89df4bf7bbfc40f0" target='_blank'>
              TAMs-mediated resistance to oncolytic virus M1 in solid tumors
              </a>
            </td>
          <td>
            Xuanming Liang, Jingjie Li, Jie-Si Chen, Chaoxin Chen, Honghui Li, Caixin Yan, Cui Guo, Yu Han, Wenfeng Liu, Ke Sai, Yuan Lin, Guangmei Yan, Wenbo Zhu, Ying Liu
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/276902406914fa26315122d32de7c8926d35072f" target='_blank'>
              Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing
              </a>
            </td>
          <td>
            Tanja Eisemann, M. Masihi, Theophilos Tzaridis, Veronika Pister, Isaac Youm, Kendall R. Chambers, Aditi Dutta, Alexander T Wenzel, Koei Chin, Scott L. Pomeroy, J. Mesirov, E. Fraenkel, Anindya Bagchi, Lukas Chavez, Robert J Wechsler-Reya
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d6db7c438373e1be32f3e8f8962c7eb002d2e0ff" target='_blank'>
              Single-cell profiling reveals that dynamic lung immune responses distinguish protection from susceptibility to tuberculosis
              </a>
            </td>
          <td>
            Fergal J. Duffy, M. L. Neal, Courtney R. Plumlee, Sarah Cohen, B. Gern, A. Diercks, Michael Y Gerner, K. Urdahl, J. Aitchison
          </td>
          <td>2025-10-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Previously, we defined the transcriptomes and clonality of intragraft CD8+ T cell during renal allograft rejection. Here, using single cell RNA sequencing (scRNAseq), we investigated non-CD8+ immune cells during T-cell-mediated rejection (TCMR) under different maintenance immunosuppression (mIS) regimens: tacrolimus, and co-stimulatory blockade (CoB) with belatacept (CTLA4-Ig) or iscalimab (anti−CD40). Myeloid cells comprised of DCs, monocytes and macrophages whose proportion and gene expression were similar between mIS regimens. Given their transcriptiomic similarities, we analyzed publicly-available scRNAseq/CITEseq datasets as well as immunofluorescence staining to resolve independent subpopulations of γ/δ T cells and NK cells. Intragraft B cells consisted of clusters of naïve, plasmablast, and class-switched B (BCS) cells, with the latter being diminished in CoB mIS. Intragraft CD4+ T cells consisted of FoxP3+ regulatory (Treg), exhausted, Th17, and CXCL13+ peripheral helper (Tph) cells whose proportions differed based in mIS, and the latter two had increased clonal expansion. Notably, cell-cell communication analysis indicated Th17 and Tph cell interactions with BCS cells in tacrolimus, but not CoB, samples. Thus, although failing to prevent TCMR, CoB mIS modulates the accrual of CD4+ T cells and inhibits the intragraft accrual of BCS cells, possibly reflective of clinical observations of less chronic antibody-mediated rejection under CoB mIS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6a9f3325348d0e9acac4d1170eb3ed6e4599ca92" target='_blank'>
              Co-Stimulatory Blockade Prevents Intragraft Accrual of Class-Switched, Activated B Cells Despite Failing to Prevent T-Cell Mediated Rejection
              </a>
            </td>
          <td>
            J. T. Caldwell, Tiffany Shi, Ashley R. Burg, Ashley Koby, Krishna M. Roskin, Anna L. Peters, E. DePasquale, E. Woodle, D. Hildeman
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Relapsed and refractory multiple myeloma (RRMM) remains a major clinical challenge, as most patients eventually relapse following standard treatments and are left with limited therapeutic options. Although b-cell maturation antigen (BCMA) CAR-T cell therapy has recently shown remarkable efficacy in select patients, broader implementation is hindered by its reliance on autologous cells, prolonged manufacturing timelines, high costs, and severe immune-related toxicities. These challenges have prompted an urgent demand for safer, more accessible, and rapidly applicable immunotherapeutic alternatives. CBMC (cord blood mononuclear cells) were cultured with irradiated BMMC (bone marrow mononuclear cells) from RRMM patients in the presence of defined cytokines, aiming to develop a new therapeutic immune cell product for RRMM. Their phenotypic and functional characteristics, including non-MHC-restricted and MHC-restricted cytotoxicity mechanisms, were analyzed using surface marker profiling, cytokine secretion assays, in vitro cytotoxicity assays, functional and blocking assays. Antitumor activity was evaluated in xenograft mouse models using MM.1 S and RPMI-8226 cells. We successfully generated CD8+ NKT-like cells through tumor priming, which exhibited potent cytotoxicity and elevated cytokine production against multiple myeloma cell lines and primary RRMM samples. Mechanistically, tumor-priming CD8+ NKT-like cells (TPNC) cytotoxicity was mediated by both non-MHC–restricted pathways involving LFA-1 and DNAM-1, and MHC-restricted, TCR-mediated recognition. TPNC efficiently formed immune synapses, rapidly polarized cytotoxic granules, and engaged in serial killing. In xenograft models, TPNC significantly suppressed tumor progression, prolonged survival, and persisted in circulation without observable toxicity. Based on these findings, we extended the tumor-priming strategy to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), successfully generating TPNC with robust cytotoxic activity. In ALL samples, TPNC exhibited cytotoxicity comparable to anti-CD19 CAR-NK cells. TPNC represents a novel cytotoxic lymphocyte product generated through tumor-driven priming. Their dual recognition capacity, functional versatility, and favorable safety profile highlight their potential as a scalable and personalized immunotherapy platform for hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93312d628496ab87e87c047dff1fc445e08f269c" target='_blank'>
              Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma
              </a>
            </td>
          <td>
            Juheon Lee, E. Choi, Bohwa Han, Jeongmin Kim, Dana Jung, Kyeong-Hee Kim, Sung Yong Oh, Sung-Hyun Kim, Kyungsoo Ha, Ji-Hoon Kim, Ji Hyun Lee, Duck Cho, Junsang Doh, Seok-Ho Kim
          </td>
          <td>2025-09-29</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/686609950c5f9a2748b6c9d3a59879f149b910cb" target='_blank'>
              Autoantibody origins in lupus and in relapse post CAR-T therapy
              </a>
            </td>
          <td>
            Amalie Grenov, Jongwon Yoon, Daniel M. Snell, Anna Mikolajczak, Hao Wang, Erdem Gürel, Ana Rodriguez Ronchel, G. Yegen, Lydia Lee, B. Esen, Anisur Rahman, P. Maciocia, Carola G. Vinuesa
          </td>
          <td>2025-10-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/929f5e64525cee92d0f3fab0ebf61c85bfdd0623" target='_blank'>
              The spatial landscape of infectious mononucleosis tonsils
              </a>
            </td>
          <td>
            Ciara I Leahy, Matthew Pugh, Aoife Hennessy, Nadezhda Nikulina, Stefan Dojcinov, Gerald Niedobitek, Graham S. Taylor, Paul G Murray, É. Fennell
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ee5dbb33a6a382fa70961ac781d31dc13ae0aa3f" target='_blank'>
              Tumor cell dissemination is facilitated through regulatory T cell-driven extracellular matrix remodeling
              </a>
            </td>
          <td>
            Ailen D. Garcia-Santillan, Jessanne Y. Lichtenberg, He Shen, Jasmine M. Rodriguez, Sandra Makar, Jonathan Barra, Nicholas M. Clark, Wei Du, Leandro M. Martinez, Ashley D. Hadjis, Taylor Calicchia, Mikhail G. Dozmorov, J. Bravo-Cordero, Amy L. Olex, Priscilla Y. Hwang, Paula D. Bos
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Overcoming immune resistance remains the critical barrier to durable immunotherapy responses. Tumors with non-inflamed, “cold” microenvironments exclude cytotoxic lymphocytes and evade checkpoint blockade. Innate nucleic acid-sensing pathways—including TLRs, RIG-I-like RNA sensors, and the cGAS–STING DNA-sensing axis—can recondition this hostile landscape by licensing dendritic cells, restoring antigen presentation, and recruiting effector T and NK cells. In this review, we synthesize mechanistic insights into how these receptors function across tumor and immune compartments and evaluate recent translational advances spanning small-molecule and nucleic acid agonists, engineered delivery systems, and clinical trials. We highlight challenges that have limited clinical impact, including pathway silencing, systemic toxicity, and lack of predictive biomarkers, while emphasizing emerging solutions such as tumor-intrinsic targeting, CAR-T/NK engineering, and biomarker-guided patient selection. By integrating innate activation into rational combination regimens, innate immune reprogramming offers a blueprint to convert resistant disease into one susceptible to durable immune control.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/566c93fdf5aadf323615afa2ec69c6516b114831" target='_blank'>
              Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming
              </a>
            </td>
          <td>
            Giada Mandracci, Nardine Soliman, Nadia El Khawanky
          </td>
          <td>2025-09-30</td>
          <td>International Journal of Molecular Sciences</td>
          <td>1</td>
          <td>2</td>
        </tr>

        <tr id="Malaria, an infectious disease caused by Plasmodium, is primarily characterized by anemia and splenomegaly. CD8 ⁺ T cells are known to play a key role in anti-malaria immunity. Lymphocyte Activation Gene 3 (LAG3), a critical immune checkpoint molecule, is pivotal in CD8 ⁺ T cell-mediated anti-tumor responses. However, the role of LAG3 ⁺ CD8 ⁺ T cells in anti-malarial immunity and the regulatory factors governing LAG3 expression in CD8 ⁺ T cells remain unclear. In this study, C57BL/6 mice were subcutaneously infected with Plasmodium yoelii NSM. Splenic lymphocytes were isolated and analyzed using flow cytometry (FACs) and single-cell RNA sequencing (scRNA-seq). Results showed a significant upregulation of LAG3 expression in splenic CD8 ⁺ T cells post-infection. These LAG3 ⁺ CD8 ⁺ T cells displayed enhanced activation, responsiveness, proliferative capacity, and cytokine production. Additionally, activated nuclear factor of activated T cells 1 (NFATc1) was found to co-express with LAG3 in splenic CD8 ⁺ T cells from infected mice. Dual-fluorescence reporter gene assays in 293T cells identified NFATc1 as a key transcription factor that binds to the LAG3 promoter sequence. Knockdown of NFATc1 via small interfering RNA (siRNA) reduced LAG3 expression. In conclusion, our findings suggest that splenic LAG3 ⁺ CD8 ⁺ T cells in Plasmodium yoelii NSM-infected C57BL/6 mice display enhanced functionality and imply that NFATc1 could positively regulate LAG3 expression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/701cb5eebc64fee04dae0516c62ef93e3f03170b" target='_blank'>
              NFATc1 regulates LAG3+CD8+ T cells in the spleen of mice infected with Plasmodium yoelii NSM
              </a>
            </td>
          <td>
            Xingfei Pan, Feng Mo, Li Pan, Wei Xiao, G. Liang, Xiongyu Xie, Haiwen Yuan, Haixia Wei, Shan Zhao, Lu Li, Lei Jia, Hongyan Xie, Jun Huang
          </td>
          <td>2025-10-01</td>
          <td>PLOS Neglected Tropical Diseases</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Administration of IL-2 may promote the suppressive function and proliferation of Treg cells that cause immune tolerance in patients with cancer, which causes low-dose IL-2 to fail in achieving an optimal anti-tumor effect. Here, we designed an immunocytokine by fusing IL-2 and an anti-TIGIT monoclonal antibody, named αTIGIT-IL2, that targets Treg cells and promotes their fragility in the tumor milieu. These fragile-like Treg cells show impaired suppressive function and high IFN-γ production, triggering an immune-reactive tumor microenvironment. Such inflammation leads to the recruitment and functional reprogramming of intratumoral neutrophils, improving cross-talk between neutrophils and CD8+ T cells and enhancing the antitumor ability of CD8+ T cells. Combination therapy with αTIGIT-IL2 and PD-1 blocker could eliminate triple-negative breast cancer (TNBC) tumors resistant to immune checkpoint blockade (ICB) therapy. These findings provide the basis for developing a new generation of immunocytokines that target Treg cells and promote their fragility in the tumor milieu, resulting in robust antitumor immunity. Interleukin-2 (IL-2) and checkpoint inhibitors such as anti-TIGIT have been used individually as tumour therapies. Here the authors fuse IL-2 and anti-TIGIT in a combined therapeutic and show that this promotes Treg cell fragility in the tumour environment which in turn promotes neutrophil function to enhance CD8 T cell anti-tumour function in mouse models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a8f381b44371297ad7f4ba1f04d5155ffd6052c5" target='_blank'>
              αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models
              </a>
            </td>
          <td>
            Tianci Wang, Yupu Xu, Zhengfeng Zhang, Yaqi Wu, Long Chen, Xiaodong Zheng, Hui Peng, Qiang Zou, Rui Sun, Hongdi Ma, Haoyu Sun, Zhigang Tian, Xiaohu Zheng
          </td>
          <td>2025-10-17</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Lung mononuclear phagocyte (MNP) subsets differ in their ability to restrict Mycobacterium tuberculosis (Mtb) during chronic infection, yet the mechanisms underlying this difference are not well defined. Here, we show that CD11clo monocyte-derived cells (MNC1), the subset of lung cells that is most permissive for Mtb viability during chronic infection, express lower levels of interferon-gamma (IFNγ) signaling proteins, resulting in reduced responses to IFNγ compared to alveolar macrophages (AM) and CD11chi MNC2. Moreover, type I IFN signaling suppresses IFNγ-mediated MHC-II expression, impairing CD4 T cell activation by MNC1 cells. Importantly, prior immunity conferred by contained Mtb infection enhances IFNγ responsiveness of monocyte-derived cells, reducing bacterial burdens in lungs and within MNC subsets. Our findings indicate that heterogeneous IFNγ responsiveness is exploited by Mtb for persistence in vivo. Overcoming or bypassing impaired IFNγ responsiveness may guide the development of more effective TB vaccines and host-directed therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1185bf27cd38b33e534c27d9aa87381e2cd898fa" target='_blank'>
              Impaired IFNγ responsiveness of monocyte-derived lung cells limits immunity to Mycobacterium tuberculosis
              </a>
            </td>
          <td>
            Weihao Zheng, J. Limberis, Zachary P. Howard, Alexander Mohapatra, Enzo Takagi, J. Ernst
          </td>
          <td>2025-11-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="CD8+ T cells exert a significant effect in immune infiltration, drug resistance and cell survival in cancers, but the roles and mechanisms in skin cutaneous melanoma (SKCM) remain unclear. In the present study, prognostic biomarkers associated with CD8+ T cell subsets were screened, and the significance of CD8+ T cells in SKCM immunotherapy was explored by integrated single-cell RNA sequencing (scRNA-seq) and Bulk RNA sequencing (Bulk RNA-seq) analyses. Based on scRNA-seq analysis, CD8 + T cells were divided into two subgroups: CD8 + LAG3 + T cells and CD8 + LAG3-T cells. Cell-cell communication analysis revealed that both subsets closely interact with melanoma cells. Differential gene expression analysis showed that LAG3 was up-regulated in SKCM, and immune infiltration analysis showed that the survival prognosis was significantly better in the Score-High group than in the Score-Low group. Assay results demonstrated that both the LAG3 inhibitor ZYF0033 and the monoclonal antibody Miptenalimab significantly suppressed tumor proliferation and metastasis, while enhancing immune cell infiltration in murine models. This study revealed the functional heterogeneity of CD8 + T cells in SKCM and demonstrated that LAG3 inhibition suppresses tumor proliferation and metastasis. Moreover, reduced LAG3 expression significantly enhanced CD8 + T cell immune infiltration, highlighting the regulatory role of LAG3 in CD8 + T cell function within the tumor microenvironment. These findings provided further evidence that SKCM may be effectively treated by targeting LAG3.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bbf34bb6f4316c74b7aa5aff29c8c5dde444bb0c" target='_blank'>
              Targeting LAG3 to alter the tumor immune reactivity of CD8+T cells is a potential therapy for skin cutaneous melanoma
              </a>
            </td>
          <td>
            Jin Gong, Yan Zhao, Shaozhi Gong, Chunyu Deng, Yajie Zhou
          </td>
          <td>2025-10-29</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="It is increasingly recognized that innate T cells such as natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells play an important role in shaping adaptive immune responses following influenza infection or vaccination. This is largely through the multiple cytokines these cells release upon activation, which have downstream effects on the scope and magnitude of virus-specific T and B cells, and antibodies which form. Here, we examined the contribution of NKT cells using pigs, which are considered a highly translational model of human influenza A infection. CD1D-expressing and CD1D-deficient pigs that respectively possess and lack NKT cells were infected with the swine influenza virus H3N2 A/Swine/Colorado/23619/1999 (CO99), with or without prior mucosal immunization with a recombinant H3N2 A/Swine/Texas/4199-2/1998 (TX98) modified live vaccine encoding a truncated NS1 protein (TX98 NS1Δ126). Vaccination reduced virus load and pulmonary pathology by similar amounts in both genotypes. However, NKT cells status had a significant impact on the underlying immune response: Unlike following vaccination, virus-specific T cell expansion after infection was greater in CD1D-deficient than -intact pigs, indicating that NKT cells play opposing roles in different phases of the immune response. NKT cell-deficient pigs also had reduced T cells cuffing around airways and higher numbers of expanded T and B cell clones according to single-cell αβ T cell receptor (TCR) and B cell receptor (BCR) sequencing. Using our newly developed porcine-specific γ and δ chain primers, we characterized the pulmonary γδ TCR repertoire. This revealed a high frequency of expanded clones, especially within the CD2− subset, and a tendency for larger expansion in NKT cell-expressing pigs. Overall, our results indicate a homeostatic role for NKT cells on several important features of the influenza immune response, including the dynamics of T cell expansion and contraction.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/23d1526f5a77ff12eace732146acf8b49367f516" target='_blank'>
              Pigs lacking Natural Killer T cells have altered cellular responses to influenza
              </a>
            </td>
          <td>
            T. Kwon, Weihong Gu, Igor Morozov, Mariano Carossino, Eu-Lim Lyoo, Chester D. McDowell, Yonghai Li, U. Balasuriya, Yi Huang, Kiho Lee, Juergen A Richt, John P Driver
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4abcaf5776ad97c1813abd2abb8852a605b524d" target='_blank'>
              Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies
              </a>
            </td>
          <td>
            A. Carturan, Mathew G. Angelos, P. Guruprasad, R. Patel, R. Pajarillo, Andrew Lee, Yunlin Zhang, Yi-Hao Chiang, Wei Xie, Jesse L. Rodriguez, Jaryse Harris, Pooja Devi, Olabisi I. Afolayan-Oloye, Jason Xu, Jonathan Sussman, Omar Elghawy, Austin Yang, Adam Barsouk, J. Cho, Carolyn E. Shaw, Ekta Singh, O. Ugwuanyi, D. Espie, L. Paruzzo, Federico Stella, Shan Liu, Siena Nason, Antonio Imparato, Antonia Rotolo, Jean Lemoine, David M. Barrett, A. Posey, A. Rook, Vinodh Pillai, Adam Bagg, S. Pileri, Dongfang Liu, Kai Tan, S. Schuster, D. Teachey, P. Porazzi, M. Ruella
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>66</td>
        </tr>

        <tr id="Myeloid cells are a diverse group of immune cell types with systemic and organ-specific functions. Myeloid cells are frequently found in the tumor microenvironment and their infiltration correlates with survival and response to treatment. High myeloid infiltration is typically a poor prognostic factor, and the immune suppressive and prometastatic roles of myeloid cells are well established. However, there is an increasing appreciation of the antitumor functions performed by myeloid cells, which include direct tumor cell killing, phagocytosis, antigen presentation and T and natural killer cell recruitment. Moreover, advances in immune phenotyping have uncovered myeloid subsets with positive prognostic significance, including subsets correlating with higher response rates to immunotherapy. This review summarizes recent progress in mapping and dissecting the opposing effects of myeloid cells on cancer progression and immunotherapy response. The overall impact of myeloid cells is context-dependent, and combination therapies are needed to leverage the antitumor potential of these cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3823ee46218e3233f5b48e60b02f6fa9d09ba69f" target='_blank'>
              Positive and negative roles of myeloid cells in cancer immunotherapy
              </a>
            </td>
          <td>
            Jaroslav Zak, Judith A. Varner
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18d334efdd4d167f301eb6b862ccafe18092402f" target='_blank'>
              Localized immunomodulation with cytokine-producing cells to mitigate host immune rejection responses in rodents and a non-human primate
              </a>
            </td>
          <td>
            Boram Kim, Dilrasbonu Vohidova, A. Nash, Yuen San Chan, Samantha Fleury, Shravani Deo, Danna Murungi, Peter D Rios, Ira Joshi, Hafsa Nasir, Daisy Lopez, Mor Sela Golan, Cassidy Hart, Jose Oberholzer, H. C. Hodges, O. Veiseh
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) exhibits profound immune dysregulation, driven in part by the opposing roles of regulatory T cells (Tregs) and T helper 17 (Th17) cells. Tregs facilitate tumor progression through immune suppression, angiogenesis, and checkpoint engagement, while Th17 cells display dual effects depending on the tumor microenvironment, either promoting anti-tumor responses or enhancing malignancy. Importantly, plasticity between these subsets, orchestrated by cytokines such as TGF-β, IL-6, and IL-1β, allows dynamic interconversion that shapes immune outcomes. This review comprehensively summarizes the differentiation, molecular mechanisms, and functions of Tregs and Th17 cells in NSCLC. We highlight recent advances in targeting the Th17/Treg axis via immune checkpoint inhibitors, Treg depletion, and metabolic reprogramming. Understanding this immunological balance offers promising avenues for restoring anti-tumor immunity and improving therapeutic efficacy in NSCLC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc2fe215418a201aa8b5de519c7cfb5b11dfb23a" target='_blank'>
              Rewiring immune suppression in NSCLC: Roles and plasticity of Tregs and Th17 cells
              </a>
            </td>
          <td>
            Shasha Zhu, Ning Zhou, Qingling Li, Xiaoxing Liu
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) disease. B-cell maturation antigen (BCMA)-targeted CAR-T therapy, exemplified by FDA-approved agents like ide-cel and cilta-cel, offers promise, yet accessibility barriers necessitate local production. This single-arm trial evaluated safety/efficacy of autologous BCMA CAR-T cells in six R/R MM patients. Cytokine release syndrome (CRS) occurred in 83% (grade 1), managed with tocilizumab without neurotoxicity. Toxicities were transient and resolved. Serum cytokine (IFN-γ, IL-6/8/10) peaked during CRS. Responses included 83% overall response (67% stringent complete response), unaffected by extramedullary disease or high-risk cytogenetics. Median PFS/OS were unreached, with an estimated 12-month OS rate of 83.33% and PFS rate of 66.67%. CAR-T cell persistence, with a median Cmax at 20.5 days, remained detectable in 83% at 1 month and 67% at 6 months. Single-cell RNA sequencing (scRNA-seq) and T-cell receptor sequencing (TCR-seq) demonstrated complementary roles of functionally specialized CD8⁺ Te subsets. Clonal evolution in the sustained responder (patient 2) revealed a shift from a polyclonal infusion product (IP) to oligoclonal dominance, with shared clones exhibiting enhanced cytotoxic and NK-like activity. Transcriptional adaptation of persistent clones over time indicated distinct phases of proliferation, stress response, and long-term persistence, with a concomitant shift in cellular phenotype from IP-derived Tem/circling T cells to a mixed Tem/Te_1/Te_2 population. Comparative analysis of two patients with divergent clinical outcomes (sustained remission vs. transient remission) revealed that early CAR-T exhaustion and increased regulatory T cells (Tregs) were associated with relapse. Locally produced BCMA CAR-T is safe and effective in heavily pretreated R/R MM, inducing deep responses. scRNA-seq/TCR-seq findings highlight interplay of CAR-T heterogeneity, clonal adaptability, and immune regulation. CD8⁺ subset specialization and clonal persistence matter for durable responses; exhaustion and immunosuppression may cause relapse.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/76117249dd52f6888eb3aa89445e38c1d032598c" target='_blank'>
              Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma
              </a>
            </td>
          <td>
            Chuling Fang, Lixin Wang, Weiqiang Zhao, Lei Wang, Wenfa Huang, Ziren Chen, Yiran Wang, Kun Tan, Xiao Guo, Yuanyuan Xu, Shuhong Wang, Lijun Wang, J. Qiao, Xiangyu Meng, Ziqian He, Chuan Yu, Junhui Mei, Hongxin Wang, Yisheng Li, Li Yu
          </td>
          <td>2025-11-10</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Neoantigen-targeted immunotherapies hold promise for cancer treatment, but current personalized approaches are time-consuming and costly. Here, we identify neoantigens encoded by Ptprs and Igf2r that are shared across murine mismatch repair-deficient colorectal and breast tumors and unexpectedly conserved in human colorectal, endometrial, gastric, and prostate cancers. These neoantigens elicit spontaneous, organ-spanning CD8+ T cell-mediated memory responses that are enhanced by immune checkpoint blockade. Vaccination with mRNA/lipid nanoparticles encoding these conserved neoantigens suppresses tumor growth across prophylactic and therapeutic models, including checkpoint-resistant orthotopic tumors. Tumor rejection is accompanied by antigen spreading, abscopal effects, and infiltration by clonally diverse T cells, dendritic cells, and MHC I/II+ macrophages producing CXCL9/10, CCL5/8, and TNF. Tumor cells also show activation of innate and adaptive pathways, including MHC and ISGs overexpression. Our results uncover a conserved anti-tumor immune mechanism and support the development of off-the-shelf neoantigen vaccines across tissues and species.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/64a8bf2f0e1e9b9b72d805335f54c3671ab83124" target='_blank'>
              Targeting neoantigens conserved across organs and species overcomes tumor immune escape
              </a>
            </td>
          <td>
            G. Mestrallet, Ross W. Ward, Matthew Brown, Jesse Boumelha, Frederika Rentzeperis, Natalie Vaninov, Miriam Saffern, Ezekiel Olumuyide, Prerna Suri, Sreekumar Balan, L. Velazquez, Aparna Ananthanarayanan, Zhihong Chen, Aimee L Lucas, Miriam Merad, C. C. Bozkus, Nicolas Vabret, R. Samstein, Nina Bhardwaj
          </td>
          <td>2025-09-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Acute ischemic stroke triggers immunosuppression, yet existing therapies struggle to balance neuroprotection with poststroke immunosuppression. We demonstrated that bone marrow mesenchymal stem cells (BM-MSC) reverse stroke-induced thymic atrophy by promoting T-cell differentiation and restoring peripheral T-cell populations. Bulk RNA sequencing of BM-MSC-treated thymuses revealed enhanced proliferative signatures. Mechanistically, BM-MSC secrete migrasomes (organelles derived from migrating cells) that traverse the blood‒thymus barrier. Single-cell RNA sequencing analysis demonstrated that migrasome-mediated proliferation occurred specifically in medullary thymic epithelial cell I (mTECI) subpopulations. Proteomic profiling via liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) identified Pin1—a cell cycle regulator—as the predominant cargo in BM-MSC-derived migrasomes. In vivo and in vitro studies confirmed migrasome-mediated thymic epithelial proliferation, T-cell niche reconstruction, and immune homeostasis restoration. Migrasome monotherapy improved neurological deficits and survival rates in stroke model mice, demonstrating dual neuroprotective-immunomodulatory efficacy. This work addresses the clinical dilemma between neuroprotection and immunosuppression alleviation, establishing migrasomes as a cell-free therapeutic strategy for poststroke immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e21a53a77f8bdc47edb44b216f414ef301654933" target='_blank'>
              BM-MSC-derived migrasomes reverse stroke-induced thymic atrophy and immunosuppression via Pin1 delivery to thymic epithelial cells
              </a>
            </td>
          <td>
            Haotong Yi, M. Hu, Liling Yuan, Xiaotao Su, Shilin Wu, Tiemei Li, Shisi Wang, Xinmei Kang, Yuxin Liu, Zhiruo Liu, Qin Qin, Weihua Yu, Yifan Li, Wei Qiu, W. Cai, Zhengqi Lu
          </td>
          <td>2025-11-15</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Autoimmune diseases (ADs) arise from the breakdown of self-tolerance, leading to pathogenic immune responses against healthy tissues. The PD-1/PD-L1 immune checkpoint is pivotal for maintaining peripheral tolerance by suppressing autoreactive T cells, and its dysfunction drives the pathogenesis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and other ADs. Conventional approaches—including monoclonal antibodies, soluble PD-L1 fusion proteins, small-molecule or RNA regulators, and cell- or gene-based therapies—have shown promise. However, their broader application is constrained by systemic immunosuppression, off-target effects, infection and malignancy risks, and manufacturing complexities. Nanomedicine offers transformative solutions by leveraging polymeric nanoparticles, liposomes or lipid nanoparticles, extracellular vesicles (EVs), and biomimetic cell-membrane coatings to deliver PD-1/PD-L1 agonists with high spatial and temporal precision. These nanocarrier platforms enable localized checkpoint activation, co-delivery of tolerogenic agents, and improved biodistribution with reduced systemic toxicity. Here, we systematically review the structural and signaling features of the PD-1/PD-L1 axis, outlines the limitations of conventional therapeutic modalities, and highlights how nanocarrier-based approaches overcome these barriers to restore immune homeostasis in ADs. By integrating mechanistic insights with advanced delivery technologies, this review outlines a roadmap for next-generation, precision-engineered interventions aimed at reestablishing immune tolerance and improving clinical outcomes in ADs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d85a0518d53bd3098fe8f73e4b78cdf5aac3692d" target='_blank'>
              Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance
              </a>
            </td>
          <td>
            Gang Xiang, Yuanxu Cui, Pan Wang, Yuantao Feng, Chengyuan Zhang, Jie Lou, Xing Zhou
          </td>
          <td>2025-10-11</td>
          <td>Journal of Nanobiotechnology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="T cell responses are generally curtailed by suppressive mechanisms within the tumor microenvironment (TME) that prevent T cell infiltration and function. Consequently, T cell-based therapies for solid tumors have yielded limited and often non-durable clinical responses. Tumors develop a hostile TME, where tumor-associated macrophages (TAMs) that initially support T cells are converted into immune suppressive TAMs that facilitate tumor evasion from T cell control. In fact, immune suppressive TAMs represent a dominant fraction of immune cells within the TME and their presence is associated with poor prognosis and resistance to immunotherapy. Often in close contact with effector T cells, TAMs directly suppress CD8+ T cells through mechanisms involving metabolic mediators, co-signaling receptors, their ligands and/or cytokines. Here, we revisit molecular interactions behind TAM-mediated suppression of T cell responses and address the potential targeting of such molecules and pathways to re-boost anti-tumor T cell immunity. This perspective, focusing on molecular interactions between TAM and T cells, may aid the improvement of T cell-based therapies for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c01dfbcf193a83248342e1e2c8db14cdc37f598" target='_blank'>
              Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy
              </a>
            </td>
          <td>
            R. M. Coelho, R. Debets, Dora Hammerl
          </td>
          <td>2025-10-16</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Myeloid cells play critical roles as Fc effector cells in antibody‐mediated immunity. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) is a pleiotropic cytokine that promotes the recruitment and activation of multiple myeloid populations and has been used in combination with vaccines/treatments against infectious diseases, inflammatory conditions and cancers. To evaluate GM‐CSF‐mediated kinetics of immune cell expansion and immune outcomes, we compared subcutaneous (subQ) and topical hypoosmolar (intravaginal/intrarectal) administration in vivo using rhesus macaques (RM), as they provide easy access to longitudinal mucosal tissue sampling and are a critical model species for vaccines/therapeutics development. While topical GM‐CSF did not result in a major change, neutrophils, eosinophils and monocytes were elevated within 1–3 days of subQ GM‐CSF administration, with peak eosinophil and neutrophil enrichment in blood at days 7 and 8, respectively. Corresponding elevations of neutrophils, eosinophils, total CD64+ and total CD32+ were observed at days 7 and 14 in rectal biopsies, indicating general Fc effector cell accumulation in these animals. Histological evaluations of vaginal biopsies showed myeloid cell infiltration at day 14 of subQ GM‐CSF treatment. Further, subQ GM‐CSF administration resulted in myeloid cell activation and trafficking, as evidenced by elevated levels of cytokines (CXCL13, MCP‐1, IL‐1RA). Importantly, neither subQ nor topical GM‐CSF administration induced overt systemic inflammation or adverse clinical impacts. Overall, our findings delineate the kinetics of systemic and mucosal myeloid cell expansion, activation and trafficking achieved by subQ GM‐CSF administration in RM. These findings will inform the use of GM‐CSF as an adjuvant in clinical applications where myeloid cell mobilization is advantageous.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/492d90767cafd39d09bc074bbefa23b57af9983b" target='_blank'>
              Myeloid cell recruitment and activation through systemic and mucosae‐directed cytokine therapy
              </a>
            </td>
          <td>
            C. Manickam, Rhianna Jones, Nihar R. Deb Adhikary, Kyle W. Kroll, Karen Terry, Hari Balachandran, Griffin Woolley, G. Tomaras, François J. Villinger, R. K. Reeves
          </td>
          <td>2025-10-07</td>
          <td>Immunology and Cell Biology</td>
          <td>0</td>
          <td>82</td>
        </tr>

        <tr id="Chimeric Antigen Receptor (CAR) T cell therapy has revolutionised the treatment of relapsed/refractory B cell leukaemia, lymphoma and multiple myeloma through targeting of CD19 and BCMA antigens on the surface of these cells. A growing body of evidence has recently demonstrated that these cell-based therapies can also target autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravis, idiopathic inflammatory myositis, multiple sclerosis and rheumatoid arthritis. To date, ten patients with rheumatoid arthritis have been treated with CAR T cells targeting CD19/CD20 or BCMA antigens on B cells. Nine patients with seropositive disease have shown remarkable responses, including depletion of circulating B cells, ablation of autoantibody levels and drug-free remission. A tenth patient with seronegative disease initially responded to CAR T cell therapy but later relapsed. This review provides in-depth analysis of these single case studies and highlights emerging in-vitro and animal model studies where T cell subsets have been engineered with CARs to fine-tune their immune responses for the treatment of rheumatoid arthritis, including targeting of autoreactive B cells, autoreactive T cells or fibroblasts. CAR T cell therapy holds enormous promise for the treatment of difficult-to-treat rheumatoid arthritis, but more research and large clinical trials are needed to confirm its efficacy and safety.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/686117008b9c94d2ee07f5685b2e3b4c4d782625" target='_blank'>
              CAR T Cell Therapy for Rheumatoid Arthritis
              </a>
            </td>
          <td>
            Michael Freeley
          </td>
          <td>2025-11-19</td>
          <td>Clinical Reviews in Allergy & Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Autoimmune kidney diseases (AIKDs) are a consequence of the dysregulation of immune response and the loss of tolerance to self-antigens, which led to glomerulonephritis and tissue damage. Autoantibody-producing B cells, as well as T cells, neutrophils and macrophages play a pivotal role in the pathogenesis and progression of various AIKDs. In recent years, B cell-depleting/modulating therapies and molecules that modulate T cell differentiation pathways and cytokine production have become a new hope for patients with immune-mediated kidney diseases. However, these biologicals often do not bring satisfactory therapeutic benefits, which is most likely related to incomplete B cell depletion of tissue-resident B cells. A new hope is immunotherapy with chimeric antigen receptor (CAR) effector cells. In CAR therapy, immune cells (mostly T cells) are genetically modified to express a CAR, which enables the recognition of the specific antigen on a target cell. This interaction leads to the formation of immune synapse and cytotoxicity. CAR-based strategies are a potent form of cell therapy that offers a better chance for deep and durable response than other recently approved immune therapies. Moreover, CAR-T cells can be programmed for higher precision and safety. This review explores the current landscape of CAR-T cell therapy in AIKDs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f214144b87a7be044bf71857fed9fe114ce14c2a" target='_blank'>
              CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?
              </a>
            </td>
          <td>
            Beata Kaleta
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="T-cell exhaustion is a terminal state of immune dysfunction characterized by impaired proliferation and effector functions, diminished cytokine secretion, and sustained expression of inhibitory receptors. In coronavirus disease 2019 (COVID-19), increasing evidence links exhausted T-cell phenotypes with poor clinical outcomes, including severe disease, delayed viral clearance, and persistent symptoms associated with Long COVID. Exhaustion results from prolonged antigenic stimulation and inflammatory signals and is marked by transcriptional reprogramming, metabolic and epigenetic dysregulation, and co-expression of inhibitory receptors such as programmed cell death protein-1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Notably, exhausted phenotypes in COVID-19 frequently coexist with hyperactivation, raising the unresolved question of whether inhibitory receptor expression reflects transient activation or irreversible dysfunction. Emerging therapeutic strategies to reverse these dysfunctional states include immune checkpoint inhibitors, cytokine modulation, metabolic interventions, and epigenetic therapies, although their clinical translation remains at an early stage. Critical research gaps include the scarcity of longitudinal data, incomplete profiling of T-cell subsets across disease stages during COVID-19 and Long COVID-19, and contradictory evidence of vaccine-induced exhaustion with limited understanding of its consequences. This non-systematic literature review synthesizes current advances in COVID-19 immunopathology and therapeutic strategies, underscoring that understanding T-cell exhaustion is crucial to improving outcomes and shaping next-generation immunotherapies and vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fcda848fedb31d45bcaf7a6be07292887c93eed0" target='_blank'>
              T-cell exhaustion in COVID-19: what do we know?
              </a>
            </td>
          <td>
            Roderick Chen-Camaño, Rodrigo DeAntonio, S. López-Vergès
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Simple Summary Breast cancer is one of the most common and deadly cancers in women, and its treatment remains challenging because tumors can hide from the body’s natural defenses. A special group of immune cells called regulatory T cells normally prevent harmful inflammation, but in breast cancer they are often taken over by the tumor to block protective immune responses. This review explains what is currently known about how these cells influence breast cancer growth, spread, and resistance to therapy. We also describe new approaches being studied to control or reprogram regulatory T cells so that the immune system can better fight cancer. By bringing together findings from laboratory studies and clinical research, our goal is to highlight opportunities for more precise treatments. Understanding the role of regulatory T cells may help doctors develop strategies that improve survival and quality of life for patients. Abstract Regulatory T cells (Tregs) are a specialized subset of CD4+ T lymphocytes essential for maintaining immune tolerance and preventing autoimmunity. However, in breast cancer, tumors exploit Tregs to establish an immunosuppressive microenvironment that enables immune evasion, accelerates progression, and contributes to therapeutic resistance. This review synthesizes current evidence on the role of Tregs in invasive breast cancer (IBC), highlighting their prognostic significance across molecular subtypes, mechanisms of immune suppression, and impact on treatment response. We integrated mechanistic and clinical insights to discuss opportunities for Treg-targeted therapeutic strategies, with attention paid to challenges such as autoimmunity, compensatory resistance, and subtype-specific heterogeneity. Finally, we outline future directions, including biomarker-driven precision medicine, novel therapeutic combinations, advanced preclinical models, as well as potential artificial intelligence-assisted approaches that aim to selectively disrupt tumor-promoting Treg functions while preserving the systemic immune balance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c6aec98f0588e69ab6be9f3f1432d83d168785ae" target='_blank'>
              Regulatory T Cells in Invasive Breast Cancer: Prognosis, Mechanisms and Therapy
              </a>
            </td>
          <td>
            Aizhang Xu, Sama Ayoub, Haijun Zhang, Yuhang Wu, Marcellino Rau, Xiaojing Ma
          </td>
          <td>2025-09-29</td>
          <td>Cancers</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1dc5d3c63e2c8a598b2458f56705187d3452201c" target='_blank'>
              Neutrophils induce effective antibody responses to the pneumococcal conjugate vaccine by inhibiting regulatory T cells
              </a>
            </td>
          <td>
            Essi Y. I. Tchalla, Anagha Betadpur, Andrew Y. Khalil, Elena Lopez, Manmeet Bhalla, Musea Chang, Elizabeth A. Wohlfert, E. Ghanem
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Cancer remains a leading cause of mortality worldwide, with rising incidence and death rates continuing to rise. While conventional treatments such as surgery, radiotherapy, and chemotherapy form the backbone of cancer care, they are often limited by adverse effects, recurrence risk, and incomplete tumor eradication. Tumor immunotherapy—particularly immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapy—has emerged as a transformative approach by activating and reprogramming anti-tumor immune responses. Despite these advances, significant challenges persist, including limited response rates to checkpoint inhibitors, the immunosuppressive nature of the tumor microenvironment (TME), and resistance mechanisms employed by tumor cells. Growing evidence suggests that immune cell senescence is a critical contributor to TME-driven immunosuppression. Senescent immune cells exhibit functional decline, elevated expression of inhibitory immune checkpoint molecules, and increased secretion of pro-inflammatory cytokines, collectively impairing anti-tumor immunity and reducing the efficacy of immunotherapy. This review highlights the role of immune cell senescence in shaping the immunosuppressive TME and driving resistance to immunotherapy. It further discusses emerging therapeutic strategies that combine immunotherapy with senescence-targeting interventions, aiming to provide novel insights into the development of more effective cancer treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56cdaa455cdfae646c5bce11b54ada6d03f2699c" target='_blank'>
              Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance
              </a>
            </td>
          <td>
            Duolun Gao, Peiyan Kan, Yanjie He, Siyu Sun, Lei Tang, Fan Yang
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Background/Objectives: Whilst adoptive cell therapy (ACT) using chimeric antigen receptor-engineered T (CAR-T) cells represents an efficient approach for the treatment of patients suffering from several hematological malignancies, solid tumors have been shown to be far more challenging to tackle, mainly due to the hostile tumor microenvironment that inhibits optimal T cell functionality. As proven by the broad clinical success of immune checkpoint inhibitors, blocking the interaction of programmed cell death ligand 1 (PD-L1) expressed on tumor cells and the checkpoint receptor programmed cell death 1 (PD-1) expressed on activated T cells allows an intrinsic T cell-mediated anti-tumor response to be unleashed. We developed a cellular product (MDG1015) consisting of New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/L antigen family member 1a (LAGE-1a)-specific CD8+ T cell receptor-transduced (TCR-)T cells co-expressing the costimulatory switch protein (CSP) PD1-41BB, which turns an inhibitory signal mediated by the PD-1:PD-L1 axis into positive T cell costimulation. Methods: In vitro co-cultures of MDG1015 and PD-L1-positive or -negative target cells were used to analyze TCR-T cell functionality, such as TCR-T (poly-)cytokine release, the killing of target cells, and TCR-T proliferation. The safety of MDG1015 was evaluated via different panels of antigen-negative cell lines or primary cells expressing or lacking PD-L1. Results: Preclinical analyses demonstrated TCR-gated activation of the CSP, leading to enhanced functionality of MDG1015 against antigen-expressing, PD-L1-positive tumor cells without any impact on antigen-negative target cells. Conclusions: The favorable, preclinical functionality and safety profile qualifies MDG1015 as a promising cellular therapy for explorative clinical testing in hard-to-treat solid tumor indications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0061d8fd9c6ec9b1979ffcc32d15a525ae895b20" target='_blank'>
              Preclinical Development of Costimulatory Switch Protein (CSP)-Armored NY-ESO-1/LAGE-1a-Specific TCR-T Cells for Therapy of Hard-to-Treat PD-L1-Positive Solid Tumors
              </a>
            </td>
          <td>
            M. Bürdek, Petra U. Prinz, Katrin Mutze, Miriam Bosch, S. Tippmer, A. Coluccio, C. Geiger, Snigdha Majumder, G. Longinotti, Dolores J. Schendel
          </td>
          <td>2025-09-26</td>
          <td>International Journal of Translational Medicine</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Background The triple-negative breast cancer (TNBC) microenvironment (TME) undergoes progressive reprogramming, transitioning from an early immune-active state to a late immune-suppressed state. While tumor cell plasticity has been extensively studied, the molecular plasticity of T cells in vivo remains poorly defined. Objectives To characterize transcriptional changes in T cells during TNBC progression and identify stage-specific shifts in T cell function, polarization, and antigen-presenting cell (APC)-T cell interactions. Results Transcriptional analysis of T cells from BALB/c mice bearing 4T1 tumors at 1, 3, and 6 weeks revealed a decline in T cell-associated genes from 194 at 1 week to 156 at 6 weeks, with a significant late-stage loss of TCR diversity and contraction of natural killer T (NKT)- and γδ T cell-related transcripts. Cytokine and transcription factor dynamics reflected temporal T cell polarization: early (1 week) IL-12α/β-STAT4 signaling supports CD4+ type 1 T helper cell (Th1) and type 1 CD8+ cytotoxic T cell (Tc1) responses; intermediate (3 weeks) IL-21 and BCL6 expression suggest transient CD8+ cytotoxic follicular T cell (Tfc) skewing; and late (6 weeks) AhR and IL-1β induction reflect interleukin 17/22 producing CD8+ T cell (Tc17/Tc22) transition. Pro-inflammatory cytokines and chemokines increased over time, while immunosuppressive mediators (e.g., IL-10) declined significantly. Antigen-presenting cell (APC)-T cell crosstalk deteriorated at 6 weeks, characterized by a reduction in the expression of co-stimulatory and APC genes. Despite an early dominance of M1-like macrophage signals (e.g., IL-12α/β), persistent expression of arginase 1 (ARG1) and other M2-associated genes indicated a stable tolerogenic niche. Conclusions TNBC progression is characterized by progressive T cell functional decline, narrowing of TCR diversity, impaired APC-T cell interactions, and sustained macrophage-driven immunosuppression. These temporally coordinated immune shifts suggest tumor-driven adaptation toward immune evasion and identify potential windows for stage-specific immunotherapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb0d181b971ab9d5141b1475ee18608b8080d802" target='_blank'>
              Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors
              </a>
            </td>
          <td>
            Md. Iftehimul, Robert H. Newman, Scott H Harrison, Roshonda B. Jones, P. Muganda, Bryan L. Holloman, M. T. Hossain, C. J. Rorie, Misty D. Thomas, Joseph L. Graves, H. Kaufman, Dipongkor Saha
          </td>
          <td>2025-10-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/25cf0de6f70fb418ecf166b4bb716bc0fd141f86" target='_blank'>
              Myeloid Specific Ablation of SHIP1 Boosts ex vivo Expansion and Regulatory Function of Myeloid-Derived Suppressor Cells in Inflammatory Arthritis
              </a>
            </td>
          <td>
            E. So, Moon Jung Choi, Young Eun Lee, Bedia Akosman, Euy-Myoung Jeong, Anthony M. Reginato, Olin D. Liang
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Aged tissue is characterized by chronic inflammation known as “inflammaging”. While this aging immune phenotype supposedly drives some of the most common diseases affecting the elderly, little is known about the structural drivers of inflammaging. In this study, we demonstrate that age-dependent activation of NF-kB in tissue fibroblasts remodels the immune architecture, promoting the emergence of an exhausted T cell population (GZMK+/CD8+) recently identified in normal aging, as well as autoimmunity and cancer. Fibroblast-specific NF-kB activation triggered a fibroblast-macrophage-T cell circuit to form tertiary lymphoid structures in the lung and promoted the emergence of exhausted GZMK+ T cells. Fibroblastic activation of NF-kB increased host susceptibility to acute lung injury and mimics severe pneumonia commonly seen in elderly patients, which was alleviated by deletion of GZMK+ T cells. Our data provide a structural basis for inflammaging, where fibroblasts orchestrate the complex immune aging phenotype in non-immune tissues, increasing susceptibility to age-related diseases. Highlights - Bronchus-associated lymphoid tissue (BALT) enriched for GZMK+ T cells develop with age - Lung adventitial fibroblasts demonstrate increased NF-kB activation with age. - Fibroblast activation of NF-kB in young animals recapitulates multiple features of normal lung immune aging - Depletion of GZMK+ cells decreases lung inflammation in a mouse model of acute respiratory distress syndrome (ARDS)">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d8a754f463ab7baffd2a9daeb1d70ff841b56ea" target='_blank'>
              Fibroblast orchestration of inflammaging via NF-kB activation
              </a>
            </td>
          <td>
            Nancy C. Allen, Christian Ringler, Jin Young Lee, Nabora S. Reyes, Ritusree Biswas, Sofia E Caryotakis, M. Magnen, Pedro Ruivo, V. Auyeung, M. Looney, Averil Ma, Ari B. Molofsky, Tien Peng
          </td>
          <td>2025-10-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="Cold tumors, defined by insufficient immune cell infiltration and a highly immunosuppressive tumor microenvironment (TME), exhibit limited responsiveness to conventional immunotherapies. This review systematically summarizes the mechanisms of immune evasion and the therapeutic strategies for cold tumors as revealed by multi-omics technologies. By integrating genomic, transcriptomic, proteomic, metabolomic, and spatial multi-omics data, the review elucidates key immune evasion mechanisms, including activation of the WNT/β-catenin pathway, transforming growth factor-β (TGF-β)–mediated immunosuppression, metabolic reprogramming (e.g., lactate accumulation), and aberrant expression of immune checkpoint molecules. Furthermore, this review proposes multi-dimensional therapeutic strategies, such as targeting immunosuppressive pathways (e.g., programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors combined with TGF-β blockade), reshaping the TME through chemokine-based therapies, oncolytic viruses, and vascular normalization, and metabolic interventions (e.g., inhibition of lactate dehydrogenase A (LDHA) or glutaminase (GLS)). In addition, personalized neoantigen vaccines and engineered cell therapies (e.g., T cell receptor-engineered T (TCR-T) and natural killer (NK) cells) show promising potential. Emerging evidence also highlights the role of epigenetic regulation (e.g., histone deacetylase (HDAC) inhibitors) and N6-Methyladenosine (m6A) RNA modifications in reversing immune evasion. Despite the promising insights offered by multi-omics integration in guiding precision immunotherapy, challenges remain in clinical translation, including data heterogeneity, target-specific toxicity, and limitations in preclinical models. Future efforts should focus on coupling dynamic multi-omics technologies with intelligent therapeutic design to convert cold tumors into immunologically active (“hot”) microenvironments, ultimately facilitating breakthroughs in personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f521c611e55896b93cee504ac14c36afaf25953" target='_blank'>
              Igniting Cold Tumors: Multi-Omics-Driven Strategies to Overcome Immune Evasion and Restore Immune Surveillance
              </a>
            </td>
          <td>
            Xinyao Huang, Renjun Gu, Ziyu Li, Fangyu Wang
          </td>
          <td>2025-09-26</td>
          <td>Oncology Research</td>
          <td>1</td>
          <td>3</td>
        </tr>

        <tr id="The immune system plays a central role in anticancer defense by coordinating antitumor responses that inhibit the initiation, progression, and metastasis of malignancies. Emerging evidence underscores the crucial interplay between regulated cell death (RCD) pathways and immune activation, particularly immunogenic cell death (ICD). ICD refers to a specific form of regulated cell death in which tumor cells undergo death and release damage-associated molecular patterns (DAMPs) and other signaling molecules, thereby reshaping the tumor immune microenvironment (TIME). While the canonical RCD pathways are well-established, the inducers of ICD, the spatiotemporal regulation of TIME dynamics, and the functional states of immune cells remain incompletely understood. We thoroughly evaluated contemporary therapeutic approaches that exploit the mechanisms of RCD-driven immunomodulatory effects, including strategies to potentiate ICD and amplify antitumor immune responses. The novelty of this review lies in its dual perspective: delineating how tumor-intrinsic death programs reprogram the tumor TIME and how immune-cell death directly dictates its polarization toward immunostimulatory versus immunosuppressive states, ultimately shaping therapeutic outcomes. We analyzed in depth how different forms of RCD shape antigen presentation, guide immune cell infiltration, and affect checkpoint signaling, underscoring their dual potential to support or hinder antitumor responses. Furthermore, we summarized the current landscape of ICD-inducing interventions, including chemotherapy, radiotherapy, oncolytic viruses, tumor vaccines, and nanotechnology-based platforms, underscoring their potential to convert immunologically “cold” tumors into “hot” ones and to synergize with immune checkpoint blockade. In addition, we highlighted promising combination strategies aimed at directly modulating immune cell death pathways to sustain effector cell function and overcome exhaustion, offering novel insights for the development of next-generation precision immunotherapies. By delineating the crosstalk between tumor/immune cell death pathways, this study provides a roadmap for developing precise immunotherapies that exploit RCD-TIME interactions to overcome treatment resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/631a2a5dc4fb23c25118a02f99c55209530ff87b" target='_blank'>
              Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment
              </a>
            </td>
          <td>
            Haixia Zhang, Shizhen Li, Siyang Liu, Yaqi Liao, Huiqin Liu, Minghua Yang, Pan Chen
          </td>
          <td>2025-10-31</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="ABSTRACT Introduction Hepatocellular carcinoma (HCC) is a major cause of cancer-related death globally, characterized by an immunosuppressive tumor microenvironment (TME) that impairs immune surveillance. Immunotherapy has emerged as a transformative option; however, durable responses remain limited. The purpose of this review is to synthesize recent advances in HCC immunology, immunotherapy, and the TME. Areas Covered Literature was identified via PubMed and ClinicalTrials.gov (January 2001–May 2025), focusing on clinical and translational studies. We outline the immunological landscape of HCC, emphasizing the roles of T cells, natural killer cells, macrophages, dendritic cells, myeloid-derived suppressor cells, and regulatory T cells in shaping tumor immunity. TME components include cancer-associated fibroblasts, tumor-associated macrophages, suppressive cytokines, angiogenesis, hypoxia, metabolic reprogramming, and the gut-liver axis. Interactions with immunotherapy, mechanisms of resistance, and combination strategies were described. Emerging biomarkers – such as tertiary lymphoid structures, PD-L1, tumor mutational burden, gene signatures, and gut microbiota – are reviewed relative to patient stratification. Expert Opinion Immunotherapy has reshaped HCC management, but resistance, biomarker limitations, and heterogeneity remain major challenges. Advances will require TME reprogramming, multi-parametric biomarkers, and personalized strategies. Integration with targeted and locoregional approaches may achieve durable responses and move toward precision immuno-oncology, transforming HCC into a manageable or curable disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f81fb97115d4549912d0ac1a8a271a719cc8ad4" target='_blank'>
              Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: a comprehensive review
              </a>
            </td>
          <td>
            Miho Akabane, Yuki Imaoka, Ghee Rye Lee, T. Pawlik
          </td>
          <td>2025-09-29</td>
          <td>Expert Review of Clinical Immunology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Autoimmune diseases represent a broad group of chronic conditions characterized by loss of immune tolerance, autoreactive lymphocyte activation, and pathogenic autoantibody production. CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for hematologic malignancies, has emerged as a promising strategy to directly eliminate autoreactive B cells and reprogram immune function. CD19-CAR T infusion can induce rapid remission, reduce autoantibody levels, and sustain drug-free disease control. Despite these encouraging results, current evidence is limited to small patient cohorts with short follow-up, leaving uncertainties regarding long-term safety, durability of remission, and the stability of immune reconstitution. Most studies implicitly assume that quantitative B-cell recovery equates to restored immune health, yet the functional resilience of the post-CAR-T immune system—its ability to protect against infection, respond to vaccines, and maintain durable tolerance—remains unexplored. To address this gap, we propose an integrated framework for evaluating the functional competence of immune reconstitution following CAR T-cell therapy and for designing next-generation targeting strategies. Functional recovery should be assessed not only by quantitative B-cell repopulation but also by vaccine responsiveness, infection surveillance, and immune repertoire diversity. Vaccine challenge studies and infection monitoring can reveal whether protective immunity is restored, while sequencing-based profiling of B- and T-cell repertoires can clarify whether regulatory balance and clonal diversity are re-established. In parallel, translational innovations such as dual-target CAR constructs (e.g., CD19 + BAFF-R) and chimeric autoantibody receptor (CAAR) T cells offer complementary solutions to broaden target coverage and improve selectivity. Moreover, Epstein–Barr virus (EBV)–mediated immortalization of patient-derived autoreactive B cells provides a feasible ex vivo platform for generating physiologically relevant antigenic stimuli during CAR engineering. This approach could yield T cells that are functionally “educated” to eliminate pathogenic clones while preserving protective immunity, thereby addressing the central challenge of rebuilding a resilient and tolerant immune system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/803ca15907028d5ecd42afcef39a38a8ff458830" target='_blank'>
              Application of CD19-CAR T cell therapy in autoimmune diseases
              </a>
            </td>
          <td>
            Lynn Choi
          </td>
          <td>2025-10-24</td>
          <td>Journal of High School Science</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract Background Mounting evidence shows that myeloid‐derived suppressor cells (MDSCs) reprogramming can significantly enhance the outcomes of immunotherapy. However, the therapeutic potential of targeting MDSCs alone is limited by persistent immunosuppressive cytokines and cellular crosstalk. In our previous study, we found that novel cryo‐thermal therapy (CTT) can drive MDSCs maturation and induce CD4+ T helper type (Th)1‐dominant differentiation, improving long‐term survival in spontaneous high metastatic mouse models. Considering the established roles of Interleukin (IL)‐6 and IL‐17A in non‐small cell lung cancer (NSCLC) progression and immune evasion, we developed a combination strategy integrating cytokine neutralization with CTT (combination therapy) in LLC1 tumor‐bearing mice. Although the combination therapy successfully promoted MDSCs maturation and Th1 differentiation, the underlying mechanistic basis remained unclear. Methods The combination therapy was implemented in LLC1 tumor‐bearing mice. We then observed its impacts on MDSCs maturation and Th1 differentiation and explored the related mechanisms by examining various aspects including the expression of CD40, the reactive oxygen species (ROS)‐nuclear factor‐kappa B (NF‐κB) pathway, and the induction of tumor necrosis factor‐α (TNF‐α). Results It was observed that the combination therapy increased the expression of CD40 on MDSCs through the ROS‐NF‐κB pathway‐dependent TNF‐α induction. This TNF‐α‐mediated CD40 upregulation facilitated Th1 polarization via CD40L engagement on CD4+ T cells. Our results provided the first mechanistic evidence that autocrine TNF‐α production by reprogrammed MDSCs governs CD40 expression following combination therapy. Conclusion Our research elucidated the methods and mechanisms of MDSCs reprogramming and offered a promising therapeutic strategy for patients with NSCLC and other types of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b5c584eeb86580107a4b77d49be11b90194d483" target='_blank'>
              Reprogrammed MDSCs promote Th1‐dominant antitumour response via CD40 induced by autocrine TNF‐α after combining cryo‐thermal therapy with IL6 and IL17A neutralization
              </a>
            </td>
          <td>
            Yuankai Hao, Shicheng Wang, Junjun Wang, Zelun Zhang, Yichen Yao, Ke-fu Wang, Ping Liu, Lisa X. Xu
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Cancer-associated fibroblasts (CAFs) are known to shape the tumor microenvironment, yet the role of extracellular vesicles they produce, particularly migrasomes, in hepatocellular carcinoma (HCC) remains largely unexplored. In this study, we identified a subset of POSTN+ CAFs as the main source of migrasomes in HCC, predominantly located at the tumor–stroma interface. Transcriptomic data from TCGA and ICGC were used to compute a Migrasome_Score via GSVA, revealing strong associations with poor prognosis and immune checkpoint blockade resistance across cancers. Mechanistically, POSTN+ CAF-derived migrasomes enhanced endothelial angiogenic activity by delivering VEGFA and activating the VEGFR2–PI3K–AKT–eNOS pathway, promoting vascular remodeling within tumors. Migrasomes also induced malignant reprogramming of nearby hepatocytes by boosting oxidative phosphorylation and reactive oxygen species (ROS) production, leading to DNA damage and oncogenic transformation—effects reversed by ROS scavenging. Additionally, POSTN+ CAFs and their migrasomes physically hindered immune cell infiltration, forming a barrier that shielded tumor cells from immune surveillance. Together, these findings identify POSTN+ CAF-derived migrasomes as key drivers of HCC progression by promoting angiogenesis, malignant transformation, and immune exclusion. Their strong links to poor prognosis and immunotherapy resistance suggest that they may serve as promising therapeutic targets and prognostic biomarkers in HCC and beyond.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e8f448cce9ddf3977da321301e1fc4919158389" target='_blank'>
              POSTN+ CAF-Derived Migrasomes Drive Hepatocellular Carcinoma Progression and Confer Resistance to Immunotherapy
              </a>
            </td>
          <td>
            Zhenhua Zhu, Kangnan Zhang, Wei Wu, Jingyi Zhou, Mingming Zhang, Jiong Chen, Jinlu Han, Na Wang, Biao Li, Wenhao Weng, Qinghui Zhang, Min Zhou, Ling Xu
          </td>
          <td>2025-09-28</td>
          <td>Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Cancer stem cells (CSCs) are a minor subpopulation of tumor cells characterized by self-renewal capacity and stemness features and are responsible for tumor progression and therapy resistance. Several studies have shown that CSCs possess immunomodulatory properties that allow them to evade from immune responses. One of the mechanisms by which CSCs can escape from immune cells recognition and killing is represented by the overexpression of immune checkpoints (ICPs). The observation that cancer patients may still display or acquire resistance to immunotherapy despite targeting the PD-1/PD-L1 axis, highlights the importance of other ICPs as potential mediators of immune resistance. In this review, we summarize the immunomodulatory properties of CSCs and comprehensively discuss the crosstalk between these cells and selected ICPs (i.e., B7-H3, B7-H4, CD200 and CD155, VISTA, TIGIT, CD47, CD70, CEACAMs, and galectins) that are thought to be involved in CSC mediated immune evasion. Open questions regarding the immunological profile of CSCs, especially in relation to ICPs expression and their underlying regulatory mechanisms, are also addressed. Improved immunological profiling of CSCs will contribute to the identification of prognostic and predictive biomarkers for cancer patients and the development of effective therapeutic interventions that may lead to the eradication of malignant tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1811aab8b4ff863825064d5f429510095d9edbe9" target='_blank'>
              The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy
              </a>
            </td>
          <td>
            Ola J. Hussein, Menatallah Rayan, Tasnim R. Matarid, Dana Elkhalifa, Hanan H. Abunada, Lubna Therachiyil, Ashraf Khalil, Shahab Uddin, Cristina Maccalli, H. Korashy
          </td>
          <td>2025-11-13</td>
          <td>Journal of Experimental & Clinical Cancer Research : CR</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate under pathological conditions such as cancer, where they contribute to immune evasion, tumor progression, and resistance to therapy. These cells exert potent immunosuppressive effects by inhibiting T cell activation, inducing regulatory T cells, modulating antigen-presenting cells, and shaping an immunosuppressive tumor microenvironment (TME). Their suppressive functions involve multiple mechanisms, including amino acid depletion, production of reactive oxygen and nitrogen species, expression of immune checkpoint ligands, and secretion of immunoregulatory cytokines such as IL-10 and TGF-β. Besides these immune-related roles, MDSCs also promote tumor growth through non-immunological mechanisms, including the stimulation of angiogenesis and undergoing metabolic reprogramming. These adaptations support their survival and function in the hostile TME. Given their multifaceted role in cancer, MDSCs represent a promising target for therapeutic intervention. Furthermore, their abundance and dynamic modulation during treatment confer them tremendous potential as biomarkers to monitor therapy efficacy and stratify patients. This review provides a comprehensive overview of MDSC biology, their mechanisms of action, and their emerging clinical relevance as biomarkers and therapeutic targets. We also explore current strategies aimed at targeting MDSCs, including their depletion, inhibition of recruitment, functional blockade, and promotion of their differentiation into mature myeloid cells. Integrating these approaches with existing cancer therapies holds great promise for enhancing antitumor immunity and overcoming resistance in both solid tumors and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d195f524c3054c9a1106fbc8581ac237b69c234e" target='_blank'>
              Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
              </a>
            </td>
          <td>
            S. Silva-Romeiro, Rocio del, Carmen Flores-Campos, M. L. Sánchez-León, V. Sánchez-Margalet, L. Cruz-Merino, María, Luisa Sánchez-León
          </td>
          <td>2025-11-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Cancers are a risk factor for active tuberculosis (TB), and anti-cancer drugs can independently cause TB progression. To understand the underlying mechanisms, mice infected with Mycobacterium tuberculosis (Mtb) were treated with gemcitabine (Gem), cisplatin, or paclitaxel. These treatments delay Mtb-specific T cell responses, increase bacterial loads, and cause hyperinflammation with permissive neutrophils in the lungs. However, depleting Mtb-permissive neutrophils reduce bacterial levels and G-CSF production, thereby attenuating lung immunopathology. Additionally, Mtb-specific T cell responses generated by BCG vaccination inhibit bacterial growth and neutrophil infiltration even after Gem treatment. Gem induces granulocyte-biased generation in the bone marrow via G-CSF signaling, which led to lung neutrophil inflammation. However, pre-existing Mtb-specific T cell responses from BCG vaccination normalizes granulopoiesis by restricting G-CSF production. These findings show the mechanism of anti-cancer drug-induced neutrophilic lung inflammation in TB and highlight the role of Mtb-specific T cell responses in maintaining balanced hematopoiesis against Gem-induced TB immunopathogenesis. Anti-cancer drugs could independently promote TB progression. Here, the authors show using mouse models, that anti-cancer drug treatments could induce delayed Mtb-specific T cell responses, followed by G-CSF dependent neutrophil manifestation in the lungs, leading to TB exacerbation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8a2b78a64e7e259f4ab9a6f5256f8cca0ff830d" target='_blank'>
              Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis
              </a>
            </td>
          <td>
            Kee Woong Kwon, T. Kang, Jii Bum Lee, Eunsol Choi, Hagyu Kim, Minchul Park, S. Choi, Kyungmin Kim, Hyeong Woo Kim, Su Jin Jeong, H. R. Kim, Sung Jae Shin, Sang-Jun Ha
          </td>
          <td>2025-10-06</td>
          <td>Nature Communications</td>
          <td>1</td>
          <td>17</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related death worldwide. Despite the success of immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1 pathways, a significant number of patients exhibit either primary resistance or acquire resistance over time. While genomic and epigenetic mechanisms contribute to this resistance, increasing evidence points to the pivotal role of immunometabolism—the interface of cellular metabolism and immune regulation. This review focuses on how altered metabolic states in both immune cells and cancer stem-like cells (CSCs) within the lung tumor microenvironment contribute to ICI resistance. We discuss key metabolic pathways involved in immune suppression, the metabolic plasticity of CSCs, and how these factors interact to shape a metabolically hostile tumor niche for immune effector cells. Finally, we explore emerging therapeutic strategies targeting immunometabolism to enhance immunotherapy efficacy in lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1ff0a30d0ef98d677493dbe8ab0f277a0639e63e" target='_blank'>
              Immunometabolic reprogramming in lung cancer: interplay between immune and stem-like cells in immune checkpoint inhibitor resistance
              </a>
            </td>
          <td>
            Ji-Yong Sung, Eui Tae Kim
          </td>
          <td>2025-10-29</td>
          <td>Journal of Translational Medicine</td>
          <td>1</td>
          <td>10</td>
        </tr>

        <tr id="Immunotherapy has emerged as a promising strategy against cancer, but many patients fail to achieve durable responses. Inefficiency of immunotherapy is often caused by the immunosuppressive tumor microenvironment. Previously, we demonstrated that treatment with an FcαRI-stimulating bi-specific antibody (BsAb), designed to recruit myeloid cells as cytotoxic effector cells, significantly decreased tumor growth in a murine cancer model. Nonetheless, complete tumor eradication was not achieved. In this study, we investigated if co-treatment with the pro-inflammatory cytokine TNF-α enhances the therapeutic efficacy of FcαRI BsAb. Although TNF-α did not affect antibody-dependent cellular phagocytosis (ADCP) of tumor cells, macrophage polarization, or antibody-dependent cellular cytotoxicity (ADCC) by natural killer cells, its combination with FcαRI BsAb increased tumor cell trogocytosis, neutrophil degranulation and tumor cell death. To exploit this synergy, we engineered a TNF-α x FcαRI bi-specific immunocytokine (FcαRI-TNF). Surface plasmon resonance and cellular binding assays demonstrated that FcαRI-TNF retained binding affinities for FcαRI, FcɣRIII, and the tumor-associated antigen EGFR comparable to FcαRI BsAb. Consistent with the combination of TNF-α and FcαRI BsAb, FcαRI-TNF neither influenced macrophage function nor polarization but enhanced neutrophil-mediated tumor killing in vitro. Intravital imaging in a murine MC38-cEGFR tumor model showed that FcαRI-TNF promoted in vivo neutrophil activation and swarming behavior. These findings suggest that FcαRI-TNF represents a promising candidate to improve neutrophil-driven immunotherapy of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/daef39666d7e3c31a100539f6ce30c0fe1bb9fb2" target='_blank'>
              TNF-α x FcαRI bi-specific antibody potentiates neutrophil-mediated anti-tumor effects
              </a>
            </td>
          <td>
            D. Y. Gout, C. A. Sewnath, G. Duru, R. van der Mast, C. Tuk, A. Bentlage, M. Gruijs, G. Vidarsson, N. Heemskerk, M. van Egmond
          </td>
          <td>2025-10-03</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a malignant plasma cell tumor. Regulatory T cells (Tregs), key components of the immunosuppressive tumor immune microenvironment (TIME), play a significant role in MM progression. One mechanism of anti-MM activity of anti-CD38 monoclonal antibodies is reducing CD38+ Tregs. Cyanidin-3-O-glucoside (C3G), a natural CD38 inhibitor, effectively suppresses enzymatic activity of CD38. Consequently, we investigated whether C3G could serve as a novel therapeutic agent for MM by targeting Tregs. A MM-bearing mouse model was established and treated with C3G to investigate whether C3G can modulate the TIME for therapeutic effects. Tumor growth was monitored, and changes in peripheral blood lymphocyte subsets were assessed to evaluate the immune-modulating effects of C3G. In addition to that, C3G was applied to Naive CD4+ T cells derived from the peripheral blood of healthy individuals in vitro to verify its impact on level of Tregs. Network pharmacology and RNA sequencing (RNA-seq) were employed to explore the potential mechanisms by which C3G targets Tregs, and validation was performed using real-time PCR. C3G demonstrated therapeutic effects in MM-bearing mice, reducing the proportion of Tregs in peripheral blood while showing no significant effects on T cells, B cells, or NK cells. In vitro studies revealed that C3G’s effects on Tregs were concentration-dependent and capable of reducing Tregs even in the presence of MM cells. Integration of network pharmacology and RNA-seq results suggested that downregulation of granzyme B (GZMB) and upregulation of heme oxygenase 1 (HMOX1) at the transcriptional level are key mechanisms by which C3G influences Tregs. C3G exerts therapeutic effects on MM by reducing the proportion of Tregs and thereby restoring anti-tumor immunity. The mechanism may be related to the decrease of GZMB level mediated by the inhibition of CD38.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e7de6430cc5c55592eb2decaf8b204e233f28658" target='_blank'>
              Cyanidin-3-O-glucoside-mediated reduction of regulatory T cells: a therapeutic strategy for multiple myeloma
              </a>
            </td>
          <td>
            Huixian Chen, K. Fang, Jinbao Zong, Xiaotian Chang
          </td>
          <td>2025-10-08</td>
          <td>BMC Immunology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Introduction Tumor-associated macrophages (TAMs) promote immunosuppression, hindering immune checkpoint blockade and immunotherapy efficacy. To overcome this, we developed a novel multifunctional nanovaccine based on hepatitis B core virus-like particles (HBc VLP) to synergistically remodel the immunosuppressive tumor microenvironment through integrated TAM reprogramming and B7-H3 checkpoint blockade. Methods The core VLP co-displayed tumor antigen peptide MAGE-A10 and TAM-targeting peptide M2pep via fusion expression. Immunostimulatory CpG oligodeoxynucleotide 1826 (CpG) was encapsulated within VLP. Anti-B7-H3 antibody (αB7-H3) and polyethylene glycol (PEG) were chemically conjugated to the surface for checkpoint blockade and prolonged circulation, forming CpG@VLP-αB7-H3-PEG. Results Structural characterization using transmission electron microscopy and dynamic light scattering confirmed the hollow spherical self-assembly of VLP. Nanovaccines efficiently targeted TAMs in vitro and in vivo. Following CpG encapsulation (5.60 µg/mg), the nanovaccine reprogrammed M2-like TAMs into an M1-like phenotype. This was achieved by elevating the M1/M2 ratios of CD86/CD206 and MHC II/CD206 to 15.50-fold and 3.11-fold, respectively, as determined by flow cytometry. Further conjugation of αB7-H3 (250 µg/mg) significantly enhanced T-cell activation in TAM-T cell co-culture assays. In B16-F10 melanoma-bearing mice, reprogrammed iNOS+ M1-like macrophages triggered robust antitumor immunity, achieving a tumor inhibition rate of 63.47%. These macrophages also function as antigen-presenting cells and increase the proportion of tumor-infiltrating Granzyme B+CD8+ T cells. αB7-H3 conjugation further boosted infiltrating immune cells, M1-like macrophages, activated CD69+CD4+/CD8+ T cells, and cytotoxic T lymphocytes. PEGylation amplified systemic tumor-specific immunity and increased tumor inhibition by 80.12%. Conclusion This HBc VLP-based nanovaccine constitutes a pioneering multifunctional platform designed to overcome TAM-mediated immunosuppression through synergistic integration of three modalities: antigen presentation, TAM phenotype reprogramming, and B7-H3 checkpoint blockade. To the best of our knowledge, this is the first nanovaccine architecture to enable coordinated immunomodulation. Its modular design supports the clinical translation of solid tumors and personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b26fad415e7667975cc7d27803dcdbb589e0756" target='_blank'>
              Multifunctional HBc Virus-Like Particles Reprogram Immunosuppressive Macrophages and Potentiate CD8+ T Cell Responses for Enhanced Cancer Immunotherapy
              </a>
            </td>
          <td>
            Shuntao Liang, Xiaoxuan Yin, Yongjie Chi, Keyue Wang, Li Ma, Zhuo Yang, X. Xue, Shoucheng Wang, K. Zhao, Lianyan Wang, Juan Ma
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="ABSTRACT Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Macrophages are highly plastic immune cells that adopt diverse functional states in response to the local microenvironment. The traditional M1/M2 polarization model that has long been used to describe macrophage activation is insufficient to capture the full spectrum of macrophage diversity observed in vivo. Advances in single-cell RNA sequencing (scRNA-seq) have revealed that macrophages exist in a continuum of transcriptional states formed by tissue-specific and disorder-specific cues. This insight has led to the recognition of disorder-specific macrophages, defined as macrophage subpopulations that emerge in response to pathological stimuli and play unique roles in disease progression. These macrophages exhibit distinct transcriptional signatures, epigenetic modifications, and functional properties shaped by their ontogeny and microenvironmental signals, arising from the reprogramming of resident macrophages or the differentiation of bone marrow–derived progenitors. Notable examples include macrophages in chronic infections (e.g., tuberculosis), immunosuppressive tumor-associated macrophages, lipid-associated macrophages in obesity, and disease-associated microglia in neurodegeneration. These subsets exhibit unique regulatory mechanisms, including enhancer remodeling driven by histone H3 lysine 27 acetylation in non-alcoholic steatohepatitis, CCAAT enhancer binding protein α-mediated differentiation in obesity, and Jmjd3-IRF4 axis control in allergic inflammation. Additionally, their function and fate are strongly influenced by their subtissular niche, as evidenced by crown-like structures in adipose tissue, tumor microenvironments, fibrotic lesions, and granulomas, where distinct microenvironmental cues shape macrophage behavior. Furthermore, interindividual heterogeneity in macrophage function, driven by genetic polymorphisms, is increasingly recognized, highlighting the role of host genetic background in disease susceptibility and macrophage-driven pathology. Here, we review the conceptual evolution of the disorder-specific macrophage, tracing its origins from the limited M1/M2 model to its refinement through scRNA-seq-based classification. We summarize the ontogeny, transcriptional regulation, and spatial heterogeneity of these macrophages across various disorders, emphasizing how the subtissular niche dictates functional specialization. Finally, we discuss potential therapeutic strategies targeting disorder-specific macrophage subsets, highlighting the need for integrative multi-omics approaches to refine their classification and functional characterization. Understanding the regulatory networks that govern disorder-specific macrophages will advance our knowledge of macrophage biology while facilitating the development of precision medicine for immune-related disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9feef19310b98a25e6e67c81bcaeb9daa262ec04" target='_blank'>
              Functional diversity of disorder-specific macrophages involved in various diseases
              </a>
            </td>
          <td>
            Yuichi Mitsui, Takashi Satoh
          </td>
          <td>2025-10-01</td>
          <td>Inflammation and Regeneration</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="Immunotherapy is currently effective in less than half of patients with solid tumors, and most responders develop secondary progression. High infiltration of the tumor microenvironment (TME) with CD8+ cytotoxic T cells (CTLs) and low infiltration with regulatory T cells (Treg) predicts the patients’ responses to immunotherapy and long-term outcomes. To identify the mechanisms regulating long-term stability of CTL infiltration, we analyzed the impact of CTL-produced cytokines on the TME by co-culturing patient-isolated ascites cells with activated T cells. Unexpectedly, we observed that activated CTLs selectively induce cytotoxic T cell-attracting chemokines but not chemokines that attract T regulatory cells in ovarian cancer TME and tumor-associated myeloid cells, resulting in recruitment of additional CTLs without Tregs. This selectivity resulted from the unique dependence of CCL22 induction on both canonical and alternative NF-κB and the suppression of alternative NF-κB signaling by T cell-released IFNγ. Our data demonstrate that T cell-produced IFNγ suppresses alternative NF-κB signaling in TME-associated myeloid cells, allowing for the induction of CTL-attracting chemokines with the concomitant suppression of Treg-attracting CCL22. These novel functions of IFNγ and activated T cells in regulating the balance between canonical and alternative NF-κB signaling in myeloid cells provide new opportunities to enhance and stabilize the selective CTL influx in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5a5a14adab24415a821ab9194596f9d27a53e37" target='_blank'>
              IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells
              </a>
            </td>
          <td>
            Adam Brinkman, Ravikumar Muthuswamy, Bowen Dong, Robert P Edwards, Pawel Kalinski
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e655b3f34a47917eb0c1eab5cc8dbd65bd366140" target='_blank'>
              P2RY2 is a purinergic immune checkpoint linking extracellular ATP to immune evasion and adaptive resistance to immunotherapy
              </a>
            </td>
          <td>
            Zhaoqing Hu, Hitoshi Matsuo, Shangce Du, Cecilia Berzain Battioni, L. Jassowicz, Rafael Carretero, Melanie Sator-Schmitt, Xiyue Zhao, Beiping Miao, Cansu Eris, Helena Engel, Mohamed A.A. Mahmoud, Elke Laport, Yanling Xiao, Ilse Hofmann, Christel Herold-Mende, Chong Sun
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Cells of the innate immune system, particularly natural killer (NK) cells, serve as the first line of defense against tumor development and play a critical role in antitumor immunity. Characterizing the immune cell pool and its functional state is essential for understanding immunotherapy mechanisms and identifying key cellular players. However, defining NK cell populations in mice, the primary model for cancer immunotherapy, is challenging due to strain-specific marker variability and the absence of a universal NK cell marker, such as human CD56. This study evaluates surface markers of NK and other peripheral blood immune cells in both humans and mice, associating these markers with specific functional profiles. Bioinformatic approaches are employed to visualize these markers, enabling rapid immunoprofiling. We explore the translational relevance of these markers in assessing immunotherapy efficacy, including their gene associations, ligand interactions, and interspecies variations. Markers compatible with rapid flow-cytometry-based detection are prioritized to streamline experimental workflows. We propose a standardized immunoprofiling strategy for monitoring systemic immune status and evaluating the effectiveness of immunotherapy in preclinical and clinical settings. This approach facilitates the design of preclinical studies that aim to identify predictive biomarkers for immunotherapy outcomes by monitoring immune status.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c056c4312c009fdcdac0c3dbc8561a4799333a4b" target='_blank'>
              Translational Insights into NK Immunophenotyping: Comparative Surface Marker Analysis and Circulating Immune Cell Profiling in Cancer Immunotherapy
              </a>
            </td>
          <td>
            Kirill K. Tsyplenkov, Arina A. Belousova, M. V. Zinovyeva, Irina Alekseenko, V. Pleshkan
          </td>
          <td>2025-09-30</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Adoptive T cell therapies (ACT) have revolutionized the management of hematologic malignancies; however, their efficacy in solid tumors remains limited. Accumulating evidence implicates the tumor microenvironment (TME) - a highly complex and immunosuppressive niche as a major barrier to their effectiveness. In this review, we propose that the next generation of ACT will require a fundamental shift from a reductionist focus on T cell engineering alone to an integrated approach that considers the interactions between immune cells and the TME. A comprehensive literature review identified several emerging strategies to enhance the efficacy of ACT, including reprogramming tumor vasculature, repolarizing immunosuppressive myeloid and stromal cells, leveraging oncolytic viruses to remodel antigen presentation, inducing acute sterile inflammation, and targeting the physical properties of the extracellular matrix. While many of these approaches remain in early-stage development, some have already progressed to clinical trials, indicating their potential for clinical translation. Additionally, we found that conventional therapies, such as surgery, chemotherapy, and radiotherapy, can be strategically integrated with ACT to improve therapeutic outcomes. These findings highlight a shift in the field toward more integrative approaches. Future advances will likely depend on reprogramming the TME to support T cell persistence and functions. Addressing these interconnected challenges will require closer collaboration between immunology, oncology, and bioengineering disciplines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5845940292899bbb8a96147c6b79326179c978e6" target='_blank'>
              Reprogramming the tumor microenvironment to boost adoptive T cell therapy
              </a>
            </td>
          <td>
            Maria Fernanda Meza Pacheco, Lee-Hwa Tai
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9df59581d16bbc7c53120355c1f9a6d0a14f9300" target='_blank'>
              The Role of Inflammation in CMML Pathobiology and Progression
              </a>
            </td>
          <td>
            Niraj Neupane, E. Padron
          </td>
          <td>2025-10-09</td>
          <td>Current Hematologic Malignancy Reports</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Background Despite the notable success of programmed death ligand 1 (PD-L1)/programmed death 1 (PD-1) immune checkpoint blockade in cancer, resistance remains a substantial challenge. Combining immune checkpoint blockade with direct targeting of effector T cells to tumor cells might improve outcome for a broader spectrum of patients with cancer. Phosphoantigen-responsive Vγ9Vδ2-T cells are potent immune cells that play a pivotal role in tumor immunosurveillance and can coordinate downstream immune activity. Here, we explored whether a Vδ2 bispecific T cell engager (bsTCE) directed against PD-L1 could combine lysis of PD-L1+ tumor cells with PD-L1 immune checkpoint blockade. Methods PD-L1 specific single domain antibodies (VHHs) were tested for binding to PD-L1 and their ability to interfere with PD-1 binding and function. One PD-L1 VHH was selected for fusion to a Vδ2-T cell receptor specific VHH (PD-L1xVδ2 bsTCE) and tested for its ability to activate Vγ9Vδ2-T cells and lyse melanoma cell lines, as well as patient-derived renal cell carcinoma (RCC) and metastatic melanoma cells. These patient-derived tumor suspensions were also used to explore effects on CD4+ and CD8+ T cells and myeloid cells. Infiltration of Vγ9Vδ2-T cells and tumor kill was tested in a three-dimensional tumor spheroid melanoma model. Results A PD-L1xVδ2 bsTCE was generated and shown to block PD-1 binding resulting in the release of PD-1+ cells from PD-L1 mediated inhibition. The PD-L1xVδ2 bsTCE also mediated robust Vγ9Vδ2-T cell activation, efficient lysis of RCC and melanoma cell lines and/or patient-derived tumor cells, and infiltration of Vγ9Vδ2-T cells into a three-dimensional melanoma spheroid model. Of interest, exposure of co-cultures of Vγ9Vδ2-T cells and patient-derived tumor suspensions to the PD-L1xVδ2 bsTCE resulted in upregulation of activation markers on tumor-infiltrated CD4+ and CD8+ T cells and lysis of PD-L1+ myeloid cells with a shift in the myeloid compartment from macrophage-like cells to more mature dendritic cells with costimulatory molecule expression. Conclusions A PD-L1xVδ2 bsTCE was generated that acts as PD-1/PD-L1 immune checkpoint inhibitor, enhances Vγ9Vδ2-T cell activation, infiltration and tumor lysis and reshapes the tumor microenvironment towards a more proinflammatory state. By targeting both PD-L1 expressing tumor and myeloid cells, it addresses key challenges of current therapies and thereby offers a promising novel therapeutic strategy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45e254ff0cd2f6e1d2390b4f7c4c0ffff07130de" target='_blank'>
              PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment
              </a>
            </td>
          <td>
            L. King, Myrthe Veth, Marieke Roos, George L Scheffer, Marko A Popovic, Tanja D de Gruijl, H. J. van der Vliet
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Mesenchymal stromal cell (MSC) transplantation has achieved significant clinical benefits for many diseases, such as systemic lupus erythematosus (SLE) and inflammatory diseases. However, the detailed therapeutic mechanism of MSCs is not fully understood. Here, in the SLE treatment, we show that MSC transplantation triggers recipient bone marrow neutrophil aggregation to generate an endogenous extracellular vesicle (EV) storm in the circulation via the TNFα/ICAM-1/Rab11b axis. Interestingly, blockade of the EV storm abolishes the MSC-mediated therapeutic effect for SLE. The level of EV storm is positively associated with the therapeutic effect of MSCs in SLE patients. Mechanistically, aggregated neutrophils-derived EV storms equalize Th17 and T-regulatory (Treg) cells to promote immune tolerance and disease remission via the DHA/LILRB4/STAT5/STAT3 pathway in the MSC treatment for SLE. Taken together, our findings reveal a new immune-modulating function of MSCs through the induction of endogenous neutrophil aggregation in the bone marrow, which results in the secretion of EV storms for immune tolerance in SLE mice and patients. In addition, this study revealed a previously unknown role of the recipient EV storm in determining the therapeutic effect of MSC in SLE, and the recipient EV storm can be used to predict the therapeutic efficacy of MSCs in SLE therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/95b613d65045593441abfdbbf4cbbb2a0630d4f2" target='_blank'>
              Mesenchymal stromal cells induce neutrophil aggregation and extracellular vesicle storms for systemic lupus erythematosus
              </a>
            </td>
          <td>
            Qianmin Ou, L. Niu, Dandan Wang, Genhong Yao, Qianhui Ren, Zhengshi Li, Xueli Mao, Wei Teng, Zetao Chen, Andy Peng Xiang, Songtao Shi, Lingyun Sun
          </td>
          <td>2025-10-13</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Mesenchymal stem/stromal cells (MSCs) have shown significant therapeutic effects in a range of autoimmune and hyperinflammatory diseases through their strong immunomodulatory properties, both in animal models and clinical settings. Exposure to inflammatory cytokines is crucial for MSCs to acquire immunoregulatory functions; however, the detailed mechanisms underlying this process remain largely unexplored. MSCs with pharmacological inhibition or genetic knockout of poly ADP-ribose polymerase1 (PARP1) were treated with the inflammatory factors IFNγ and TNFα for 24 h. The mRNA and protein expression of chemokines and immunosuppressive molecules were detected by qRT-PCR and Western blotting, respectively. The therapeutic efficacy of MSCs was evaluated using a mouse concanavalin A-induced acute liver injury model and a dextran sulfate sodium-induced inflammatory bowel disease model. The phosphorylation of signal transducer and activator of transcription 1 (STAT1) was analyzed in activated MSCs, and STAT1 inhibition through either a STAT1 inhibitor or STAT1 knockout was employed to confirm the role of STAT1 in enhancing the immunoregulatory function of MSCs during PARP inhibition. PARP inhibition or genetic knockout of PARP1 further enhanced the immunoregulatory function of MSCs elicited by inflammatory cytokines IFNγ and TNFα, as evidenced by the upregulation of genes associated with immunoregulation in MSCs, augmentation of immunosuppressive functions of MSCs on T cells, and increased therapeutic effects of MSCs in mouse models of autoimmune and hyperinflammatory diseases. PARP inhibition was further shown to enhance the expression of immunosuppressive factors in primed MSCs through increased phosphorylation at the tyrosine 701 site on STAT1. Our study indicates that like its pro-inflammatory role in macrophages, PARP also functions to undermine the immunosuppressive effects of MSCs, and PARP inhibition represents a strategy to further unleash the immunoregulatory power of MSCs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/081fa2fccf2feefb290399606b252a37b5badd68" target='_blank'>
              PARP inhibition augments immunomodulatory function of mesenchymal stem/stromal cells by promoting STAT1 phosphorylation
              </a>
            </td>
          <td>
            Tingting Wang, Ya-nan Li, Jinyi Tian, Guofu Sun, Tingting Yang, Zhenzhen Meng, Wen Li, Xiao Su, Rui Liu, Pi-dong Gong, Lijuan Cao, Chao Feng, Dongyan Zhao, Peishan Li, Yufang Shi, Jiankai Fang, Changshun Shao
          </td>
          <td>2025-10-08</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="ABSTRACT Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Regulatory T cells (Treg cells or Tregs), a subset of CD4⁺ T cells with immunosuppressive properties, are essential for immune homeostasis and self-tolerance. Characterized by their immunosuppressive capabilities and reliance on the transcription factor Foxp3 (Forkhead box protein P3), Tregs employ multiple mechanisms, including cytokine secretion, metabolic control, and cell contact inhibition, to restrain excessive immune activation to prevent autoimmunity while maintaining tissue repair processes. However, dysregulation in their frequency or function—whether deficiency or hyperactivity—is implicated in diverse pathologies, spanning autoimmune disorders, cancer progression, transplant rejection, and emerging associations with neurological and cardiovascular diseases. Thus, Treg-targeted strategies represent a promising approach for restoring immune balance under various conditions. This review synthesizes current knowledge on Treg biology, from their discovery and definition of markers to their new regulatory mechanisms. We further explore the roles of Tregs across diseases, emphasizing their context-dependent therapeutic potential. Strategies to deplete or inhibit Tregs in cancer immunotherapy contrast with approaches to expand or stabilize their function in autoimmunity and transplantation. However, challenges persist, including achieving tissue-specific targeting, ensuring the functional stability of engineered Tregs, and minimizing off-target effects. By integrating mechanistic insights with translational innovations, this review provides a roadmap for advancing Treg-based therapies, ultimately aiming to restore immune equilibrium in a disease-specific manner.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4664303d5c8731e32a24c5f6aff938bbbbb96dc7" target='_blank'>
              Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
              </a>
            </td>
          <td>
            Lingling Wang, Ying Liang, Chunxia Zhao, Peijun Ma, Shulin Zeng, Dongen Ju, Minggao Zhao, Min Yu, Yun Shi
          </td>
          <td>2025-10-14</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>2</td>
          <td>7</td>
        </tr>

        <tr id="Memory T cells endow the mammalian host with an essential form of adaptive immunity that generates durable and rapid protection following re-exposure to an infectious pathogen or a cancerous transformation1–4. How naive CD8⁺ T cells develop into memory T cells that bifurcate into long-lived central (TCM) versus effector (TEM) subsets after such an antigen encounter remains ill-defined at the molecular level. To address this gap, here we dissect the functional T-cell receptor (TCR) repertoire of 242 murine CD8⁺ TCRαβ clonotypes specific for the peptide-major histocompatibility complex molecule (pMHC) comprising an immunodominant influenza A virus (IAV) oligopeptide epitope NP366–374 presented by H-2Db 5,6. Using single-cell transcriptomics with TCR sequencing, biophysical measurements of force-dependent TCR-pMHC interactions, in vivo memory development, and structural analyses, we integrate these data to define relationships between signaling polarity and memory fate. We find that TCM and TEM polarities are reflected in distinct subunit-related mechanotransduction biases: TCM-associated TCRs favor TCRβ-driven pMHC engagement, whereas TEM-associated TCRs preferentially favor TCRα-driven pMHC engagement. Moreover, “bipolar” clonotypes (TBP) capable of generating both memory subsets exhibit more balanced signaling, the largest average clonal expansions, and broadest heterosubtypic crossreactivities. By contrast, variegated TCM TCR sequences foster mostly clonal singlets with the greatest IAV mutant recognition potential within the overall memory repertoire, thus revealing two complementary memory niche crossreactivity strategies. Weak, force-sensitive TCR bonds are pervasive for this entire repertoire, being most conspicuous amongst TCM clonotypes. At the atomic level, highly nuanced variation in TCRαβ bonding to either peptide and/or MHC modulates mechanical load transmission across the holoreceptor’s ectodomains, transmembrane segments, and CD3 cytoplasmic tails to differentially influence downstream tyrosine phosphorylation and memory development. Collectively, TCR diversity anticipates epitope-specific pathogen evolution, whereas divergent TCR signaling regulates memory fate with implications for adoptive T-cell immunotherapies seeking to maximize persistence and minimize functional exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47c5e8a658084ff1675ec010b34b843ae8e69de3" target='_blank'>
              Atomistic TCR-ligand interactions instruct memory T-cell differentiation
              </a>
            </td>
          <td>
            A. Akitsu, Kemin Tan, R. J. Mallis, Matthew A. Booker, J. Duke-Cohan, K. Brazin, Evan H Kirkpatrick, Andrew N. Parkins, Sarita Aryal, V. Cinella, Jonathan J Lee, Kaveri I. Uberoy, Jenna K. Koenig, Matthew Biddle, Cameron M. Messier, P. Lizotte, M. Tolstorukov, Wonmuk Hwang, Matthew J Lang, Ellis L. Reinherz
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Chimeric antigen receptor T cell (CAR-T) is the main salvage therapy for relapsed or refractory large B-cell lymphoma (r/r LBCL). However, over 50% of patients relapse after CAR-T therapy. In this work, we transduced the CAR gene into hematopoietic stem cells (HSCs) using a lentiviral vector. Chimeric antigen receptor-modified HSC (CAR-HSCs) were transplanted into mice after lethal irradiation. CAR gene transduction did not compromise the ability of HSCs to expand, self-renew, or reconstitute. CAR was expressed on T cells, natural killer cells, B cells, monocytes, and neutrophils in the peripheral blood. CAR-HSCs transplantation significantly reduced CD19+ tumor burden and prolonged the survival of mice with preclinical tumor without severe toxicity. CAR-HSCs also differentiated into different CAR-expressing immune cells that reshaped the tumor microenvironment by increasing the proportion of antitumor cells (like CD8+ T cells) and the antitumor response, and by decreasing immunosuppressive cells, such as tumor-associated macrophage subtype 2. This study demonstrated a preclinical proof-of-principle for CAR-HSCs therapy in r/r LBCL, suggesting an opportunity for its clinical translation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/699a2afcf60d13e0d7c490646a6df52053b04045" target='_blank'>
              Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice
              </a>
            </td>
          <td>
            Tao Wang, Ping Liu, Dongliang Zhang, Zhiqiang Song, Mingyang Yu, D. Feng, Xuejun Yu, Na Liu, Gusheng Tang, Jianmin Yang
          </td>
          <td>2025-10-22</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In this study, we demonstrate through RNA sequencing and flow cytometry analyses of acute myeloid leukemia (AML) cell lines and primary patient samples that BCMA is also a relevant AML-associated antigen. Its robust surface expression on AML cells positions it as a promising candidate for targeted immunotherapy. Functionally, our findings indicate that BCMA in AML operates similarly to its role in MM – engaging the NF-kB pathway upon ligand binding, thereby activating gene expression programs that support leukemia cell survival and proliferation. We assessed several BCMA-targeted immunotherapeutic strategies, including bispecific T-cell engagers (TCE) and chimeric antigen receptor (CAR) transduced T-cells, NK-cells, and macrophages. We found that TCE treatment and BCMA CAR engineering markedly improved effector cell mediated cytotoxicity against AML cells, underscoring BCMA’s potential as a viable therapeutic target in AML. Furthermore, BCMA- directed TCE therapy significantly augmented the anti-leukemic activity of adoptively transferred CD8+ T-cells in a human AML xenograft model. Taken together, these findings support BCMA as a novel immunotherapeutic target in AML. Leveraging existing BCMA-directed treatments developed for MM could enable rapid clinical translation and broaden immunotherapy options for patients with AML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/436fa158d1ac2800e0090f3db5638326935534d4" target='_blank'>
              B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia
              </a>
            </td>
          <td>
            Ashley Varkey, Manpreet Bariana, Mark Batistick, John Church, Elena Cassella, Shaina A. Anuncio, Shabnam Samimi, Alexander J Vallone, Zephyr Hameem, Sarvarinder K. Gill, James McCloskey, Yiming Chen, Ming Tan, M. Albitar, Benjamin Tycko, Kar F Chow, Giuditta Mantile-Selvaggi, David S Siegel, Johannes L Zakrzewski
          </td>
          <td>2025-10-24</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies but faces significant challenges in solid tumor therapy. The tumor microenvironment (TME) of solid tumors, including the dense extracellular matrix (ECM) and immunosuppressive factors, creates physical and biochemical barriers that hinder CAR-T cell infiltration, function, and persistence. Despite advances in CAR-T cell engineering, overcoming these TME barriers remains a major obstacle. The ECM in solid tumors restricts CAR-T cell penetration and limits their antitumor efficacy. Recent studies have explored ECM modulation as a strategy to enhance CAR-T therapy. Nattokinase (NKase), a natural fibrinolytic enzyme, has shown potential in degrading ECM components, promoting TME remodeling, and improving therapeutic responses. In this study, we evaluate the therapeutic efficacy of NKase in combination with MSLN-targeted CAR-T cells for solid tumors. We hypothesize that NKase will reduce tumor fibrosis by degrading ECM components, facilitating CAR-T cell infiltration and enhancing their cytotoxic activity. In vitro and in vivo experiments will assess the effects of NKase on CAR-T cell infiltration, activation, memory phenotype maintenance, and antitumor activity. This study aims to optimize CAR-T therapy for solid tumors and supports the clinical potential of NKase as an adjunctive therapeutic agent.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ffa57177469f0ff558649a171c513941cf5b51e" target='_blank'>
              Nattokinase-driven remodeling of tumor microenvironment enhances the efficacy of MSLN-targeted CAR-T cell therapy in solid tumors
              </a>
            </td>
          <td>
            Lianfeng Zhao, Yan Zhang, Xinhao Yang, Tianyu Chen, Jiaqi Liu, Zhi-Cheng Guo
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e8782e43d5a359ec11f1397979fbb249cbe9fbe7" target='_blank'>
              Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
              </a>
            </td>
          <td>
            Alexandre Marraffa, C. Berrevoets, Margherita Mosiello, R. Wijers, Daphne Roelofs, Mandy van Brakel, Kim Kroese, Marlies J. W. Peeters, Wim Dik, A. Kunert, Rachel Judith Mary Abbott, Dora Hammerl, C. Schliehe, R. Debets
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Exosomes, nanoscale extracellular vesicles secreted by various cell types, play pivotal roles in intercellular communication. In cancer, tumor-derived exosomes—referred to as cancer-derived exosomes (CDEs)—have emerged as critical regulators of immune evasion, tumor progression, and therapy resistance within the tumor microenvironment (TME). CDEs modulate immune cell function through the transfer of immunosuppressive proteins, cytokines, and non-coding RNAs, ultimately reprogramming immune surveillance mechanisms. This review provides an in-depth analysis of how CDEs influence major immune cell subsets—including T cells, B cells, NK cells, dendritic cells, macrophages, and myeloid-derived suppressor cells—thereby establishing an immunosuppressive TME. We also explore the potential of immune cell-derived exosomes (IDEs) as emerging immunotherapeutic tools capable of counteracting the suppressive effects of CDEs. Furthermore, we highlight exosome engineering strategies aimed at improving therapeutic cargo delivery, tumor targeting, and antitumor immune activation. Finally, we discuss how exosome profiling offers promise in liquid biopsy diagnostics and how integration with 3D tumor models and advanced bioengineering can accelerate the clinical translation of exosome-based cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eae1e39741f5db67d36338284089286232d39875" target='_blank'>
              Cancer-derived exosomes: mediators of immune crosstalk and emerging targets for immunotherapy
              </a>
            </td>
          <td>
            Ridwan Mahamed, Bernice Monchusi, Clement Penny, S. Mirza
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Abstract Background Chimeric antigen receptor (CAR) T cells targeting CD19 achieve remarkable remissions in refractory B cell malignancies, yet deleterious side effects such as cytokine release syndrome (CRS) limit their broader application. Current preclinical assays on manufactured cell products do not predict human clinical function. We hypothesized that variability in the CAR proximal protein interaction networks that mediate CAR signal transduction may correlate with patient-to-patient differences in toxicity. Methods Using banked, preinfusion 41BB–CD3ζ CAR T cell products with known clinical outcomes, we applied quantitative multiplex co-immunoprecipitation (QMI) to profile ∼200 binary interactions among 21 key signaling proteins following CD19 stimulation. Bioinformatic analysis clustered interactions into functional modules, and correlated protein interaction patterns with clinical outcomes. Results Correlation network analysis, which clusters interactions into coregulated modules, identified a stimulation-responsive module with similar behavior in all products, and a second module that correlated with the presence of CRS. The CRS module was enriched for interactions among CD28, FYB, and the SRC family kinases LCK and FYN. In a head-to-head validation cohort, a similar CD28–FYB–kinase module again correlated with the presence of CRS. Using a combined dataset, a machine learning classifier trained on top QMI features retrospectively identified CRS samples with high accuracy. Conclusions These data indicate that subtle, batch-to-batch differences in CAR signalosome assembly may correlate with CRS, and they support the further development of a preinfusion proteomic assay to forecast CRS risk in CAR T cell products.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/17efcf9a76f9233541576eecccf77b8453a7d369" target='_blank'>
              CD28 signaling complexes are correlated with patient outcomes in anti-CD19 41BB-costimulation CAR T cell therapy
              </a>
            </td>
          <td>
            Isabella Draper, William Selke, Samuel A. Ritmeester-Loy, Felicia Harsh, Colleen Annesley, Corinne Summers, Rebecca Gardner, Wooyoung Kim, Stephen Smith
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent challenges. Unlike tolerance, differentiation, or priming, trained immunity relies on epigenetic and metabolic rewiring of resident myeloid cells, particularly in mucosal barriers such as the skin, gut, and lungs, where these cells provide continuous protection against toxins and pathogens. Here, we review recent advances showing how an initial stimulus endows monocytes and macrophages with long-lasting functional changes that can be either protective or maladaptive upon re-exposure. We highlight therapeutic opportunities that harness trained immunity to boost vaccine efficacy and discuss strategies to modulate this program in cancer and hyper-inflammatory disorders. Finally, we propose new directions for enhancing or dampening trained immunity to promote human health.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57f6e83421893f19b268537080a2332361f2582c" target='_blank'>
              Innate immune memory: The evolving role of macrophages in therapy
              </a>
            </td>
          <td>
            Payal Damani-Yokota, Kamal M. Khanna
          </td>
          <td>2025-11-14</td>
          <td>eLife</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b5bcb6ae407b6468805f3b43958f785ac3821d33" target='_blank'>
              Inhibition of neutrophil degranulation by Nexinhib20 delays the development of radiation-induced pulmonary fibrosis
              </a>
            </td>
          <td>
            Stefanie Ruhland, Konstantina Nikolatou, Victoria Bridgeman, Tatiana Rizou, E. Sahai, Jayanta Bordoloi, Emma Nolan, Alberto Elosegui-Artola, I. Malanchi
          </td>
          <td>2025-10-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Multidrug transporters, including multidrug resistance-1 (MDR1), are recognized chiefly for effluxing chemotherapeutic drugs out of tumor cells. However, they are also expressed in many normal cells and tissues, including lymphocytes, but their physiological role is less well-understood. Here, we investigated the role of MDR1 in tumor-specific CD8 T cells (TST), which are critical in antitumor immunity and key targets of immunotherapies. Using a clinically-relevant genetic liver cancer mouse model, we investigated the efflux dynamics of TST as they underwent activation, proliferation, and differentiation to dysfunctional states in tumor-bearing hosts. Surprisingly, we found that late-stage/terminally dysfunctional TST had the highest efflux capacity in both murine and human liver tumors. TST upregulated transcription of Abcb1a, encoding MDR1. We used CRISPR/Cas9 to generate MDR1-deficient TST, which persisted poorly in tumor-bearing mice as compared to MDR1-sufficient TST. MDR1 expression improved TST viability and reduced reactive oxygen species accumulation. Loss of MDR1 made T cells more susceptible to cytotoxic chemotherapy-induced cell death. Our findings demonstrate a role for MDR1 in regulating TST persistence and oxidative stress, with implications for antitumor T cell therapies in patients and immune regulation following cytotoxic chemotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec8ea28c3a73d8bccee752af246eb06ea28bc890" target='_blank'>
              MDR1 promotes CD8 T cell persistence in tumors and protects against cytotoxic chemotherapy
              </a>
            </td>
          <td>
            Lincoln A. Brown, Megan M. Erwin, Natalie R Favret, Claudia N. McDavid, Jessica J Roetman, Zachary D. Ewell, Melissa M. Wolf, Kristen A Murray, Jack E. Smithwick, Marti A. Goemann, Mary Philip
          </td>
          <td>2025-09-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Adoptive cell therapy (ACT) employing chimeric antigen receptor (CAR) engineering represents a transformative advancement in cancer immunotherapy. CAR-T cell therapies have demonstrated significant clinical success in hematological malignancies, yet their application to solid tumors faces persistent challenges. Key limitations include the paucity of tumor-specific antigens, poor intratumoral infiltration, immunosuppressive tumor microenvironment (TME), and treatment-related toxicities such as cytokine release syndrome (CRS) and neurotoxicity. In contrast, CAR natural killer (CAR-NK) cells show promise in solid tumors such as ovarian, pancreatic, and glioblastoma, with encouraging preclinical and early clinical evidence, although limited persistence and antigen heterogeneity remain major challenges. Unlike CAR-T cells, CAR-NK therapies mediate tumor clearance through both cytotoxic (e.g., granzyme/perforin release) and cytokine-mediated mechanisms while mitigating toxicity risks. Their lack of human leukocyte antigen (HLA) dependency enables “off-the-shelf” manufacturing from allogeneic donors, circumventing patient-specific production bottlenecks. CAR-macrophage (CAR-M) therapies further address solid tumor barriers by leveraging innate phagocytic clearance, antigen-presenting functions, and TME penetration. Macrophages inherently infiltrate hypoxic tumor regions and remodel stromal barriers, enabling CAR-Ms to synergize with adaptive immunity by cross-priming T cells. Preclinical models highlight CAR-M efficacy in depleting immunosuppressive tumor-associated macrophages (TAMs) and reversing TME-driven immune evasion. Emerging CAR- Gamma-Delta T (CAR-γδ T) cell therapies combine CAR-mediated antigen specificity with the intrinsic tumoricidal activity of γδ T cells, which recognize stress-induced ligands independently of major histocompatibility complex (MHC) presentation. This dual-targeting capability enhances tumor selectivity while reducing on-target/off-tumor toxicity. This review systematically examines cellular sources, mechanistic advantages and clinical progress. By evaluating these platforms’ complementary strengths, we propose rational strategies for integrating CAR-NK, CAR-M, and CAR-γδ T cells into tailored therapeutic regimens for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/16660cddda122d54c3120ac509cae2db5d21a2e3" target='_blank'>
              Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy
              </a>
            </td>
          <td>
            Yingjie Hou, Shihua Hu, Chong Liu, Xin Chen, Yuru Wang, Youzherui Li, Zihe Fu, Chunjing Feng, Yanhua Gong, Zichuan Liu, Shouchun Peng
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="The tumor microenvironment in breast cancer is typically immunosuppressive. Combined neoadjuvant chemotherapy and immunotherapy is the standard of care for high-risk, triple-negative breast cancer patients, but it is not routinely applied to other breast cancer subtypes. Somatic mutation of STK11 (serine/threonine kinase 11), a tumor suppressor, occurs in the MSK-IMPACT platform in 1.9% of 3116 breast cases. A potential link between inactivation of STK11 and immune response regulation has been suggested in breast cancer, but the impact of STK11 suppression on tumor–immune interactions remains under investigation. In this study, we established Stk11-knockout (Stk11-KO) mouse breast cancer cell lines, performed RNA sequencing and cytokine array analysis to assess alterations in gene expression and cytokine profiles. Our results revealed significant enrichment of several immune-related pathways and a marked increase in C-X-C motif chemokine ligand 1 (Cxcl1) expression in response to Stk11 knockout. Moreover, analysis of breast cancer patient samples showed an inverse association between the plasma CXCL1 levels and STK11 expression. To evaluate the in vivo effects of STK11 loss, we established an orthotopic breast cancer model in immunocompetent female mice. Tumors derived from Stk11-KO mouse breast cancer cells demonstrated greater tumorigenicity. In addition, mice-bearing Stk11-KO tumors exhibited elevated levels of circulating polymorphonuclear myeloid-derived suppressive cells. In summary, STK11 suppression enhances immune-related pathways and promotes Cxcl1 expression, correlating with the expansion of immunosuppressive MDSC populations. Our findings suggest that targeting STK11-associated immunosuppressive mechanisms may provide a novel therapeutic option for STK11-deficient breast cancer patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c31d86f908d14d37e2803389cd1c9e71bee4f15b" target='_blank'>
              Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer
              </a>
            </td>
          <td>
            Tzu-Hui Wei, Chi-Che Hsieh, Zhu-Jun Loh, Wei-Pang Chung, Kuo-Ting Lee, Yi-Ling Chen, Hui-Ping Hsu, Che-Hung Shen
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="B7 homolog 3 (B7-H3, CD276) has emerged as a promising target for chimeric antigen receptor (CAR) T cell therapy, with limited expression in normal tissues and high level cell-surface expression across various tumor types. Clinical studies are ongoing, with a focus on pediatric cancers. As an immune checkpoint molecule of the B7-CD28 family, B7-H3 has a proposed immune-modulatory role, though the precise nature of B7-H3-mediated cell interactions and functional contributions to immune responses are contradictory and likely context-dependent. Within tumors, B7-H3 is expressed also on non-tumor cell types in the tumor microenvironment (TME), including myeloid immune cells, endothelial cells of abnormal vasculature and cancer-associated fibroblasts. Consequently, CAR T cells directed against B7-H3 will not only target tumor cells but also components of the TME, which will affect the nature and outcome of B7-H3-targeted therapeutic immune responses. Here we review the expression of B7-H3 protein in pediatric solid tumors and in various cell types known to infiltrate the TME of solid tumors. On this background, we discuss the potential of B7-H3-targeted CAR T cells to reshape the TME and the key challenges and future directions to improve B7-H3-targeted CAR T cell therapy for pediatric patients with solid cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/649b83099536525155f2e82b6d45425c1ee80892" target='_blank'>
              B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
              </a>
            </td>
          <td>
            Lena Jansen, J. Wienke, Ronja Molkenbur, Claudia Rossig, Ramona Meissner
          </td>
          <td>2025-10-11</td>
          <td>Cancer Metastasis Reviews</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Therapy-induced senescence (TIS) generates an immunogenic state in cancer cells by altering how they present antigens, produce cytokines, and organize their surfaceome. TIS can be exploited for therapeutic purposes using “immunosenolytic” strategies, including adoptive cellular therapies such as chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells. A frequently overlooked barrier may limit the success of these living drugs: mitochondrial apoptotic priming in the target TIS cancer cells. Contrary to the prevailing dogma, recent assessments of mitochondrial apoptotic signaling via BH3 profiling (a functional assay measuring proximity to the mitochondrial apoptotic threshold and identifying BCL-2 family dependencies) have revealed that TIS cancer cells are globally less primed for apoptosis than their proliferating precursors. TIS cancer cells exhibit a conserved, druggable dependence on specific members of the BCL-2 family for survival. Interestingly, the pre-existing priming and anti-apoptotic addictions of parental, non-senescent cells, are retained upon induction of senescence. This suggests an “inherited” mitochondrial memory that may predict the (immuno)senolytic responsiveness of TIS cancer cells. BH3 profiling could help to personalize CAR-based immunosenolytic therapy according to apoptotic readiness across pre- and post-TIS states. This companion diagnostic could inform the rational use of BH3 mimetics in combination with CARs and guide the engineering of precision immunosenolytic interventions such as “armored” CAR-T/NK cells neutralizing specific anti-apoptotic dependencies at the effector-target interface. This perspective reframes mitochondria as predictive checkpoints that can be monitored and targeted to enable TIS cancer cells to respond precisely and durably to adoptive CAR-T/NK immunotherapy within “one-two punch” senogenic-immunosenolytic designs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d448509a34a438cbd0714844d26b75b81a37d50" target='_blank'>
              Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy
              </a>
            </td>
          <td>
            Javier A. Menendez, Ruth Lupu, B. Martín-Castillo, Josep Sardanyés, Tomás Alarcón, S. Verdura, E. Cuyás
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="Megakaryocytes (MKs) have traditionally been viewed as terminal hematopoietic cells responsible solely for platelet production. However, recent advances in imaging and single-cell transcriptomics have revealed substantial heterogeneity among MK populations and diverse functions beyond thrombopoiesis. MKs actively participate in innate and adaptive immunity, modulate the hematopoietic stem cell (HSC) niche, and adapt to physiological and pathological stimuli. Located in distinct anatomical sites such as bone marrow and lung, MKs exhibit compartment-specific specializations that enable them to serve as critical integrators of hemostatic, immune, and regenerative processes. Experimental models using human pluripotent stem cells and inducible MKs have enhanced mechanistic insights, while innovative bioreactor platforms and xenotransplantation strategies advance translational applications in platelet production and therapy. Furthermore, immune MK subsets derived from pluripotent stem cells show promising therapeutic potential for modulating inflammation and autoimmune diseases. Continued exploration of MK diversity, tissue-specific roles, and intercellular communication will unlock new opportunities for leveraging MK plasticity in regenerative medicine, immunotherapy, and hematologic disorders, repositioning these versatile cells as central players in systemic homeostasis and defense.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a42ed6c49b37f5e87fc8596501cc105433a716fc" target='_blank'>
              Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects
              </a>
            </td>
          <td>
            Seungjun Kim, Kiwon Lee
          </td>
          <td>2025-10-27</td>
          <td>Cells</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0e9995149be3f5f4e294cf956aefcac608aaab2" target='_blank'>
              Mesenchymal Stromal Cells Immunosuppress Osteoarthritis Synovial Fluid Tolerized Monocytes via IL-6
              </a>
            </td>
          <td>
            M. Rasti, A. Barazandeh, K. Robb, Rachel Low, R. Gandhi, Sowmya Viswanathan
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that develop in non-lymphoid organs under pathological conditions of chronic inflammation, such as cancer, autoimmune diseases, chronic infections, organ transplantation, and age-related disorders. TLSs produce various cytokines and chemokines, and orchestrate local adaptive immune responses by serving as sites for antigen presentation. TLSs have attracted significant attention because of their multifaceted roles in various diseases. However, the diversity in cellular composition, development, and maturation of TLSs, depending on the disease context and organ, makes it challenging to fully understand their characteristics. Several basic and clinical studies have demonstrated the clinical and pathophysiological roles of TLSs, revealing both their protective and harmful effects. In cancer, TLSs generally activate anticancer immune responses, leading to the suppression of tumor growth. Additionally, they contribute to host defense against pathogens in infectious diseases. Conversely, they can provide a niche for autoantibody production, exacerbating autoimmune diseases and chronic rejection in transplanted organs. In age-related diseases, they may prolong tissue inflammation and hinder tissue repair. The pathophysiological significance of TLSs has prompted the development of therapeutic strategies that target their formation and maturation. However, their potential systemic immunological effects must be carefully considered. Recent advances in single-cell omics technologies have facilitated a deeper understanding of the diverse cellular components of TLSs and their cell–cell interactions, which may contribute to the development of TLS-specific therapies. The fact that TLSs can only be identified using invasive diagnostic methods remains a barrier to further research. Advances in artificial intelligence-driven pathology diagnostics and improvements in imaging technologies for noninvasive detection are expected to accelerate TLS research. Categorizing various conditions with TLSs as 'TLS-related diseases' could deepen our understanding of TLS pathophysiology and lead to the development of novel therapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d68ec50d653bb294f0085e58df7b58caa3d717c9" target='_blank'>
              The roles of tertiary lymphoid structures in orchestrating immune responses in peripheral organs
              </a>
            </td>
          <td>
            Keisuke Taniguchi, Takahisa Yoshikawa, M. Yanagita
          </td>
          <td>2025-09-30</td>
          <td>Inflammation and Regeneration</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Despite the tremendous amount of basic knowledge in cancer immunity gained and many transitional approaches attempted, current cancer immunotherapies are still far from reaching universal effectiveness. Therefore, next‐generation cancer immunotherapies would emerge from deepened mechanistic insights on the full spectrum of cellular and molecular interactions between cancer cells and their immune sentinels. This review embarks on an exhaustive exploration of the cardinal immunological principles that catalyze robust cancer surveillance and their potential escapes and recapitulate the state‐of‐art understanding of both receptors and corresponding immune cell types involved. Both tumor intrinsic and tumor microenvironmental mediators of immune escapes are outlined in the context of current clinic applications. Following emphasizing the exceptional requisites that effective cancer immunity cycle must meet, specific cellular subsets crucial for igniting tumor immunity, notably effector and helper T cells alongside antigen presentation cells are examined, focusing on their close interactions in both antigen‐dependent and ‐independent manners. Such intricate interactions form dynamic immune hubs at the tumor site, holding promising key functionality in rendering effective cancer retreat. Grounded on these recent insights, refined immunotherapeutic strategies, especially those bolstering priming based anticancer effector functions are advocated.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f990253e887853735c5cfb22dba0a88f9cacde71" target='_blank'>
              Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
              </a>
            </td>
          <td>
            Ying Peng, Linsheng Zhan, Jianxiang Shi, Jie Wang, Yueying Li, Xiangdong Sun, J. Lv, Huiyu Yang, Zan Qiu, Xingzhao Liu, Chenyan Li, Shanshan Gong, Wen Jia, Huiying Wang, Yuqi Zhao, Bin Zhang, Wei Guo, Jiancheng Guo, Jian Shang, Qianqian Zhou, Yanan Yang, Feng Gao
          </td>
          <td>2025-10-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML), characterized by aggressive relapse and dismal survival, remains a formidable challenge despite conventional therapies. Chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells have emerged as groundbreaking immunotherapies, offering targeted eradication of leukemic stem cells (LSCs) and resistant blasts. CAR-T cells, leveraging antigens like CD123 and CD33, demonstrate early clinical success, with complete remission rates up to 66% in refractory/relapsed (R/R) AML. CAR-NK cells complement this approach through inherent tumor surveillance, reduced toxicity, and "off-the-shelf" feasibility. However, barriers such as antigen escape, heterogeneous immunosuppressive microenvironments (including intratumoral microbiota variations), and on-target/off-tumor toxicity persist, limiting durable responses. Innovations in dual-targeting CARs, cytokine-armored constructs, and CRISPR-edited universal cells aim to overcome these hurdles. Emerging strategies integrating checkpoint inhibitors, metabolic modulators, and AI-driven antigen selection promise to enhance efficacy and safety. This review synthesizes the evolving landscape of CAR-T/NK therapies, critically analyzing preclinical breakthroughs, clinical trial outcomes, and persisting challenges. By addressing manufacturing scalability, cost barriers, and long-term safety, cellular immunotherapy holds transformative potential to redefine AML management. As the field advances, interdisciplinary collaboration and biomarker-guided personalization will be pivotal in translating laboratory innovations into life-saving therapies for AML patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/720fe9b2689649cb5f5e1100d54436fd6a133f8a" target='_blank'>
              CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future
              </a>
            </td>
          <td>
            Huichao Wu, Fatemeh Sadat Shafiei, Z. Taghinejad, Mohsen Maleknia, Hanieh Noormohamadi, Atieh Raoufi, Sina Nouri, Nazli Servatian, Hamed Soleimani Samarkhazan
          </td>
          <td>2025-10-23</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20f65e1524ffb4190a28bef066a656c7fa921b4e" target='_blank'>
              B-cell Follicles in the Secondary Lymphatic Tissues Act as a Critical Microanatomical Niche for Sustained Viral Replication, Virus-host Interaction and Damage During Chronic SIV Infection of Rhesus Macaques
              </a>
            </td>
          <td>
            Yilun Cheng, Miaoyun Zhao, Jackson Chen, Subhra Mandal, , Qingsheng Li
          </td>
          <td>2025-11-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cda9104b6dcba78728f099ec4f0c6e0fcb044ff6" target='_blank'>
              LCK deficiency in CD8 T cells leads to reduced proliferation and increased effector T-cell formation in mice
              </a>
            </td>
          <td>
            Valeria Uleri, Vojtech Racek, Marta Popovic, Anna Morales Mendez, Veronika Niederlova, Arina Andreyeva, Juraj Michalik, N. Woessner, Michaela Krupkova, R. Sedláček, Susana Minguet, Ondřej Štěpánek
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="The tumor microenvironment (TME), comprising malignant and non-transformed cells like immune cells, endothelial cells, and cancer-associated fibroblasts, significantly affects tumor growth and progression. Tumor cells manipulate the TME by releasing chemokines and inhibitory cytokines, reprogramming surrounding cells to support their survival and evade immune detection. Innate immune cells within the TME play dual roles, either promoting or inhibiting tumor progression, impacting immunotherapy outcomes. Recent studies highlight the influence of innate immune cells in shaping the TME and the pivotal role of tumor-derived microRNAs (miRNAs) in modulating these cells. miRNAs regulate gene expression and enhance tumor immune evasion, angiogenesis, drug resistance, and invasion. Their tumor-specific expression patterns suggest potential as biomarkers and therapeutic targets. This study focuses on how miRNAs affect innate immune cells like macrophages, dendritic cells, myeloid-derived suppressor cells, and natural killer cells, contributing to immunosuppressive or immunogenic environments. Understanding miRNA-mediated interactions between cancer and immune cells opens new possibilities for improving targeted immunotherapy and advancing cancer treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e85aa9b654355b3e4b7e9a3784ef3b6054fa10e" target='_blank'>
              Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells
              </a>
            </td>
          <td>
            Bahar Naseri, Amirhossein Mardi, N. Shekari, Neda Shajari, Samin Abdolzadeh, Hossein Khorramdelazad, Amirhossein Hatami-Sadr, Milad Taghizadeh Anvar, Mohammad Reza Javan, Amirhossein Heibatollahi, Javad Masoumi, Farid Ghorbaninezhad, B. Baradaran
          </td>
          <td>2025-10-04</td>
          <td>BioImpacts</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Abstract Tumor-associated macrophages (TAMs) are a heterogeneous population of immune cells that play a pivotal role in the tumor microenvironment (TME) of lung cancer. TAMs, which include both monocyte-derived macrophages (MDMs) and tissue-resident macrophages (TRMs), exhibit distinct functions that influence tumor progression, metastasis, and response to therapy. Recent studies have highlighted the spatiotemporal heterogeneity of TAMs, with MDMs primarily promoting tumor growth and immune suppression, while TRMs contribute to tissue homeostasis but can be reprogrammed to support tumor progression. Both subtypes contribute to the formation of an immunosuppressive TME, facilitate tumor metastasis through matrix remodeling, and contribute to therapeutic resistance by modulating the efficacy of chemotherapy, radiation therapy, and immunotherapy. Understanding the specific roles and heterogeneity of MDMs and TRMs as components of TAMs in lung cancer opens avenues for targeted therapies, such as inhibiting their recruitment, reprogramming their polarization, or blocking their pro-tumorigenic functions. This review synthesizes current knowledge on TAMs in lung cancer, highlighting their dual roles and the potential for developing novel therapeutic strategies that target these macrophages to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a6e2f9f46ddfaa767b71c9b54ed7074ef5a63bbe" target='_blank'>
              Tumor-Associated Macrophages in Lung Cancer: Origins, Functional Heterogeneity, and Therapeutic Implications
              </a>
            </td>
          <td>
            Yeqing Tao, Jian Xiao, Yafang Li, Aiping Zou
          </td>
          <td>2025-10-01</td>
          <td>Journal of Inflammation Research</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Although significant progress has been made in medicine and antimicrobial research, viral infections continue to pose a critical global health challenge, particularly when they involve the central nervous system (CNS). Despite advances in vaccines, antiviral agents, and small molecule therapeutics, current strategies remain insufficient to address the complex consequences of many CNS infections fully. Notably, many viruses are neurotropic and can invade the CNS, triggering infectious neuroinflammation that often lead to chronic neurological disorders and lasting morbidity. Current therapeutic approaches are largely ineffective in preventing or reversing this long-term neurological damage, underscoring the urgent need for innovative prophylactic and therapeutic interventions. Mesenchymal stem cells (MSCs) have emerged as a promising strategy to counteract chronic neuroinflammation and promote tissue repair following viral CNS infections. This review provides a comprehensive overview of CNS viral infection and neuroinflammation, including epidemiology and pathophysiology, and critically examines the limitations of existing treatments, particularly their inability to mitigate persistent neurological sequelae. Furthermore, we summarize recent preclinical and clinical studies investigating the use of MSCs in the context of CNS viral infections, highlighting their immunomodulatory and neuroprotective mechanisms, and discuss the challenges and future directions for MSC-based therapies in clinical settings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d447f8a5f5315a00659815e4909ede391b25e17" target='_blank'>
              Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair
              </a>
            </td>
          <td>
            Javier Carbone-Schellman, Javiera Fontecilla-Escobar, Nicolás Sales-Salinas, William F. Chaparro-Pico, Alfredo Molina-Berríos, M. C. Ruete, Pablo A. González, Mayra A. Machuca, Ma. Cecilia Opazo, Marcelo E. Ezquer, Luisa F. Duarte
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="CD8+ T lymphocytes are central effectors of anticancer immunity. Their abundance and spatial distribution within solid tumors are strongly correlated with patient prognosis and response to immune-checkpoint inhibitors (ICIs). Tumors have been categorized into “hot,” “excluded,” and “cold” types based on the infiltration patterns of CD8+ T cells, which reflect the underlying immune contexture and therapeutic potential. However, many tumors remain resistant to T-cell infiltration, posing a significant barrier to immunotherapy. This review systematically outlines the seven critical steps of the Cancer-Immunity Cycle that govern CD8+ T-cell infiltration: antigen release, antigen processing and presentation, T-cell priming, trafficking through the vasculature, tumor infiltration, target recognition, and cytolytic activity. At each step, tumor-intrinsic and microenvironmental barriers—including low tumor mutational burden, defective antigen-presenting machinery, immunosuppressive cytokines (e.g., TGF-β, IL-10), abnormal vasculature, fibroblast-derived extracellular matrix, and inhibitory cell populations (e.g., Tregs, MDSCs, TAMs)—can stall the immune response. We further discuss the roles of immune-checkpoint signaling, metabolic competition, and suppressive cell networks in shaping T-cell exhaustion and exclusion. Cutting-edge technologies—such as single-cell RNA-sequencing, spatial transcriptomics, imaging mass cytometry, and TCR repertoire profiling—have revealed spatial and functional heterogeneity within intratumoral CD8+ T cells and informed the design of rational combination therapies. Understanding and targeting these barriers is critical for converting immune-cold tumors into immune-infiltrated, therapy-responsive states. We conclude with a perspective on the future of immunoengineering and immune-atlas integration to optimize CD8+ T-cell–based interventions in solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efa77bd4c813b73b425c3c8514e6eec6c6ede00f" target='_blank'>
              Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment
              </a>
            </td>
          <td>
            Ouyang Peng, Jianhong Zhang, Xiao He, Congcong Yang, Dingcheng Zeng, Daofeng Xu
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="Abstract 2B4 (CD244), the fourth member of the signaling lymphocyte activation molecule (SLAM) family, is expressed by virtually all human and murine hematopoietic lineages and functions as a context-dependent activating or inhibitory receptor. This review provides a comprehensive update on the gene organization, molecular architecture, glycosylation patterns, and alternatively spliced isoforms of 2B4, highlighting how these structural variables dictate ligand (CD48) affinity and downstream signaling outcome. The roles of 2B4 in natural killer (NK) cells, CD8+ T cells, dendritic cells, myeloid-derived suppressor cells, B cells, eosinophils, and basophils were then systematically demonstrated, emphasizing their dual capacity to either potentiate cytotoxicity and cytokine production or enforce immune tolerance and exhaustion. Mechanistically, the balance between SLAM-associated protein (SAP)-mediated activation and SHP-1/2/SHIP-driven inhibition emerges as a central rheostat that is dynamically tuned by SAP availability, and the microenvironment. Clinically, exaggerated 2B4 signaling is associated with viral persistence in MCMV, HCV, HIV, and SARS-CoV-2 infections, promotes tumor immune escape in melanoma, multiple myeloma, and head-and-neck cancer, and compromises maternal–fetal tolerance, whereas insufficient signaling weakens antimicrobial immunity. Parallel pre-clinical studies validate 2B4 blockade as a rational combinatorial strategy to reinvigorate exhausted CD8+ T and NK cells, while soluble CD48 emerges as a dynamic biomarker of disease activity. Collectively, these insights redefine 2B4 as a systems-level integrator of immune homeostasis and a tractable precision-immunotherapy node whose therapeutic manipulation can rebalance immunity across infection, cancer, and pregnancy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aeb93edeb7f4fdb97573b8eb3ea11ac0695f270e" target='_blank'>
              2B4/CD244 Signaling in Immune Regulation and Its Role in Infection, Cancer, and Immune Tolerance
              </a>
            </td>
          <td>
            Chao Yan, Peng Lu, Yuzhu Jiang, Shu Miao, Lichun Zhao, Xiaoyan Xu
          </td>
          <td>2025-10-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="The gut microbiome and its metabolites are critical regulators of intestinal homeostasis, with emerging evidence highlighting their influence on humoral immune responses and vaccine efficacy. The development of effective humoral immunity depends on the magnitude and quality of germinal centers (GCs), which are driven by follicular T helper (Tfh) cells. Here, we investigate the role of short‐chain fatty acids (SCFAs) in shaping humoral immunity, with a particular focus on Tfh cells. In ex vivo assays, we found that sodium butyrate, not sodium acetate or sodium propionate, directly suppresses Tfh cells differentiation and helper functions. Using antigen‐specific and influenza virus infection models, we further demonstrate that sodium butyrate impairs Tfh cell differentiation, leading to diminished GC B cell responses and compromised humoral immunity during systemic infection. Notably, mice treated with sodium butyrate succumbed to virus infection, underscoring its effect on impairing protective immunity. Mechanistically, our findings reveal that sodium butyrate mediates these suppressive effects on Tfh cells via histone deacetylase (HDAC) inhibition. Together, our findings establish sodium butyrate as a negative regulator of humoral immunity by directly suppressing the Tfh‐cell differentiation and Tfh‐derived GC responses. These insights provide a mechanistic link between gut microbiome‐derived metabolites and humoral immunity, with potential implications for vaccine efficacy and therapeutic interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad0621066f9656ea06370b6413e5bbc50ed7d207" target='_blank'>
              Short‐Chain Fatty Acid Sodium Butyrate Suppresses Protective Humoral Immunity by Inhibiting Follicular T Helper Cell Differentiation
              </a>
            </td>
          <td>
            Bhushan Nikam, Someshwar Nath Jha, Yatish Thakare, P. Coshic, Nimesh Gupta
          </td>
          <td>2025-10-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="
 The tumor immune microenvironment plays a critical role in tumor progression and responses to immunotherapy. Nevertheless, its cellular complexity and heterogeneity remain incompletely understood. In this study, we employed high-resolution single-cell RNA sequencing on CD45+ immune cells isolated from ten syngeneic murine tumor models, representing seven distinct cancer types under treatment-naïve conditions, thereby enabling a comprehensive profiling of tumor-infiltrating immune cells. We identified seven principal immune cell populations and provided an in-depth characterization of T cells, NK/innate lymphoid cells, dendritic cells, monocytes/macrophages, and neutrophils. Cross-species analyses further delineated conserved immune cell states and transcriptomic features within the T cell and monocyte/macrophage compartments that are shared across syngeneic models and human tumors. To investigate the functional relevance of the predominant monocyte/macrophage compartment and the notable presence of neutrophils in syngeneic tumors, we evaluated responses to anti-PD-1 therapy across various models and analyzed the enrichment of monocyte/macrophage subsets in tumors that responded to treatment. Furthermore, we conducted neutrophil depletion experiments using anti-Ly6G antibodies, administered both as monotherapy and in combination with PD-1 blockade. Remarkably, an interferon-stimulated gene-high (ISG
 high
 ) monocyte subset was significantly enriched in models responsive to anti-PD-1 therapy. Neutrophil depletion resulted in variable antitumor effects across models but failed to enhance the efficacy of PD-1 blockade. In summary, our single-cell profiling offered a detailed atlas of the immune microenvironment across multiple syngeneic mouse tumor models, thereby enabling rational model selection for immuno-oncology studies. We uncovered an ISG
 high
 monocyte subset enriched in anti-PD-1 responsive models, and showed the context-dependent effects of neutrophil depletion on tumor immunity and immunotherapy, underscoring the heterogeneity and functional divergence of immune cell sublineages.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f925e5b4fe351a72672a38a0505d78e0be84e52" target='_blank'>
              Single-cell atlas of the tumor immune microenvironment across syngeneic murine models
              </a>
            </td>
          <td>
            Jia Wang, Bin Jiang, Minjuan Deng, Han Yan, Peilin Zhang, Wei Jin, Zhirong Shen
          </td>
          <td>2025-11-14</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Simple Summary Autoimmune diseases happen when the immune system attacks the body’s own tissues, causing chronic inflammation and damage. Macrophages, a type of immune cell, can either fuel inflammation or promote healing. They communicate with other cells through tiny packages called exosomes, which carry proteins and genetic signals. Exosomes from inflammatory macrophages can worsen tissue damage, while those from healing macrophages help calm inflammation and repair tissues. Research in conditions like rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, and psoriasis shows these dual roles. Scientists are now exploring how to use macrophage exosomes as targeted therapies, either harnessing naturally healing exosomes or engineering them to deliver treatments. Understanding and applying this system could lead to safer, more precise, and personalized treatments, improving patient outcomes and reducing side effects from conventional drugs. Abstract Autoimmune diseases result from dysregulated immune responses that mistakenly attack the body’s own tissues, causing chronic inflammation and progressive damage. Macrophages, with their remarkable plasticity, play key roles in both promoting and resolving inflammation, with pro-inflammatory M1 and anti-inflammatory M2 states shaping disease outcomes. Macrophage-derived exosomes have emerged as important mediators of intercellular communication, reflecting the functional state of their parent cells while influencing recipient cell behavior. Exosomes from M1 macrophages amplify inflammation through cytokines and microRNAs, whereas M2-derived exosomes support tissue repair and immune regulation. Studies in rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, and psoriasis highlight their dual roles in pathology and resolution. In addition, macrophage exosomes can be engineered to deliver targeted therapeutic molecules, offering cell-free interventions with advantages in specificity, biocompatibility, and immunomodulation. This review summarizes current insights into macrophage-derived exosomes, their role in autoimmune pathogenesis, and emerging strategies to harness their therapeutic potential, highlighting their promise as precision-guided treatments for autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3edc816b764e90d140606f27c0294f3df653118" target='_blank'>
              Polarized Macrophages and Their Exosomes: Implications for Autoimmune and Immune-Mediated Diseases
              </a>
            </td>
          <td>
            Vincent G. Yuan
          </td>
          <td>2025-10-01</td>
          <td>Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The tumor microenvironment of epithelial ovarian cancer (EOC) malignant ascites remains incompletely characterized, particularly regarding CD8+ T lymphocyte differentiation and metabolic adaptations. This study investigated these characteristics and their relationship with estrogen receptor (ER) expression in 40 treatment-naïve EOC patients. Matched ascitic fluid and peripheral blood samples underwent comprehensive multicolor flow cytometric analysis to evaluate programmed death-1 (PD-1) expression, differentiation subset distribution, and mitochondrial functional parameters. CD8+ T lymphocytes demonstrated substantial enrichment among the lymphocyte population in ascitic fluid (27.9 ± 2.0%) compared to peripheral blood (13.1 ± 1.3%, p < 0.0001), accompanied by elevated PD-1 expression (62.4 ± 2.9% versus 40.9 ± 2.1%, p < 0.0001). Effector memory populations (Tem) predominated within ascites (67.9 ± 2.8%), indicating chronic antigenic exposure. Mitochondrial functional assessment revealed a distinctive metabolic phenotype: despite preserved mitochondrial mass, ascitic CD8+ T lymphocytes exhibited significantly reduced mitochondrial calcium (Rhod-2 positivity: 44.7 ± 3.8% versus 68.2 ± 4.5%, p < 0.0001) and reactive oxygen species (MitoSOX positivity: 18.7 ± 2.2% versus 28.9 ± 3.0%, p = 0.0287). Notably, ER-positive tumors (≥ 50% immunohistochemical expression) correlated with reduced frequency of CD8+ T cells among lymphocytes (22.1 ± 2.2% versus 32.5 ± 2.9%, p = 0.0040) and decreased PD-1 expression (55.7 ± 3.4% versus 74.5 ± 2.5%, p = 0.0003), while maintaining elevated mitochondrial mass (MTG positivity: 77.3 ± 2.8% versus 43.4 ± 6.9%, p < 0.0001). These findings indicate ascitic CD8+ T lymphocytes undergo metabolic reprogramming characterized by minimized mitochondrial stress, potentially representing an adaptive survival mechanism within the hostile ascitic microenvironment. The differential immune phenotypes associated with ER expression suggest distinct immune evasion strategies requiring tailored therapeutic approaches. This comprehensive characterization provides critical insights for developing personalized immunotherapeutic strategies incorporating metabolic modulation and hormone receptor status stratification.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1520938f2b260d71c90b4da7e51f988e444d6bc4" target='_blank'>
              Differentiation and mitochondrial metabolic characteristics of CD8+ T cells in malignant ascites of epithelial ovarian cancer and their correlation with estrogen signaling
              </a>
            </td>
          <td>
            Zouyu Jiang, Ying Zhou, Jiajuan Wu, Yu Shen, Danni Tang, Yuhong Wu, Qiuxia Qu, Juan Wang
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Tumor-associated myeloid populations contribute significantly to immunosuppression and treatment resistance in glioblastoma (GBM). While the pro-tumorigenic influence of tumor-associated neutrophils (TANs)—including their role in promoting angiogenesis, immunosuppression, and immune checkpoint expression—is well documented, their potential anti-tumoral functions remain insufficiently investigated.



 This study employed CT2A syngeneic murine models of GBM to investigate the immunological and oncological consequences of systemic neutrophil depletion. Anti-Ly6G antibodies were administered intraperitoneally to selectively eliminate circulating neutrophils. Tumor progression was monitored through in vivo bioluminescence imaging (IVIS), while immune profiling was conducted using flow cytometry on samples from the brain, blood, and spleen.



 Over a 21-day period, IVIS imaging revealed signficantly elevated radiance in neutrophil-depleted mice relative to controls, indicating enhanced tumor burden (mean radiance fold-change: 2.7; p = 0.042). Kaplan-Meier analysis showed that neutrophil-depleted animals had significantly shortened survival (median: 19 vs. 24 days; log-rank p = 0.0058). Importantly, this reduction in survival was not observed in neutrophil-depleted mice lacking tumors, suggesting that the neutrophil effect is context-dependent within the GBM tumor microenvironment (TME). Flow cytometric analysis confirmed effective peripheral neutrophil depletion, with CD45⁺Ly6G⁺CD11b⁺ cells reduced from 3.1% to 0.03% (p < 0.001). Additionally, a trend toward reduced brain-infiltrating CD8⁺ T cells was observed in the absence of neutrophils (p = 0.0553).



 Our findings present one of the first reported pre-clinical evidence that TANs may exert protective, anti-tumoral effects within the GBM TME. Neutrophil depletion not only accelerated tumor progression and impaired survival but also disrupted immune equilibrium in the brain. These data support a paradigm shift in which TANs may be leveraged or reprogrammed as therapeutic agents in future GBM immunotherapies. Continued investigation is warranted to delineate the molecular basis of TAN plasticity and their potential role in reshaping anti-GBM immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/225247f6ba2e8abda8f3fd79dd3a30a5922e4a2d" target='_blank'>
              TMIC-43. Tumor-Associated Neutrophils: A Double-Edged Sword in Glioblastoma Progression
              </a>
            </td>
          <td>
            Matthew A Abikenari, John Choi, Ravi Medikonda, Lily H Kim, Rohit Verma, Andrew Tran, Shreyas Annagiri, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d337f9005b90e93fdf29316d67b193863ed97ca" target='_blank'>
              CAR T-cells dysfunction in the central nervous system is mediated by BBB-induced activation-induced cell death
              </a>
            </td>
          <td>
            Yarden Aharony-Tevet, O. Ravid, A. Yanir, Amilia Meir, Hadar Levi, Daniel Burstein, Aviya Amram, Tamar Feuerstein, S. Izraeli, Itzik Cooper, E. Jacoby
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b55c35cb06dbcb951b8f88a8b1249e1f91df0097" target='_blank'>
              Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance
              </a>
            </td>
          <td>
            A. Alsugair, Abhishek Mangaonkar
          </td>
          <td>2025-09-26</td>
          <td>Current Hematologic Malignancy Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Melanoma, the deadliest form of skin cancer, poses a significant challenge due to its genetic heterogeneity and high metastatic potential. While cytotoxic T cell (CTL)‐based immunotherapies have made remarkable progress in recent years, the therapeutic potential of natural killer‐(NK) cells is increasingly recognized. However, resistance mechanisms to both CTL‐ and NK‐cell‐mediated immunotherapies hinder effective treatment. To evaluate the exclusive role of NK‐cells in anti‐melanoma immunity, we performed 2D and 3D co‐culture‐based cytotoxicity assays under varying conditions. Our findings revealed a protective phenotype in melanoma cells following prolonged exposure to primary NK‐cells. By combining experimental data with bioinformatic analyses, we identified key genes and pathways involved in melanoma cell adaptation to NK‐cell‐mediated killing (NKmK). We found that cytokines such as IFNγ play a major role in suppressing NKmK with MHC II surface expression being a critical factor. Targeting the master regulator CIITA, which governs MHC II expression and is affected by IFNγ, significantly reduced melanoma cell resistance to NKmK. This study provides potential strategies to overcome resistance to NK‐cell‐based immunotherapies and offers novel insights into melanoma immune escape mechanisms.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5764eda312a5162e966ee86f3fed7809fb2be1df" target='_blank'>
              The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity
              </a>
            </td>
          <td>
            Lena C M Krause, Rixa-Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski
          </td>
          <td>2025-10-13</td>
          <td>Molecular Oncology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Faust Akl et al. revealed in Nature a paradigm-shifting mechanism distinct from myeloid-driven immunosuppression, whereby glioblastoma induces T-cell apoptosis via tumor-derived IL-11, prompting astrocytes to reprogram into immunosuppressive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)+ effectors, thereby establishing astrocytes as active immunomodulators. Therapeutically, herpes simplex virus type 1 (HSV-1) (anti-TRAIL) achieves a dual therapeutic effect, offering novel strategies to overcome glioblastoma (GBM)'s evasion tactics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3ee38de781ba115c0898771e91e1d944adf21efa" target='_blank'>
              Beyond Passive Bystander: Glioblastoma-Educated Astrocyte Suppressing T Cell.
              </a>
            </td>
          <td>
            Yuan-Yuan Wang, Weilin Jin
          </td>
          <td>2025-10-31</td>
          <td>Frontiers in bioscience</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Inflammatory bowel diseases (IBD) are chronic and disabling disorders of the gastrointestinal tract of unknown aetiology, in which the pathologic process is triggered by multiple environmental and genetic factors that activate an excessive innate and adaptive immune response against luminal antigens. In recent years, great progress has been made in the identification of factors/mechanisms underlying the amplification of the key immune steps in IBD tissue, and this has facilitated the development of several immune-related biotherapeutic compounds that have largely improved the management of the more severe forms of IBD. However, nearly half of these patients are refractory or intolerant to novel immunotherapeutics, indicating the need for further characterization of the IBD-associated detrimental immune response to develop new therapeutics. In this article, we review the available evidence about the contribution of innate and adaptive immune cells in the development of intestinal tissue damage. We also discuss the more recent findings in the field of IBD-associated immunity, which might help identify novel pathways to be manipulated for therapeutic purposes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b7b190e1b8ec42bfa8e93bf0546dde85c456255" target='_blank'>
              Fundamental and emerging insights into innate and adaptive immunity in inflammatory bowel diseases
              </a>
            </td>
          <td>
            Giovanni Monteleone, Carlo Calisi, S. Salvatori, I. Marafini
          </td>
          <td>2025-10-21</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Ferroptotic tumor therapy is of highly significance to treat malignancies. Nevertheless, immune cells within the tumor immune microenvironment (TIME) are particularly susceptible to ferroptosis upon exposure to ferroptotic inducers, leading to the immunosuppression of TIME. In the present work, we report a dual activation strategy to initially pre-activate the T cells within TIME using genetically engineered cytolysin A-expressing outer membrane vesicles (OMVs) to enhance the interferon-γ (IFN-γ) production. We then deliver the homologous tumor cell membrane-hybridized liposomal nanovesicles containing arachidonic acid (MLipoAA) to the tumor cells for IFN-γ-potentiated ferroptosis. The combination treatment of OMVs and MLipoAA results in significant tumor destruction in colon CT26 tumor xenografts. This approach is also effective in combating tumor recurrence and metastasis. Mechanistically, the produced IFN-γ synergizes with arachidonic acid to trigger Acsl4-mediated tumor ferroptosis. The present work provides prominent immunopotentiations followed by selective tumor ferroptotic strategy with high effectiveness and biocompatibility, presenting a robust therapeutic strategy to conquer the immunosuppression drawback during in vivo ferroptotic therapy. Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5ea8aabf479b70bf359a2e32d2d9662ee7569509" target='_blank'>
              Pre-activation of T cell immunity potentiates ferroptotic cell death through arachidonic acid hybridized nanovesicles
              </a>
            </td>
          <td>
            Qi Lyu, Chang Liu, Shaoyue Li, Dandan Shan, Hong Han, Liying Wang, Huixiong Xu
          </td>
          <td>2025-11-18</td>
          <td>Journal of Nanobiotechnology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR) T cells are genetically modified T cells expressing CARs, initially developed to recognize tumor antigens and kill cancer cells that evade T-cell recognition. Because of their impressive success in hemato-oncologic malignancies, CAR T cells are being repurposed with redesigned constructs for safety and sustained efficacy to target refractory systemic autoimmune or neurologic diseases. The CD19 CAR T cells—targeting those CD19-positive, antibody-secreting, long-lived plasma cells, and plasmablasts—are now extensively explored in refractory neuroautoimmunities with promising benefits based on case series in patients with myasthenia gravis (MG), stiff person syndrome (SPS), neuromyelitis, myositis, and multiple sclerosis; some patients with MG and SPS with steadily progressive and disabling disease refractory to all available therapies, including rituximab and new biologics, exhibit impressive clinical improvements with long-lasting benefits. The review, triggered by these early results and ongoing trials, addresses what these cells are and why they show effectiveness not only in antibody-mediated B-cell neurologic diseases unresponsive to available anti–B-cell agents but also in patients with nonpathogenic antibodies, implying effects even beyond B cells; points out that CARs are “living cells” penetrating physiologic barriers, such as the blood-brain barrier, expanding within tissues to memory cells ensuring sustained effects; describes the process and challenges of preparing and administering CAR T cells and their safety profile stressing the differences in toxicities when treating autoimmunites vs malignancies; and highlights that CD19 CAR T cells can successfully target even 2 different autoimmune diseases in the same patient, such as SPS and MG, offering promising prospects of changing the therapeutic algorithm in all neuroautoimmunities with potential for achieving even an immune reset shifting immunity to a healthy state.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd2a9057315f8f06c14943c25efd07aeced41fbc" target='_blank'>
              Promising Effects of CAR T-Cell Therapy in Refractory Stiff Person Syndrome and a Hopeful Future for All Neuroautoimmunities
              </a>
            </td>
          <td>
            Marinos C. Dalakas
          </td>
          <td>2025-11-17</td>
          <td>Neurology® Neuroimmunology & Neuroinflammation</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Human immunodeficiency virus (HIV) persists in infected individuals despite effective antiretroviral therapy due to the rapid establishment of latent reservoirs, mainly composed of quiescent memory CD4+ T cells. The mechanisms governing latent reservoir formation remain poorly understood. Here, using single-cell RNA-seq and functional studies in human primary CD4+ T cell models, we show that HIV infection with reporter constructs and laboratory and patient-derived strains triggers transcriptomic remodelling, activating the p53 pathway and a quiescence programme mediated by Krüppel-like factor 2 (KLF2), a key quiescence regulator. Loss- and gain-of-function studies, including unbiased shRNA screens and confirmatory studies in CD4+ T cells from HIV+ donors, demonstrate that HIV infection drives KLF2 and p53 signalling, which downregulate MYC and proliferation pathways, resulting in proviral transcriptional silencing. This enhances latent reservoir formation in T cells, ensuring viral persistence. These findings present a mechanism for forming the latent HIV reservoir and broaden the repertoire of strategies through which viruses control host cells to their advantage. HIV infection triggers transcriptomic remodelling and a quiescence programme via KLF2 and the p53 pathway leading to proviral silencing.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/71ad439106244ffe6aee4ff6226965f5c2bc48f8" target='_blank'>
              HIV infection reprogrammes CD4+ T cells for quiescence and entry into proviral latency
              </a>
            </td>
          <td>
            Leah M Plasek Hegde, L. Gunawardane, F. Niazi, Uri Mbonye, K. Leskov, Gani Perez, C. Dobrowolski, Meenakshi Shukla, W.S. Nutt, Jonathan Karn, S. Valadkhan
          </td>
          <td>2025-09-26</td>
          <td>Nature Microbiology</td>
          <td>1</td>
          <td>24</td>
        </tr>

        <tr id="
 Although immunotherapy has transformed cancer treatment, glioblastoma (GBM) remains stubbornly resistant due to multiple immunosuppressive mechanisms. Our previous work identified polyamine metabolism as a key driver of this immunosuppression, with difluoromethylornithine (DFMO) improving survival in a T and B cell-dependent manner. However, DFMO alone, or in combination with PD-1/PD-L1 blockade, failed to yield durable benefits. This suggests the emergence of adaptive resistance mechanisms. To investigate this, we performed single-cell RNA sequencing (scRNA-seq) on DFMO-treated tumors, revealing increased T-cell inflammation and IFN-γ-driven gene expression. Surprisingly, the most upregulated gene was apolipoprotein D (ApoD), a lipid transport protein that sequesters arachidonic acid (AA). AA is an inflammatory lipid essential for T-cell-induced IFN-γ-STAT1-dependent ferroptosis of tumor cells during immunotherapy. Notably, this STAT1-ApoD axis was also acutely induced in response to other immunotherapies in murine GBM models. We therefore hypothesized that IFN-γ–induced ApoD expression represents a potential mechanism of tumor immune evasion. Our preliminary findings show that ApoD overexpression protects tumor cells from AA-induced lipotoxicity and ferroptotic cell death, decreasing survival in GBM mouse models, which was dependent on intact adaptive immunity. ApoD-overexpressing tumors displayed a higher myeloid-to-CD8⁺ T cell ratio and increased expression of immune checkpoints and suppressive markers, indicating a more immunosuppressive microenvironment. Collectively, our study demonstrates ApoD as a critical adaptive responder to inflammatory stress in GBM. Ongoing research will further explore ApoD-targeted interventions, including lipid nanoparticle-mediated siRNA delivery. We will investigate the intrinsic role of ApoD in controlling tumor cell susceptibility to ferroptosis, and, in parallel, examine its extrinsic effects as a secreted factor that reshapes the immune microenvironment by suppressing T cell function and promoting myeloid immunosuppression. This may lead to future therapies that enhance immunotherapy efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/002ee8adc2baa74e88b71b10cd71ff6d47d4f268" target='_blank'>
              TMIC-82. Sequestration of inflammatory lipids as an immune evasion mechanism in glioblastoma
              </a>
            </td>
          <td>
            Tzu-yi Chia, Chao Wei, Leah K. Billingham, Suzi Delay, Lauren Boland, Nishanth S. Sadagopan, Jay Subbiah, Si Wang, Hanxiao Wan, Jiawei Huo, J. Duffy, Alina R Murphy, Rebecca Du, Joshua Katz, Aurora Lopez-Rosas, Yu Han, G. Vázquez-Cervantes, Hardik Shah, Peng Zhang, Irina V Balyasnikova, M. Lesniak, Catalina Lee-Chang, J. Miska
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Diffuse large B-cell lymphoma and follicular lymphoma exhibit complex metabolic and immune microenvironments that influence disease progression and treatment response. Metabolic reprogramming, including glycolysis, amino acid, and lipid metabolism, supports tumor growth while suppressing anti-tumor immunity. Immune components such as tumor-infiltrating lymphocytes and checkpoint molecules (PD-L1, LAG-3, TIM-3) further modulate prognosis. Elevated tumor metabolic volume and glycolytic activity correlate with aggressive disease and poor outcomes. Conversely, high TIL density often predicts better responses. Integrating metabolic and immune biomarkers enhances risk stratification and therapeutic strategies, highlighting the potential for combined metabolic inhibitors and immunotherapies to improve precision medicine in lymphoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35d2711154e88d30ee1749837827464d818a40eb" target='_blank'>
              Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL
              </a>
            </td>
          <td>
            Chengqian Chen, Wei Guo, Haotian Wang, Luming Cao, Out Bai
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Glioblastoma, the most common and lethal primary brain tumor, creates profound immunosuppression that has resisted clinical interventions. The mechanisms behind immunotherapy failures in glioblastoma remain unclear. We conducted a systematic comparison of different immunotherapeutic approaches in mouse models to better understand treatment responses.



 Using multiomic single-cell analysis and spatial profiling, we evaluated GL261 glioma-bearing mice treated with anti-PD-L1 antibodies, NKG2D-CAR-expressing T cells, natural killer (NK) cells, or macrophages.



 All treatment models induced immune cell migration through chemotaxis. Additionally, PD-L1 and CAR T cell treatments led to an exhaustion-associated T cell signature alongside increased cytotoxic T cell presence. Further, we observed higher numbers of immunomodulatory lymphocytes and macrophages associated with these two immunotherapies. CAR macrophages and CAR NK cells exhibited enhanced cytotoxic gene signatures without increasing T cell numbers. Also, the immunomodulatory macrophage response appeared attenuated in CAR NK cells and macrophages. Notably, CAR NK cells demonstrated an enhanced antiviral response with interferon-beta expression that was not observed in other models.



 While PD-L1 and CAR cell treatments successfully polarized the lymphoid compartment toward cytotoxic phenotypes, these approaches alone appear insufficient as they were accompanied by pronounced immunomodulatory cell responses. CAR NK cells and macrophages were characterized by attenuated immunomodulatory responses. Our findings suggest that cytotoxic lymphocytes alone fail to override tumor-associated immune suppression. This is in line with recent evidence on T helper cell roles in CAR therapy. Future immunotherapy approaches should balance cytotoxic and helper lymphocyte populations while enhancing inflammatory macrophages to overcome the immunosuppressive environment of glioblastoma
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde65cb7289ab4952a15cc4d954df652b303b749" target='_blank'>
              P08.22.B SYSTEMATIC COMPARISON OF IMMUNOTHERAPIES IN GLIOBLASTOMA REVEALS DISTINCT IMMUNE RESPONSE PATTERNS
              </a>
            </td>
          <td>
            Y. Liu, T. Look, J. Fang, A. Dalmau Gasull, M. Prinz, T. Weiss, R. Sankowski
          </td>
          <td>2025-10-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background Notch receptor–ligand interaction is ubiquitous and fundamental for coordinating cellular differentiation and determining cell fate for the development of various tissues and organs. Aberrant mutations in the Notch cascade result in various pathophysiological disorders, including cancer. Diverse aspects of carcinogenesis regulated by Notch include the shaping of anti-tumour T-cell immunity through antigen-presenting cell (APC)–T cell interaction and effector functions. Chief content Notch depends on juxtacrine and paracrine signalling to influence intercellular communications in the tumour microenvironment. Several preclinical and clinical studies have revealed Notch as a bi-effector molecule, which has a differential effect depending on the immune contexture of the tumour microenvironment. The Notch cascade serves as an effective therapeutic target in preventing off-target cell death and promoting tumour-specific T-cell priming. Conclusion This review revolves around Notch crosstalk with respect to the interaction between T-cell populations and other intratumoral cellular components, including professional antigen-presenting cells like dendritic cells, macrophages, B cells, immunosuppressive myeloid-derived suppressor cells, and cancer stem cells. It also summarizes the impact of targeting Notch signalling within intratumoral T cells in combination with traditional oncotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92825b4437029c71e3d8e60010a04449b9771802" target='_blank'>
              Notch signalling in T cells: bridging tumour immunity and intratumoral cellular crosstalk
              </a>
            </td>
          <td>
            J. Sultana, Pritha Roy Choudhury, S. Bera, M. Chakravarti, A. Guha, Prodipto Das, J. Das, Gayatri S Iyer, A. Sarkar, S. Dhar, N. Ganguly, R. Baral, A. Bose, S. Banerjee
          </td>
          <td>2025-10-02</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd0bbd6c621e9fa08282926e4b3b6b4e1c0cb666" target='_blank'>
              The Immunogenic Role of Self-DNA in T Cell Immunity
              </a>
            </td>
          <td>
            Jiaxin Lei, Mengdi Liu, Xiao Huang, Xingyu Zhai, Huiyan Ji, Z. Wen
          </td>
          <td>2025-11-19</td>
          <td>Clinical Reviews in Allergy & Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Tolerogenic dendritic cells (tolDCs) that dampen T cell responses can be induced from blood monocytes in vitro using factors such as Vitamin D3 (VitD), dexamethasone, IL‐10, or rapamycin. However, challenges remain in obtaining robust and efficient generation of cell therapy‐based tolDCs without compromising their viability. We recently reported that CCR2‐dependent recruitment of monocytic cells, with the capacity to dampen T‐helper responses, occurs in mice treated with a single‐stranded oligonucleotide (ssON). Here, we investigated the effects of this immunomodulatory noncoding ssON on differentiating human monocytes towards DC in the presence of IL‐4 and GM‐CSF (moDC). The moDC differentiated in the presence of ssON upregulated CD1a but also increased their expression of PD‐L1. The differentiation of monocytes to moDC in the presence of ssON introduced transcriptomic changes, many of which overlapped with VitD‐moDC and resulted in moDCs with altered lipopolysaccharide (LPS)‐responsiveness. Moreover, ssON‐moDC exhibited a low capacity to stimulate alloreactive T cells in vitro and instead promoted the induction of CD4+FoxP3+CD25+ T cells. Experiments using chemical reagents support a role for PPAR‐γ in the generation of ssON‐moDC. Collectively, our data show that monocytes differentiated with IL‐4, GM‐CSF, and ssON generate cells with phenotypic and functional characteristics of tolDCs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7fee9e6189995b66ddd3a571d7811184f6d38e1" target='_blank'>
              Induction of Tolerogenic Dendritic Cells by a Noncoding Oligonucleotide
              </a>
            </td>
          <td>
            Kahkashan Kamal, James Trumbo, Elina Richardsdotter-Andersson, M. Wahren-Herlenius, A. Spetz
          </td>
          <td>2025-10-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, thus, there is an urgent need to develop more effective therapeutic options for this dismal condition. Tumor-infiltrating lymphocytes (TILs) are associated with improved response to immune checkpoint blockade in HCC, but their low abundance in most cases limits their therapeutic efficacy. Here, we demonstrate, in mice, that low-dose intratumoral immunovirotherapy with the trivalent measles, mumps, and rubella vaccine (MMR) induces superior tumor-growth delay and extended host survival compared to individually administered vaccines for measles, mumps, or rubella viruses. Further, our results show that MMR therapy synergizes with PD-1 and CTLA-4 blockade to reprogram the tumor microenvironment, resulting in increased CD8+ TIL infiltration and reduced PD-1 expression on TILs, among other effects. These changes in the immunological landscape translated into greater survival and more durable tumor-specific and memory immune responses for hosts. Comprehensive toxicology analysis revealed no evidence of MMR-induced liver or kidney toxicity after intrahepatic administration. This work reinforces an unrecognized role of MMR plus ICB in reprogramming the immune landscape in HCC through multimodal immune activation, providing a strong rationale for further development of MMR-based therapies for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0ee9f74230079389edd57b51b6b1e849660e18a" target='_blank'>
              Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
              </a>
            </td>
          <td>
            M. Tesfay, Aleksandra Cios, K. U. Ferdous, Randal S. Shelton, Bahaa Mustafa, Camila C Simoes, Murat Gokden, I. Miousse, Kimberly J. Krager, Marjan Boerma, Alicja Urbaniak, Anuradha Kunthur, S. Obulareddy, Joshua M. Eichhorn, Steven R Post, J. C. Chamcheu, Omeed Moaven, C. Chabu, D. Duda, Matteo Conti, Bruno Nardo, Rang Govindarajan, M. Fernandez-Zapico, Lewis R. Roberts, M. Borad, Martin J Cannon, Alexei G. Basnakian, B. Nagalo
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="The tumor microenvironment (TME) plays a critical role in cancer progression, immune evasion and therapeutic resistance. The transcriptional coactivators YAP and TAZ, key effectors of the Hippo signaling pathway, have emerged as central regulators of TME remodeling. YAP/TAZ are activated in both tumor and stromal compartments, where they function as mechanotransducers and integrate canonical Hippo pathway suppression, noncanonical microenvironmental cues and genetic or epigenetic signals to drive transcriptional programs. These changes collectively facilitate tumor immune evasion. YAP/TAZ further promote angiogenesis and upregulate PD-L1 expression in tumor cells and cancer-associated fibroblasts, and a subset of immunosuppressive cells in the TME, contributing to resistance to ICB. In addition to their tumor-intrinsic and stromal functions, YAP/TAZ impair antitumor immunity by altering immune cell differentiation and dampening effector responses. Targeting the YAP/TAZ–TEAD axis has shown potential efficacy when combined with immune checkpoint inhibitors, chimeric antigen receptor T cell therapies and tumor vaccines. Although challenges such as tumor selectivity and resistance mechanisms persist, advances in single-cell and spatial transcriptomics are enabling the dissection of YAP/TAZ-regulated networks and guiding the development of more precise therapeutic strategies. Collectively, YAP/TAZ inhibition offers a promising avenue to reprogram the TME and enhance the efficacy of next-generation cancer immunotherapies. The tumor microenvironment (TME) plays a crucial role in cancer progression and treatment resistance. This review highlights how the Hippo signaling pathway, particularly its effectors YAP and TAZ, influences the TME. YAP/TAZ activation promotes cell proliferation and survival while also reshaping the TME by altering immune cell behavior, inducing fibrosis and angiogenesis, thereby facilitating immune evasion. The review concludes that targeting YAP/TAZ could improve cancer treatments by making tumors more responsive to therapies. Future implications include developing drugs that inhibit YAP/TAZ to enhance the effectiveness of existing cancer treatments, potentially leading to better patient outcomes. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0830187497e7260f9344c5998d40deda53002703" target='_blank'>
              The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancer
              </a>
            </td>
          <td>
            Hyung-Sik Kim, Jeong-Seok Nam
          </td>
          <td>2025-10-01</td>
          <td>Experimental & Molecular Medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Therapy with chimeric antigen receptor (CAR)-T cells has revolutionized the treatment of hematological malignancies. However, their application in solid tumors remains a formidable challenge due to obstacles such as the immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence. Although second- and third-generation CAR-T cells have shown restricted efficacy in clinical trials, next-generation strategies—including cytokine-armored CAR-T cells (e.g., IL-15, IL-7/CCL19), logic-gated systems, and localized delivery approaches—demonstrate promising potential to overcome these limitations. This review examines the major barriers impeding CAR-T cell efficacy in solid tumors, evaluates clinical outcomes from conventional CAR constructs, and highlights innovative strategies being tested in recent clinical trials. Key advances discussed include the use of dominant-negative receptors (e.g., TGFβRII) to combat immunosuppression and the co-expression of bispecific T cell engagers (BiTEs) to address antigen escape.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ea0aeab6193e8e176d2fd055b56303c2fa844a41" target='_blank'>
              Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress
              </a>
            </td>
          <td>
            Sergei Smirnov, Yuriy Zaritsky, Sergey A. Silonov, A. Gavrilova, A. Fonin
          </td>
          <td>2025-10-01</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, presents major therapeutic challenges due to molecular heterogeneity and high relapse rates. While autologous hematopoietic stem cell transplantation (ASCT) has been a cornerstone for relapsed/refractory (R/R) B-cell lymphoma, its efficacy is often compromised by minimal residual disease (MRD) persistence and an immunosuppressive tumor microenvironment. Chimeric antigen receptor (CAR)-T cell therapy has transformed treatment paradigms but faces limited long-term durability due to antigen escape and T-cell exhaustion. The integration of ASCT with CAR-T therapy may offer a complementary approach to address these limitations, leveraging ASCT-induced immune reconstitution to enhance CAR-T-cell persistence and reprogram the tumor milieu. Emerging clinical evidence supports this approach, indicating improved disease control and progression-free survival. Although preliminary clinical outcomes are encouraging, unresolved challenges persist, particularly in terms of cumulative toxicity, optimal therapeutic sequencing, CAR-T-cell longevity, and financial feasibility associated with these advanced therapies. This review provides a comprehensive overview of mechanistic synergies between ASCT and CAR-T therapy, critically evaluates emerging clinical evidence on treatment sequencing, and explores innovative strategies to increase safety, efficacy, and accessibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8dabb02a640eb6c1d29c8aa3a2cf213056349991" target='_blank'>
              Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma
              </a>
            </td>
          <td>
            Xumeng Zhao, Jiaying Wu, Xiaojian Zhu, Yi Xiao
          </td>
          <td>2025-10-01</td>
          <td>Cell Transplantation</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="ABSTRACT Cancer‐associated fibroblasts (CAFs) are pivotal stromal components that shape the tumor microenvironment through their remarkable heterogeneity and dynamic functions. This review comprehensively examines the biology of CAFs, starting with their diverse cellular origins and induction mechanisms via key signaling pathways. We highlight the spatial‐temporal heterogeneity of CAF subsets and propose an updated classification system that encompasses eight functionally distinct subtypes based on recent single‐cell transcriptomic studies. The tumor‐promoting roles of CAFs are explored in depth, including their contributions to tumor behavior through novel mechanisms such as neutrophil extracellular traps formation, and multidrug resistance via metabolic reprogramming. A major focus is placed on CAF‐mediated immunotherapy resistance through immune checkpoint regulation, recruitment of immunosuppressive cells, and metabolite secretion. This review also highlights key technologies that are advancing CAF research, including patient‐derived 3D models, artificial intelligence‐enhanced spatial multiomics, clustered regularly interspaced short palindromic repeats (CRISPR)‐engineered mouse systems, and machine learning approaches for analyzing CAF heterogeneity and function. Finally, we evaluate therapeutic strategies targeting CAF activation, secreted factors, and immune crosstalk, while critically analyzing ongoing clinical trials. Overall, this review not only clarifies the biology of CAFs but also provides a translational framework for developing next‐generation stromal‐targeted therapies to overcome treatment resistance in cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e1dae86be5576422570b1acdcb11b97738bdec4b" target='_blank'>
              Cancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy
              </a>
            </td>
          <td>
            Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding
          </td>
          <td>2025-10-28</td>
          <td>MedComm</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5efa7f94822ae99000facb8bcf334e922c852364" target='_blank'>
              Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells
              </a>
            </td>
          <td>
            Lauren Sarko, David Givand, Claire Shepley, Brendan Rattin, Allen Attar, Rachel Taylor, Benjamin Kutler, Roshini M. Traynor, Anika Upadhyaya, Mackenzie Mnuk, Cavin Gehrke, Nat Murren, Tyler K. Ulland, Theresa Kotanchek, Krishanu Saha
          </td>
          <td>2025-10-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Innate immune cells and pathways are central to shaping the tumor microenvironment (TME), where they influence tumor growth, metastasis, and responsiveness to immunotherapy. Although research on innate immunity in cancer has expanded considerably, the mechanisms driving immune dysfunction remain incompletely understood. This review summarizes current knowledge on the functional states of innate immune cells within the TME and highlights how metabolic reprogramming contributes to immune suppression and tumor progression. We further discuss recent advances in therapeutic strategies targeting innate immune pathways, emphasizing their translational potential. Importantly, we also examine unresolved controversies and knowledge gaps across innate immune cells, metabolic networks, and innate immune factors such as complement and cytokines, outlining key challenges for clinical translation. By linking mechanistic insights with emerging interventions and identifying future directions, this review provides a framework for integrating innate immunity into next-generation cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c04681fced7ce655cf3c2cb9b142258798132d57" target='_blank'>
              Innate immunity in tumors: roles and therapeutic targets
              </a>
            </td>
          <td>
            Songze Leng, Yuyue Ren, Yao Tian, Weiwei Zhao, Yue Mou, Xingyu Chen, Hong Zhou, Wei Wang
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Fusobacterium nucleatum (Fn) has been increasingly recognized as a crucial mediator of colorectal cancer (CRC) biology, particularly in microsatellite-stable (MSS) tumors, where immune checkpoint inhibitors (ICIs) have shown limited efficacy. Rather than representing a passive microbial passenger, Fn actively shapes tumor behavior by adhering to epithelial cells, activating oncogenic signaling, and promoting epithelial–mesenchymal transition (EMT). At the same time, it remodels the tumor microenvironment, driving immune suppression through inhibitory receptor engagement, accumulation of myeloid-derived cells, and metabolic reprogramming of tumor-associated macrophages. These mechanisms converge to impair cytotoxic immunity and contribute to both intrinsic and acquired resistance to ICIs. Beyond immune escape, Fn interferes with conventional chemotherapy by sustaining autophagy and blocking ferroptosis, thereby linking microbial colonization to multidrug resistance. Most of these mechanisms derive from preclinical in vitro and in vivo models, where causal relationships can be inferred. In contrast, human data are mainly observational and provide correlative evidence without proving causality. No interventional clinical studies directly targeting Fn have yet been conducted. Its enrichment across the adenoma–carcinoma sequence and consistent detection in both tumor and fecal samples highlight its potential as a biomarker for early detection and patient stratification. Importantly, multidimensional stool assays that integrate microbial, genetic, and epigenetic markers are emerging as promising non-invasive tools for CRC screening. Therapeutic strategies targeting Fn are also under exploration, ranging from antibiotics and bacteriophages to multifunctional nanodrugs, dietary modulation, and natural microbiota-derived products. These approaches may not only reduce microbial burden but also restore immune competence and enhance the efficacy of immunotherapy in MSS CRC. Altogether, current evidence positions Fn at the intersection of microbial dysbiosis, tumor progression, and therapy resistance. A deeper understanding of its pathogenic role may support the integration of microbial profiling into precision oncology frameworks, paving the way for innovative diagnostic and therapeutic strategies in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5de3392ea1b80bc011c9950b5aa6328802a1377a" target='_blank'>
              Fusobacterium Nucleatum in Colorectal Cancer: Relationship Among Immune Modulation, Potential Biomarkers and Therapeutic Implications
              </a>
            </td>
          <td>
            Dalila Incognito, Giuliana Ciappina, Claudia Gelsomino, Antonio Picone, Pierluigi Consolo, A. Scano, T. Franchina, Nicola Maurea, V. Quagliariello, Salvatore Berretta, A. Ottaiano, M. Berretta
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="


 Glioblastoma (GB) is a lethal primary brain tumor frequently driven by amplification and aberrant activation of the epidermal growth factor receptor (EGFR). Tumor-associated myeloid cells (TAMs) comprise the majority of tumor infiltrating leukocytes (TILs) and secrete inflammatory molecules that promote tumor growth including IL-6, IL-1β, and EGF, a canonical EGFR ligand. These TAMs orchestrate a suppressive tumor immune microenvironment (TIME) with poor T cell infiltration. However, whether EGFR activation plays a direct role in mediating TAM recruitment and phenotype is poorly understood.



 We leveraged the MADR-mEGFRvIII murine GB model which expresses constitutively active mEGFRvIII under a tetracycline-off promoter. Orthotopic MADR-mEGFRvIII-bearing mice were treated with doxycycline (dox) for one week followed by flow cytometric TIME profiling. Tumor conditioned media (CM) and orthotopic tumor lysates were assessed via ELISA and cytokine array. Lymphocytes (CD4, CD8, NK) were depleted via antibody administration. Magnetically isolated CD45+ TILs from MADR-mEGFRvIII and newly diagnosed (nd) GB patient tumors with known EGFR status underwent bulk or single-cell RNA sequencing.



 Immunophenotyping of TILs from MADR-mEGFRvIII tumors revealed EGFR activation is associated with significantly enhanced F4/80+ myeloid cell infiltration. Assessment of MADR-mEGFRvIII tumor CM identified EGFR-dependent secretion of myeloid chemoattractants CCL2 and CXCL10 in vitro, which was corroborated in tumor lysates from mice. Further, sequencing of TILs revealed EGFR activation is significantly associated with interferon (IFN)-stimulated gene (ISG) expression in both brain-resident microglia and monocytic macrophages. Lymphocyte depletion prior to tumor implantation did not affect the EGFR-driven induction of ISGs in TILs, suggesting type I IFN is responsible for the observed TAM phenotype. Pan-IFNα and IFNβ ELISAs confirmed type I IFN was not present in tumor CM, indicating IFN is secreted by other constituents in the TIME. Importantly, ndGB patient TILs were assessed to determine if EGFR activation is associated with TAM ISG expression in human GB. Indeed, significant differential expression of numerous ISGs including IRF7, IFI44, and MX1 was observed in TAMs from EGFR activated tumors compared to wild type further supporting the concept that EGFR orchestrates the induction of a chronic TAM IFN response in GB.



 Our results indicate tumor-intrinsic EGFR activation promotes TAM recruitment via CCL2 and CXCL10 secretion and potentiates robust induction of type I IFN signaling within the TIME, ultimately resulting in a TAM phenotype characterized by ISG expression. Therapeutically targeting this EGFR-driven tumor-TAM crosstalk may be a viable strategy to reduce immunosuppression arising from chronic IFN signaling.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0bb75248939bcd6df103aac0aac16aeca77d9ce5" target='_blank'>
              P02.31.B INDUCTION OF A CHRONIC INTERFERON STIMULATED TUMOR-ASSOCIATED MYELOID CELL PHENOTYPE IS DIRECTLY ORCHESTRATED BY ABERRANT TUMOR-INTRINSIC EGFR-ACTIVATION IN GLIOBLASTOMA
              </a>
            </td>
          <td>
            M. Pioso, M. Li, K. Grausam, J. Breunig, D. Nathanson, R. Prins
          </td>
          <td>2025-10-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15−/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15−/− BMDCs. Isg15−/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15−/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05fa00535a2acdc99ae44733e69601b7e28b4dad" target='_blank'>
              ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells
              </a>
            </td>
          <td>
            P. Martínez-Fleta, Clara Pertusa, Irene Fernández-Delgado, R. Izquierdo-Serrano, M. Ramírez-Huesca, Nieves Fernández-Gallego, D. Calzada-Fraile, Elena Moya-Ruiz, Raquel Castillo-González, Susana Guerra, E. Martín-Gayo, F. Sánchez-Madrid
          </td>
          <td>2025-10-24</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Simple Summary Donor-derived Vγ9Vδ2 T cells demonstrate potent anti-leukemic activity both in vitro and in vivo, offering a promising immunotherapeutic approach for acute myeloid leukemia (AML). These γδ T cells efficiently induce apoptosis in AML cells in vitro, highlighting their direct cytotoxic potential. In an aggressive AML xenograft mouse model, treatment with donor-derived Vγ9Vδ2 T cells significantly prolonged survival, indicating their therapeutic relevance in a clinically challenging setting. Importantly, these cells remain effective against venetoclax-resistant AML; in vivo studies further show that Vγ9Vδ2 T cells extend survival in mouse survival with or without venetoclax. These findings suggest the therapeutic potential of harnessing donor-derived Vγ9Vδ2 T cells as a novel strategy to overcome drug resistance and improve outcomes in AML, including in patients with limited responses to existing therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6e72a592035e114a06e58e1013ea6e52ae060ba" target='_blank'>
              Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach
              </a>
            </td>
          <td>
            Amanda Eckstrom, Anudishi Tyagi, Maryam Siddiqui, Jenny Borgman, Jieming Zeng, Adishwar Rao, A. Maiti, V. Battula
          </td>
          <td>2025-09-29</td>
          <td>Cancers</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/13803e7a45b223704e5dd94cfb872f40cfec3de9" target='_blank'>
              Beadex modulates hematopoiesis and innate immune defense against microbial infection in Drosophila melanogaster
              </a>
            </td>
          <td>
            Sakshi Jain, Kashish Salian, Vrushti Shah, U. Nongthomba
          </td>
          <td>2025-10-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Interferon-gamma (IFN-γ), as a pleiotropic cytokine, plays a pivotal role in antitumor immunity. Its remarkable immunostimulatory, antiproliferative, and pro-apoptotic effects make it a promising candidate for tumor immunotherapy. Here, we highlight the dual role of IFN-γ in the tumor microenvironment during tumor development and treatment. IFN-γ can enhance antigen presentation, boost cytotoxic T cell and natural killer cell activity, and inhibit angiogenesis, promoting tumor regression and correlating with favorable therapeutic outcomes. However, prolonged exposure may induce the upregulation of immune checkpoint molecules such as programmed death-ligand 1, trigger T cell exhaustion, and recruit regulatory T cells, phenomena associated with the development of treatment resistance in cancer therapy. This dual nature poses significant challenges for harnessing IFN-γ in tumor treatment, necessitating an in-depth understanding of its mechanisms within specific microenvironments. Although numerous studies have explored IFN-γ-based tumor therapies, their outcomes have been inconsistent. Thus, although IFN-γ-based therapeutic strategies hold considerable promise, their clinical translation requires precise modulation to fully exploit its antitumor effects while mitigating potential protumor risks. See also the graphical abstract(Fig. 1).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48bdd0772c494cb7597b77c69e2cc5a685517ff" target='_blank'>
              IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy
              </a>
            </td>
          <td>
            Jiahui Cui, Yi Zhang, Li Yang
          </td>
          <td>2025-10-14</td>
          <td>EXCLI Journal</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="The immunosuppressive microenvironment and limited immune cell infiltration into the tumor bed contribute to the proliferation, metastasis, and invasion of breast cancer (BC) cells. Reprogramming the tumor immune microenvironment has emerged as a promising therapeutic target for BC, but remains challenging in clinical practice. Artemisia annua, a medicinal plant, has shown immune-enhancing and anti-tumor activities, although its potential therapeutic applications in BC remain underexplored. Extracellular vesicles (EVs) were isolated from fresh Artemisia annua using gradient centrifugation and characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), Zetasizer Nano ZS90, ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS/MS), and high-performance liquid chromatography (HPLC). Single-cell RNA sequencing (scRNA-seq) analysis was performed to investigate the mechanism of AEVs on tumor growth in vivo and mRNA sequencing (mRNA-seq) was employed to further explore the mechanism of AEVs-induced polarization shift from M2-like to M1-like macrophages. In vitro and in vivo assays were conducted to assess the polarization of macrophages and recruitment of T lymphocytes into the tumor bed. AEVs were successfully isolated and characterized. In vivo, AEVs inhibited tumor growth by shifting macrophage polarization from the M2-like to the M1-like phenotype, and synergistically enhancing the recruitment of CD8+ and CD4+ T cells into the tumor microenvironment. AEVs activated the NF-κB signaling pathway while inhibiting the PPARγ pathway, thereby promoting the M1-like polarization of macrophages. Polarized M1-like macrophages secreted chemokines (CCL5 and CCL3), which facilitated T lymphocyte infiltration into the tumor bed. Notably, AEVs reshaped the BC immune microenvironment without inducing systemic toxicity. AEVs from Artemisia annua efficiently reprogrammed the immune microenvironment of breast cancer by inducing macrophage polarization and enhancing T lymphocyte infiltration. This study lays the foundation for using AEVs as a potential immunotherapy for BC and highlights the medicinal value of Artemisia annua in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ae2b76c7e2982ae527e2b31089269c261024d90" target='_blank'>
              Artemisia annua-derived extracellular vesicles reprogram breast tumor immune microenvironment via altering macrophage polarization and synergizing recruitment of T lymphocytes
              </a>
            </td>
          <td>
            Yun Wang, Lin Meng, Sicheng Su, Yu Zhao, Xiaoxian Hu, Xiaoqing Xu, Chao Han, Jianguang Luo, Zhong-Rui Li
          </td>
          <td>2025-10-01</td>
          <td>Chinese Medicine</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="Monocytes and macrophages are sentinels of the immune system that distinguish themselves from other cells by expressing the beta isoform of the folate receptor (FRβ). Because FRβ does not bind folate until the monocyte/macrophage is exposed to immunosuppressive cytokines, the question naturally arose whether FRβ might also perform an immune-related function. To examine this matter, we compared the properties of wild type (WT) and FRβ knockout mice. We observe that FRβ knockout (KO) mice display autoimmune symptoms that can include alopecia, enlarged spleens, and dermatitis, despite having normal cellular folate levels. We further demonstrate that syngeneic tumors (TRAMP C2, MC38) grow much slower in FRβ KO mice than wildtype mice. Comparison of cells extracted from syngeneic tumors of KO mice further reveal that CD69+ T cells are increased while PD1+ T cells and PD-L1+ myeloid cells are decreased in KO tumors. More detailed comparison of the bone marrow-derived macrophages from KO and WT mice demonstrates that KO mice have upregulated pro-inflammatory genes and downregulated anti-inflammatory genes. Because blockade of FRβ with a monoclonal antibody or deletion of FRβ impairs direct macrophage suppression of T cell activation in vitro, we conclude that FRβ performs a checkpoint function that regulates the immunologic properties of tumor myeloid cells. Since FRβ expression in human cancers is shown to correlate inversely with overall survival, we further posit that FRβ similarly performs an immunosuppressive function in human tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6350926a82e6aa0f4f7b912a7cea7a3b3cca511a" target='_blank'>
              Folate receptor β performs an immune checkpoint function in activated macrophages
              </a>
            </td>
          <td>
            Fenghua Zhang, Md. Yusuf Al-Amin, Sagar M. Utturkar, Rina Jiang, Gregory M. Cresswell, Rami A. Alfar, Ian Ophaug-Johansen, Gabriel Bachman, M. Srinivasarao, Richard Finnell, Amaya Puig-Kröger, Timothy Ratliff, P. Low
          </td>
          <td>2025-09-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="As a key lymphocyte population in shaping and controlling adaptive immune response, T cells play an important immunomodulatory role in the early stages of autoimmune diseases. Although CD3+CD4−CD8− T (DNT) cells constitute only a small proportion of peripheral T lymphocytes, they may be closely linked to the occurrence and development of autoimmune diseases. However, the role of DNT cells in autoimmune disease pathogenesis still needs to be elucidated. In this review, we first present the origin, functions, and heterogeneity of DNT cells. We then summarize the role of DNT cells in the pathogenesis of various autoimmune diseases. Subsequently, we clarify the recent advances in the applications of DNT cell-based therapy for autoimmune diseases and outline potential drugs (including active ingredients extracted from Chinese medicinal treatments) and approaches that can target the proliferation and expansion of DNT cells. Lastly, the limitations and challenges of applying DNT-cell-based therapy are analyzed. In conclusion, we present an overview to further the understanding of the role of DNT cells in autoimmune disease pathogenesis and of DNT cells as a potential therapeutic tool for immune disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130f579f8c6e0a3374a93d0e8f2050f3b8d8e91f" target='_blank'>
              CD3+CD4−CD8− T cells: a new potential therapeutic target in treating autoimmune diseases
              </a>
            </td>
          <td>
            Xin Li, Di Guo, Isabelle Xinyue Zou, Lingyan Zhao, Na Yang, Yang Liu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Immunology</td>
          <td>2</td>
          <td>1</td>
        </tr>

        <tr id="Checkpoint inhibitors have revolutionized hepatocellular carcinoma (HCC) treatment, yet their efficacy remains limited in advanced stages, with suboptimal objective response rates. Growth differentiation factor 15 (GDF15), a dual-functional cytokine implicated in tumor progression and immunosuppression, represents a promising therapeutic target. This study aims to develop a novel GDF15-targeted strategy to improve HCC management and synergize with PD-1 blockade. GFRAL-Fc fusion proteins were generated by fusing the extracellular domain of GFRAL with IgG1 Fc. The anti-tumor efficacy and the anti-cachexia ability of GFRAL-Fc was evaluated in a spontaneous HCC model on GDF15 humanized mice. Additionally, the half-life and drug safety were evaluated in mice. To investigate the underlying mechanisms, a CyTOF analysis was utilized to analysis the immunoregulation effects of GFRAL-Fc within HCC. Finally, the anti-tumor effects of GFRAL-Fc in combination with Programmed Death-1 (PD-1) inhibitors were assessed. GFRAL-Fc targets GDF15 to simultaneously prevent GDF15-CD48 interaction-driven ERK activation and block GDF15-GFRAL binding. Treatment with GFRAL-Fc achieved dual antitumor effects: reducing tumor progression and attenuating cancer-associated cachexia. Combination with PD-1 blockade further enhanced antitumor efficacy, resulting in a substantial decrease in tumor nodules. Mechanistic studies revealed that GFRAL-Fc reprograms the immunosuppressive tumor microenvironment by suppressing Treg activation while enhancing CD8+ T cell cytotoxicity. Our findings validate GDF15 targeting as a viable strategy to overcome checkpoint inhibitor resistance in HCC. The GFRAL-Fc fusion protein demonstrates multimodal therapeutic benefits through metabolic regulation and immune remodeling, providing a clinically translatable approach to optimize PD-1-based regimens. This study addresses critical gaps in current HCC management and warrants further clinical validation. Schematic diagram of GFRAL-Fc functional: After binding with GDF15, GFRAL-Fc inhibits the GDF15-GFRAL pathway to suppress cancer-associated cachexia, while also inhibiting the GDF15-CD48 pathway to reprograming the tumor immune microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f424c4cc08908ec0d690fea5ad9e9738200e0f9" target='_blank'>
              GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Gege Shi, Wangqian Zhang, Fei Xie, Jiaxin Shi, Minghui Yan, Lei He, Zhaozhao Li, Yang Xiao, Duo Yu, Haiyan Cao, Haichen Du, Yueyuan Qiu, Kuo Zhang, Shuning Wang, Meng Li, Jieyu Zhang, Zhaowei Wang
          </td>
          <td>2025-10-15</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Gliomas present as highly heterogeneous and aggressive central nervous system (CNS) tumors with challenging diagnosis and management. Traditional and current therapies are lacking efficacy in overcoming the complex and dynamic behavior of gliomas and the local tumor microenvironment. Emerging research highlights the significant role of innate immune receptors including Toll-like, NOD-like and RIG-like receptors, as well as cGAS-STING receptors, scavenger and C-type lectin receptors in glioma development and progression. These receptors can both impact immune modulation as well as facilitate tumor growth through interactions with tumor-associated macrophages, myeloid-derived suppressor cells and cytokine networks, contributing to immune evasion in the tumor microenvironment. Herein, we discuss the main signaling pathways induced through innate immune receptors in gliomas along with their functional properties in glioma pathology while exploring current applications to treatment. Utilizing innate immune receptors as therapeutic targets holds great promise, especially when used along with traditional chemotherapy and radiation schemes, strengthening immune responses. Future studies focusing on the deeper understanding of innate immune receptors signaling and complexity are highly required to enable novel immunoregulatory treatment schemes for gliomas.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b2b7b3e02786ee96fe5c12a17a3e23bd5c3a936a" target='_blank'>
              Innate Immune Signaling in Gliomas: Regulatory Mechanisms and Targeting Potential in Tumor Progression
              </a>
            </td>
          <td>
            Edmund Jung, Sara Al Jadidi, C. Piperi
          </td>
          <td>2025-10-01</td>
          <td>Life</td>
          <td>1</td>
          <td>16</td>
        </tr>

        <tr id="T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion, senescence, metabolic dysregulation, an immunosuppressive tumor microenvironment (TME), and limited persistence. This review analyzed these key issues and proposed targeted improvement strategies. Emerging approaches encompass pharmacological modulation of T cell activation and survival pathways, epigenetic reprogramming to reverse exhaustion and senescence, metabolic engineering, combinatorial targeting of immunosuppressive TME components and advanced genetic tools, notably CRISPR-Cas9–based CAR-T optimization, which exemplifies how precise genome editing can enhance therapeutic efficacy. We review the progress and prospects of T-cell improvement strategies in tumor immunotherapy, emphasizing the need for further exploration to enhance the broader application and long-term efficacy of T-cell therapies. This review highlights recent advances and future directions in T-cell engineering, metabolic modulation, and microenvironment targeting, aiming to translate innovations into effective cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/576f0048bd963a53102bad036edb12f448a68a45" target='_blank'>
              Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression
              </a>
            </td>
          <td>
            Guangmei Li, Dengju Li, Xiaojian Zhu
          </td>
          <td>2025-10-13</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) play critical roles in tumor immune evasion. These heterogeneous cells are broadly classified into granulocytic (G-MDSC), monocytic (M-MDSC), and their immature precursors, early-stage MDSCs (e-MDSCs). Elucidating their differentiation and expansion mechanisms is crucial for advancing cancer immunotherapy. This review examines the key signaling pathways (e.g., JAK/STAT, NF-κB, Notch), regulatory cytokines, metabolic factors, and epigenetic modifications central to MDSC biology. A comprehensive understanding of these intricate networks provides valuable insights into tumor immune evasion and facilitates the identification of novel therapeutic targets designed to overcome MDSC-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4682b63ca9757bb9c1ba2dada7a0f722d5dd5cac" target='_blank'>
              Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            Ke Wang, Xiao Wang, Nan Sun
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="T cells play a central role in the immune response to gastric cancer, and their dysfunction directly contributes to immune escape from the tumor and limits the efficacy of immunotherapy. The immune microenvironment of gastric cancer consists of a wide range of cells and molecules, and this complex and dynamic environment exerts profound inhibitory effects on T cell function. upregulation of PD-1, CTLA-4, and other inhibitory molecules is a key mechanism of T cell depletion, and metabolic reprogramming and chronic antigenic stimulation further weaken the anti-tumor activity of T cells. In recent years, PD-1/PD-L1 inhibitors have demonstrated some efficacy in gastric cancer, but the problem of drug resistance remains prominent. To address these challenges, combinatorial therapeutic strategies have gradually become the focus of research, especially combining immune checkpoint inhibitors with chemotherapy, radiotherapy, or targeted therapy to enhance the antitumor effect of immunotherapy. This review delves into the molecular mechanisms of T-cell depletion and its impact in gastric cancer immunotherapy, and analyzes the potential application of biomarkers in predicting treatment response. By comprehensively analyzing T-cell depletion and the immune microenvironment in gastric cancer, this paper provides a theoretical basis for the development of future personalized combinatorial therapeutic strategies, with the aim of improving patient prognosis and enhancing the overall therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98ef3d84371b71530557b38bd98704c81b59dc80" target='_blank'>
              Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application
              </a>
            </td>
          <td>
            Huanyu Luo, Jianxi Wu, Yalan Yan, Danqi Xu, Jieying Zhang, Xuancheng Zhou, Guanhu Yang, Xiaolin Zhong
          </td>
          <td>2025-09-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Type 2 innate lymphoid cells (ILC2s) are critical mediators of type 2 immunity that play non-redundant context-dependent modulatory functions. Primarily associated with responses against helminths and allergens via the activation of a potent epithelial-ILC2 axis, a growing body of evidence also suggests that a crosstalk between ILC2 and T cells is equally important in maintaining tissue homeostasis. In barrier tissues and secondary lymphoid organs, ILC2s co-localize with T cells, forming hubs where bi-directional signals are exchanged. Here, we describe the diversity of functional interactions between ILC2s and T cells, detailing known contact-dependent and -independent mechanisms, including a relatively new and still poorly defined antigen-presenting function during inflammation. Understanding these complex interactions is necessary to fully elucidate how this specific crosstalk helps maintain tissue homeostasis and regulate inflammatory responses. Identifying the spatial and temporal specificities of these interactions will certainly open new avenues for future targeting of this axis to improve immune-mediated host protection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9091d8a7d8543597d9b4583a6f2834ed1e2f0b" target='_blank'>
              Unspoken words: decoding the dialog between type 2 innate lymphoid cells and T cells
              </a>
            </td>
          <td>
            Zahra Jamila Ikra, Qiutong Huang, Huiyang Yu, Gabrielle T. Belz, Craig N. Jenne, Nicolas Jacquelot
          </td>
          <td>2025-10-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Ovarian cancer (OC) remains one of the most aggressive gynecological malignancies, with a five-year survival rate below 45% despite the recent advances in the introduction of targeted therapy. Moreover, immunotherapy, such as immune checkpoint inhibitors, does not improve the survival of OC patients. Lack of sufficient knowledge in understanding the complexity of the tumor microenvironment likely confers the treatment ineffectiveness. Recently, tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) have garnered research attention as they shape the tumor immune microenvironment, which plays a crucial role in disease progression and treatment response. This article reviews the complex roles of these innate immune cells in OC progression. TAMs represent a significant component of the immune infiltrate in OC, exhibiting considerable functional plasticity and can shift between anti-tumoral (M1) and pro-tumoral (M2) phenotypes. M2-like TAMs typically predominate in the tumor microenvironment, which aids in the development of immune suppression and disease progression. They also contribute to chemoresistance and metastasis; hence, their presence in tumors is associated with a worse prognosis. TANs, like TAMs, exhibit N1/N2 polarization and influence tumor progression through the formation of neutrophil extracellular traps. Understanding the biological interactions between various immune cells and cancer cells may offer new therapeutic opportunities. This review sheds light on the dynamic ecological transformation of the OC tumor microenvironment and highlights the potential of targeting TAM/TAN-mediated processes to improve OC treatment outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5bf69e7ede5135f1b9bda1d7b6d4024e3efe5c94" target='_blank'>
              Macrophages and neutrophils in ovarian cancer microenvironment
              </a>
            </td>
          <td>
            , Yu-Hsin Lin, Dao-Sian Wu, I. Shih, Tian-Li Wang
          </td>
          <td>2025-11-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>107</td>
        </tr>

        <tr id="Regulatory T cell (Treg) therapies are emerging as powerful tools for treating autoimmune and inflammatory diseases, preventing graft-versus-host disease (GvHD), and promoting organ transplant tolerance. Building on the identification of chimeric antigen receptor (CAR)-expressing Tregs as a correlate of poor patient outcomes in CD19-CAR T cell therapy, this review examines strategies for learning from clinical samples and data to improve Treg therapies. We highlight current and next-generation Treg modalities, including polyclonal, antigen-specific, converted, TCR-engineered, and CAR-engineered Tregs, provide a comprehensive overview of Treg clinical trials, and evaluate the evolving toolkit for in vivo Treg monitoring. Emphasis is placed on advanced immunomonitoring technologies, such as single-cell multi-omic profiling, epigenetic analysis, and spatial transcriptomics, which enable precise characterization of Treg persistence, function, and lineage stability. By integrating insights from adoptive T cell therapies and cutting-edge multi-omic platforms, this review outlines how Treg therapies can be optimized as “living drugs” capable of establishing immune tolerance across diverse clinical contexts.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/359c561a9b7ea1c4c0f6b3ba2070412db979dd95" target='_blank'>
              Regulatory T cell therapies: from patient data to biological insights
              </a>
            </td>
          <td>
            Kameron B. Rodrigues, P. Eggenhuizen, R. Bacchetta, Zinaida Good
          </td>
          <td>2025-10-31</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="


 Chronic graft-versus-host disease (cGVHD) is an alloimmune disease that can follow non-self hematopoietic stem cell transplantation, driven by dysregulated T cell and other immune responses. Detailed analysis of naïve and memory T cells with antigen presenting cells has not yet been paired with the role of exhausted T cells in mucosal cGVHD. Using oral mucosa (OM) biopsies collected from patients six months post-transplant, we characterized, at single-cell resolution, T cell exhaustion using transcriptomic and protein level analyses in cGVHD. Single-cell RNA sequencing identified CD8+T cell clusters with apparent dysfunction, including a CXCL13+CD8+ T cell cluster with a dual phenotype characterized by cytotoxic markers (GZMB, PRF1) and exhaustion signatures (TIM3, LAG3). Increased frequency of this cluster correlated significantly with clinical severity score, connecting these cells to disease severity. In unaffected patients, LYVE1+ macrophages and CD1C+ dendritic cells signaling supported immune homeostasis, but these populations were diminished in cGVHD, coinciding with disease progression. CODEX analysis mapped expansion of FOXP3+CD4+T cells and their proximity to CD8+T cells in cGVHD, yet this regulatory influence was insufficient to halt tissue damage. In summary, dysregulated CD8+T cells that combine exhaustion and cytotoxic functions could drive persistent damage and thwart anti-inflammatory signals, underscoring the central role of exhaustion in cGVHD pathogenesis.



 NIH Intramural Program



 Immune Mechanisms of Human Disease (HUM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/afd145d184e9fe7e66457307e5b4674f888ab08a" target='_blank'>
              T cell exhaustion in focus: single-cell mapping of CD8+ T cell dynamics in mucosal chronic graft-versus-host disease 3680
              </a>
            </td>
          <td>
            A. C. Costa da Silva, Rubina Sharma, Noemi Kedei, Frank A Boksa, Damilola F. Killanin, Drashty P. Mody, Marie Kao-Hsieh, David Kleiner, Christopher G. Kanakry, Steven Pavletic, J. W. Mays
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4051d036ff1e6c6822f8399d956a957cbaec093d" target='_blank'>
              TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS
              </a>
            </td>
          <td>
            J. Huuhtanen, S. Forstén, B. Ford, J. Smolander, O. Bruck, S. Lundgren, A. Kreutzman, O. Dufva, M. Kankainen, M. Ilander, H. Lahteenmaki, T. Kasanen, J. Klievink, J. Leitner, P. Steinberger, M. Kontro, M. Pelletier, H. Lahdsemaki, C. Sabatos-Peyton, M. Rinne, K. Porkka, K. Peltonen, S. Mustjoki
          </td>
          <td>2025-11-19</td>
          <td>None</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="
 Myeloid-rich microenvironment is a hallmark of glioblastoma (GBM), the most aggressive and lethal brain malignancies in adults, leading to profound immunosuppression and therapy resistance. Metabolic dysregulation in tumor-associated myeloid cells (TAMCs) has been recognized as a key player driving immune evasion and supporting their pro-tumorigenic roles. Our single-cell RNA sequencing analysis and multiplex immunofluorescence have demonstrated high overexpression of monocarboxylate transporter 4 (MCT4), a key lactate transporter, in TAMCs in both murine and human GBMs, which may greatly contribute to TAMC-mediated GBM immunosuppression. To enable a myeloid-specific targeting of MCT4 in GBM, we have developed MCT4 nano-therapeutics using our antibody-directed immune targeting (ADIT) nano-platform. Lipid nanoparticles were surface functionalized with anti-PD-L1 antibody and encapsulated with small interfering RNA (siRNA) that targets MCT4. Our data indicated a robust and durable MCT4 inhibition, achieving over 90% gene knockdown efficiency. In vitro, MCT4 nano-therapeutics effectively targeted and reprogrammed immunosuppressive TAMCs, and restored CD8+ T cell proliferation and activation. In vivo, MCT4 nano-therapeutics through intracranial administration significantly improved the anti-glioma effectiveness of radiotherapy in CT-2A glioma-bearing C57 mice, leading to enhanced brain tumor infiltration of effector CD8+ T cells and CD103+ dendritic cells as well as much prolonged animal survival. When further combined with anti-CTLA-4 immune checkpoint therapy, over 60% of mice were cured from CT-2A glioma, and the long-term survivor animals developed anti-glioma immunological memory. Besides intracranial injections, we have also demonstrated the effectiveness of MCT4 nano-therapeutics through a systemic intranasal delivery route. These findings altogether may highlight a great potential of targeting lactate transport for modulating myeloid-mediated GBM immunosuppression and create a new immunotherapeutic approach to improve the existing standard treatments and immunotherapies for GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3cbe44139c87ecba179bf8e865f8c5ead1c37390" target='_blank'>
              DDEL-27. Nano-therapeutic modulation of lactate transport in myeloid cells potentiates anti-tumor immunity and radiotherapy for glioblastoma
              </a>
            </td>
          <td>
            Hanchen Lin, Jiawei Huo, Xiaoyang Chen, Leah K. Billingham, H. Najem, Jingqi Sun, Caylee Silvers, Jianzhong Zhang, Rafał Chojak, Yu Han, Aurora Lopez-Rosas, Si Wang, Atique U. Ahmed, Catalina Lee-Chang, A. Heimberger, M. Lesniak, Pavithra Viswanath, J. Miska, Peng Zhang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Regulatory T cells (Tregs) are a distinctive subset of CD4+ T cells critical in self-tolerance maintenance to prevent the development of autoimmunity. The mechanisms by which these cells provide immune regulation are numerous and, consequently, deeply involved in the pathogenesis of many autoimmune disorders. Treg-based adoptive cell transfer (ACT) therapy has generated interest as a novel, promising strategy to restore self-tolerance in autoimmunity. Polyclonal Treg-based ACT therapy was first implemented in clinical trials, presenting adequate safety profiles. Subsequent preclinical studies have shown antigen-specific Tregs to be safer and more effective than polyclonal approaches, so research has recently moved in this direction. Antigen-specificity can be conferred to Tregs by viral transduction of genes coding for engineered T cell receptors (eTCRs) or chimeric antigen receptors (CARs), with encouraging outcomes in different animal models of autoimmunity. This review focuses on the biology of Tregs, as well as on current preclinical and clinical data for Treg-based ACT in the field of autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/245990f7801c19be0c77d295d5bb4e3aed2c7143" target='_blank'>
              Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity
              </a>
            </td>
          <td>
            Eduardo Gozálvez, Adrián Lario, Guillermo Muñoz-Sánchez, Francisco Lozano
          </td>
          <td>2025-10-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Recently, we observed that pars planitis (PP) patients present alterations in peripheral blood (PB) Th17/Treg associated with dysregulation in the Th1 response. Yet, little is known about the systemic distribution of myeloid cells, which drive the recruitment and differentiation of the adaptive effectors toward pathogenic inflammatory Th1 and Th17 as well as regulatory lymphocytes in PP. Although myeloid populations in patients with uveitis have previously been addressed, the data did not provide an exact description of PP patients. Using flow cytometry, we evaluated monocyte and IDO-expressing monocyte-like myeloid-derived suppressor cell (MDSC) subpopulations in PB samples from 15 patients with different courses of PP (cystoid macular edema and non-macular edema subgroups; CME and nCME, respectively) and 17 healthy controls (HCs) in relation to the Th1, Th17, and immunoregulatory subsets. We observed that only PP patients from the CME subgroup presented a significantly higher fraction of CD16+ IDO-expressing MDSCs and intermediate CD14highCD16+ monocytes compared to the HCs; this corresponded with relative up-regulation of Th1 and Th17, and down-regulation of Treg. In addition, alongside the increased percentage of IDO-expressing CD16+ MDSCs, the MDSC compartment displayed an inappropriate level of IDO (more pronounced in the CD16− subset) only in CME patients. At the same time, the fraction of CD16− myeloid cells did not differ significantly among the patient cohorts and healthy participants. Our study is the first to evaluate subpopulations of circulating myeloid cells in PP patients and indicates that an increased fraction of CD16+ myeloid cells might reflect the immunological and clinical severity of PP.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cd1fd2d076c43e8bd265181bbac902c87dc1f38" target='_blank'>
              Circulating CD16-Positive Monocyte-like Myeloid-Derived Suppressor Cells and Intermediate Monocytes Associated with Clinical and Immunological Complications in Pars Planitis Patients
              </a>
            </td>
          <td>
            A. Kosmaczewska, Joanna Przeździecka-Dołyk, L. Ciszak, Zofia Rojek-Gajda, I. Frydecka, A. Turno-Kręcicka, Marta Misiuk-Hojło, Edyta Pawlak
          </td>
          <td>2025-10-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ff39811b58af3141f8b13471490c1f390abe0d9" target='_blank'>
              Non-canonical inflammasome drives intrinsic anti-microbial responses in human Natural Killer cells
              </a>
            </td>
          <td>
            N. G. Leborgne, Jadie Acklam, Alexander J. Hogg, Zarema Albakova, Karen Hogg, K. Robinson, Grant Calder, Arnel Villamin, Callum Robson, Freya Pealing, Matthew A. Care, Monika Gonka, James M. Fox, James Iremonger, J. Hewitson, David G. Kent, Alison M. Layton, Frances E. Pearson, Max E. Noble, W. Grey, Jillian L. Barlow, Dave Boucher
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Glucocorticoids (GCs) remain the cornerstone of asthma treatment due to their potent anti-inflammatory and eosinophil-suppressive effects in the airways, including the induction of peripheral eosinophil apoptosis and downregulation of type 2 cytokine signaling. However, emerging evidence reveals a paradoxical role for GCs in the bone marrow, where they enhance eosinophil production (eosinopoiesis), especially under allergic, infectious, or surgical stress conditions. This duality reflects a complex immunoendocrine interplay involving GC-induced modulation of eosinophil progenitor survival, proliferation, and responsiveness to eosinopoietic cytokines such as interleukin-5 and granulocyte-macrophage colony-stimulating factor. Furthermore, GCs synergize with lipid mediators like cysteinyl-leukotrienes and prostaglandins, modulating both transcriptional and adhesion molecule profiles that prime eosinophil precursors for migration and differentiation. This review examines the molecular and cellular mechanisms underlying GC-induced eosinopoiesis, its functional link to airway inflammation, and its clinical implications for asthma management. We also explore potential therapeutic strategies aimed at selectively modulating bone marrow eosinophil output without compromising the peripheral anti-inflammatory benefits of GCs. Understanding this paradoxical duality holds significant translational potential for improving disease control and preventing asthma exacerbations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/897d61157bec7e651e2e45bf1d2ca628a67612fd" target='_blank'>
              Glucocorticoid-Mediated Modulation of Eosinopoiesis in Asthma: A Paradoxical Duality
              </a>
            </td>
          <td>
            Bruno Marques Vieira
          </td>
          <td>2025-10-06</td>
          <td>Allergies</td>
          <td>1</td>
          <td>2</td>
        </tr>

        <tr id="Immune tolerance in epithelial ovarian cancer (EOC) enables cancer cells to evade immune surveillance. Myeloid-derived suppressor cells (MDSCs), as crucial immunosuppressive regulators, shape the tumor microenvironment and contribute to resistance against immunotherapy. However, the regulatory mechanisms of MDSCs in ovarian cancer remain poorly understood. We examined the presence and distribution of MDSCs in peripheral blood and tumor tissues from EOC patients. Transcriptomic analysis was performed on ovarian cancer cells co-cultured with MDSCs. The role of Serum Amyloid A1 (SAA1) was investigated through in vitro functional assays, co-culture experiments, and in vivo mouse models. MDSCs were enriched in both peripheral blood and tumor tissues of EOC patients. SAA1 was significantly upregulated in ovarian cancer cells after interaction with MDSCs and confirmed in tumor samples and cell lines. Functionally, SAA1 promoted cancer cell proliferation, migration, and invasion. It also recruited MDSCs via TLR2/4, induced the differentiation of granulocyte-monocyte progenitors (GMPs), and stimulated IL-1β secretion, which in turn enhanced SAA1 expression, forming a positive feedback loop. In vivo, SAA1 promoted tumor progression and ascites formation. Clinically, high levels of SAA1, IL-1β, and CD33⁺ MDSCs correlated with poor survival. This study uncovers a novel SAA1–IL-1β feedback loop that promotes immunosuppression and progression in ovarian cancer. These findings provide insight into tumor–immune interactions and suggest a potential biomarker and therapeutic target for EOC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57a48529273e668adcbf53929e1763b6ce9f687a" target='_blank'>
              Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
              </a>
            </td>
          <td>
            Haoran Hu, Meiqin Yang, Baoyou Huang, Jianyi Ding, Yashi Zhu, Xinxin Xu, Bo Yin, Huijuan Zhou, Tiefeng Huang, Mengjie Li, Yifan Kou, Zilale Rahim, Ang Li, Wei Wang, Lingfei Han
          </td>
          <td>2025-09-30</td>
          <td>Journal of Experimental & Clinical Cancer Research : CR</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Immunosuppression within the tumor microenvironment (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This immunomodulatory vaccine was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8fef4f03c94eaba07eeff2c05c0e60c396891042" target='_blank'>
              Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
              </a>
            </td>
          <td>
            Tiyun Han, Guilai Liu, Chenyi Bao, Jian Zong, Caiyi Fei, Jing Li, Shi Xu, Qingbo Ma, Yingjuan Qian
          </td>
          <td>2025-10-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Glioblastoma multiforme (GBM) is highly lethal brain tumor with limited benefit from standard treatment, such as surgery, radiotherapy, and chemotherapy. Its location within the central nervous system, together with the blood–brain barrier, and immunosuppressive niche restricts access and efficacy of therapies. This review examines the current progress of the chimeric antigen receptor (CAR) T cell therapy in GBM, emphasizing therapeutically significant target antigens, delivery strategy and innovations designed to improve safety and persistence. Evidence from preclinical research and early phase clinical trials was assessed to identify key antigen, evaluate routes of administration, and summarize next-generation engineering concepts. Clinical experiences demonstrate that locoregional delivery can enhance tumor penetration compared with systemic infusion. Moreover, CAR-T cells engineered to recognize epidermal growth factor receptor variant III, interleukin-13 receptor subunit alpha-2, human epidermal growth factor receptor 2, or disialoganglioside have shown biological activity in GBM. Emerging platforms, such as dual-target CARs, synNotch, and cytokine-releasing “armored” T cells, develop specificity and overcome barriers posed by tumor heterogeneity and immune suppression. CAR-T therapy in GBM has moved beyond proof-of-concept, with encouraging but preliminary signals of efficacy. Future success will require multi-target approaches, integration with modulators of tumor microenvironment, and optimized delivery systems to achieve durable clinical benefit.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6db233e80fe5004bd0e0ca00a1e5584203d23761" target='_blank'>
              CAR-T cells immunotherapy in the treatment of glioblastoma
              </a>
            </td>
          <td>
            Aleksandra Królikowska, Maciej Tarnowski
          </td>
          <td>2025-11-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="
 Anti-PD-1 checkpoint blockade immunotherapy has not been successful as a monotherapy for the treatment of glioblastoma (GBM) patients. Reasons for failure of immunotherapy in GBM treatment include the onset of systemic immune suppression in these patients. Our lab was one of the first to successfully model peripheral immunosuppression using preclinical murine GBM models. We observe low circulating T cell counts and atrophy of immune organs in multiple pre-clinical murine glioma models. We hypothesized that restoration of the peripheral immune system could be achieved through combined treatment with anti-PD1 checkpoint blockade plus novel immunocytokine CD80/IL2v. GI-101 and GI-102 are novel CD80/IL-2v immunocytokines designed to selectively activate immune cells by targeting IL-2Rβγ while minimizing IL-2Rα binding. GI-101 retains partial IL-2Rα affinity; GI-102 has none. Both enhance immune cell proliferation and activation in cancer patients, with extended half-life and tumor-directed delivery via CD80. We therefore treated GL261 harboring C57Bl/6 mice with combination therapy consisting of anti-PD-1 checkpoint blockade plus GI-101 or GI-102. Animals treated with anti-PD1 plus GI-101 or GI-102 had significantly increased TCRb+ CD4+ and TCRb+ CD8+ T cell infiltration resulting in tumor clearance plus extended survival when compared to mock treated controls. Importantly, peripheral immune cell populations are preserved in animals treated with this combination therapy. Atrophy of the spleen associated with anti-PD-1 immunotherapy is also overcome with the supplementation of GI-101 or GI-102 to anti-PD-1 checkpoint blockade therapy. Furthermore, through immune depletion strategies, we determined that both CD4+ T cells and CD8+ T cells were the critical immune cell type required for these therapeutic effects. These findings imply that anti-PD-1 checkpoint blockade supplemented with fusion protein that includes CD80, and engineered IL-2 cytokine could be effective in treating human GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a65c9ba58173175555cfbdb122b6758a08d88c0e" target='_blank'>
              TMOD-32. Novel immunocytokine CD80/IL2v synergizes with α-PD-1 for treatment of preclinical murine glioblastoma models
              </a>
            </td>
          <td>
            Carley A Owens, Fang Jin, Marina Seady, M. Maynes, Zachariah P. Tritz, Katayoun Ayasoufi, I. Parney, M. Hansen, Richard Vile, Myoung Ho Jang, N. Yun, J. Campian, Aaron Johnson
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>55</td>
        </tr>

        <tr id="Therapeutic resistance and recurrent metastasis continue to pose major obstacles in the treatment of malignant tumors worldwide. Immunogenic cell death (ICD), characterized by its ability to both eliminate cancer cells and stimulate antitumor immune responses, has emerged as a promising strategy in the field of cancer immunotherapy. As key subtypes of ICD, pyroptosis and necroptosis contribute significantly to remodeling the tumor microenvironment (TME) and modulating immune responses through their distinct death-immunity coupling mechanisms. Characterized by plasma membrane pore formation and subsequent release of cytoplasmic contents, pyroptosis and necroptosis reprogram the immune microenvironment, thereby laying the groundwork for enhanced antitumor immune responses. Paradoxically, the chronic activation of pyroptosis and necroptosis pathways may contribute to cancer progression. Sustained inflammation within the TME promotes the release of pro-angiogenic and immunosuppressive factors, driving myeloid-derived suppressor cells (MDSCs) recruitment, extracellular matrix remodeling, and metastatic niche formation, thereby facilitating tumorigenesis and metastasis. The context-dependent dual roles of pyroptosis and necroptosis—shaped by tumor histotype, chronic inflammation, and stromal context—highlight the need for a nuanced understanding of their tumor-specific functions across cancer types. This review outlines the underlying mechanisms of pyroptosis and necroptosis, and summarizes recent advances, aiming to inform and inspire novel strategies in overcoming cancer immunotherapy resistance. This study focuses on the intricate interplay between cell death and cancer immunotherapy resistance, aiming to address the critical clinical challenge of cancer immunotherapy. This article systematically reviews the distinct mechanisms underlying pyroptosis and necroptosis across diverse cancer types, highlighting their influence on the tumor immune microenvironment and their context-dependent, double-edged roles in modulating antitumor immunity. The present study systematically summarizes emerging therapeutic strategies that induce pyroptosis or necroptosis to overcome immunotherapy resistance, including small-molecule agents, nanoplatforms, and novel molecular targets across various cancer types. This study focuses on the intricate interplay between cell death and cancer immunotherapy resistance, aiming to address the critical clinical challenge of cancer immunotherapy. This article systematically reviews the distinct mechanisms underlying pyroptosis and necroptosis across diverse cancer types, highlighting their influence on the tumor immune microenvironment and their context-dependent, double-edged roles in modulating antitumor immunity. The present study systematically summarizes emerging therapeutic strategies that induce pyroptosis or necroptosis to overcome immunotherapy resistance, including small-molecule agents, nanoplatforms, and novel molecular targets across various cancer types.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6532dac6e295a40e6e48f28538ef32d72e2fe585" target='_blank'>
              Cracking the code of cancer immunotherapy resistance: emerging roles of pyroptosis and necroptosis
              </a>
            </td>
          <td>
            Kunming Lei, Jiujiu Chen, Yanrong Deng, Yige Peng, Xiang Zhai, Xianghai Ren, Jianhong Zhao, Baoxiang Chen, Congqing Jiang
          </td>
          <td>2025-11-20</td>
          <td>Journal of Experimental & Clinical Cancer Research : CR</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Human cytomegalovirus (HCMV) establishes lifelong latency following primary infection, residing within myeloid progenitor cells and monocytes. To achieve this, the virus employs multiple immune evasion strategies. It suppresses innate immune signaling by inhibiting Toll-like receptor and cGAS-STING pathways. In addition, the virus suppresses major histocompatibility complex (MHC)-dependent antigen presentation to evade T cell recognition. As the downregulation of MHC molecules may trigger NK cell activation, the virus compensates for this by expressing proteins such as UL40 and IL-10, which engage inhibitory NK cell receptors and block activating signals, thereby suppressing NK cell immune surveillance. Viral proteins like UL36 and UL37 block host cell apoptosis and necroptosis, allowing HCMV to persist undetected and avoid clearance. In settings of profound immunosuppression, such as after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or solid organ transplantation, slow immune reconstitution creates a window for viral reactivation. Likewise, immunosenescence and chronic low-grade inflammation during aging increases the risk of reactivation. Once reactivated, HCMV triggers programmed cell death, releasing viral PAMPs (pathogen-associated molecular patterns) and host-derived DAMPs (damage-associated molecular patterns). This release fuels a potent inflammatory response, promoting further viral reactivation and exacerbating tissue damage, creating a vicious cycle. This cycle of inflammation and reactivation contributes to both transplant-related complications and the decline of antiviral immunity in the elderly. Therefore, understanding the immune regulatory mechanisms that govern the switch from latency to reactivation is critical, especially within the unique immune landscapes of transplantation and aging. Elucidating these pathways is essential for developing strategies to prevent and treat HCMV-related disease in these high-risk populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c0c843dc82ca4b27cae84bc783dc80e13ac42440" target='_blank'>
              The Immunoregulatory Mechanisms of Human Cytomegalovirus from Primary Infection to Reactivation
              </a>
            </td>
          <td>
            Xiaodan Liu, Chang Liu, Ting Zhang
          </td>
          <td>2025-10-01</td>
          <td>Pathogens</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Objectives Dendritic cells (DCs) are pivotal antigen-presenting cells capable of bridging innate and adaptive immunity, making them promising candidates for cancer immunotherapy. While canine mature DCs (cmDCs) have been successfully generated from circulating mononuclear cells (CMCs) in healthy dogs, their derivation and immunomodulatory capacity in tumor-bearing dogs (TbDs) remain poorly characterized. Methods In this study, we evaluated the efficiency of cmDC generation from peripheral blood of both healthy donors (HDs) and TbDs and investigated their functional responses to Toll-like receptor (TLR) agonists and mRNA-based genetic modification. Results CD14+ monocytes were successfully isolated from peripheral blood using immunomagnetic sorting and differentiated into cmDCs using recombinant canine GM-CSF and IL-4. The differentiation efficiency was comparable between the two groups. In both cohorts, cmDCs upregulated key maturation markers (CD1a, CD80, CD83) and restored DLA class II expression in TbDs. Stimulation with LPS and R848 significantly increased CD80 and CD83 expression and triggered IL-12/p70 and IL-8 production, confirming the acquisition of a functional immunostimulatory phenotype. To assess their amenability to genetic engineering, cmDCs were transfected using DE-DOPE/mRNA lipoplexes. These lipoplexes exhibited favorable physicochemical properties and achieved robust mRNA delivery, resulting in 100% GFP-positive cells and >60% viability, outperforming electroporation in terms of cytocompatibility. Conclusions Our findings demonstrate that cmDCs derived from both HDs and TbDs are phenotypically and functionally competent and can be efficiently transfected using a non-viral mRNA delivery system. This strategy offers a viable platform for the development of personalized, DC-based cancer vaccines in canine patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/214b1855d713559c7344f3f9c1196e520714ee7a" target='_blank'>
              Toll-like receptor activation and gene delivery efficiency in canine dendritic cells: a model for comparative oncology
              </a>
            </td>
          <td>
            S. Capellero, R. De Maria, Lisa Adele Piras, L. Marconato, Lorenza Parisi, Eugenio Mazzone, C. Marchiò, E. Berrino, S. Bellomo, A. Sapino, G. P. Stola, Valeria Chiono, L. Nicoletti, Luca Aresu
          </td>
          <td>2025-10-03</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are a dominant immune component within the glioma microenvironment and are increasingly recognized as key contributors to therapeutic resistance, the major challenge in glioma management. Understanding their role is critical for developing novel therapies. This review synthesizes current knowledge on TAM-mediated chemoresistance in glioma. TAMs originate from bone marrow-derived monocytes and resident microglia, exhibiting significant heterogeneity and plasticity, particularly between pro-inflammatory (M1) and pro-tumorigenic (M2) phenotypes. M2-like TAMs drive resistance through multiple mechanisms: (1) Modulating drug metabolism/clearance (e.g., via CYP450 enzymes and P-glycoprotein); (2) Secreting protumor factors (TNF-α, ILs like IL-4/IL-6/IL-10, chemokines like CCL5/CCL22, growth factors like VEGF/EGF) that activate survival pathways, induce immunosuppression, promote angiogenesis, and enhance epithelial-mesenchymal transition (EMT); (3) Interacting with glioma stem cells (GSCs) to maintain stemness; (4) Facilitating microenvironmental adaptation (e.g., hypoxia/HIF-1α response); (5) Remodeling the extracellular matrix (ECM) via MMPs, increasing stiffness and impairing drug penetration. Targeting TAMs offers promising approaches to overcome resistance. Strategies include: (1) Reprogramming M2 to M1 phenotypes using agonists (TLR, STING, CD40) or inhibitors (STAT3/STAT6); (2) Metabolic modulation (targeting glycolysis, fatty acid oxidation, glutaminolysis); (3) Blocking recruitment axes (CCL2/CCR2, CSF-1/CSF-1R, CXCL12/CXCR4); (4) Depleting M2-TAMs (e.g., trabectedin, CAR-T cells, M2pep-drugs); (5) Enhancing phagocytosis (anti-SIRPα/CD47, anti-SIGLEC). TAMs are pivotal mediators of chemoresistance in glioma through diverse molecular and cellular mechanisms. Targeting TAM recruitment, polarization, function, or metabolism represents a promising therapeutic avenue. However, the complexity of the glioma microenvironment and blood-brain barrier necessitate combination strategies for clinical translation. Further research is needed to optimize specificity and overcome challenges like compensatory pathways and drug delivery.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af7b44f62f9ab81285800350b0fbea1b42e0f4e9" target='_blank'>
              Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma
              </a>
            </td>
          <td>
            Xuebo Liu, Qi Yu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, represent a pivotal approach in the treatment of multiple myeloma (MM). However, the complex immunosuppressive tumor microenvironment (TME) poses significant challenges to their efficacy. Among the immunosuppressive cells in the MM TME, granulocytic myeloid-derived suppressor cells (G-MDSCs) are predominant; however, their functions remain incompletely understood. In this study, a comprehensive analysis of G-MDSCs was conducted using single-cell transcriptomic data from 7 MM patients before and post CAR-T therapy. Given the limited sample size and inter-patient heterogeneity, the findings should be regarded as exploratory and hypothesis-generating. The pathological activation and immunosuppressive roles of G-MDSCs were suggested to be potentially linked to patient prognosis. Functional enrichment analysis revealed that G-MDSCs are key modulators of immune responses within the TME. GSEA analysis suggested that G-MDSCs may regulate immune responses via the IFN-α/γ signaling pathway. Furthermore, G-MDSCs may facilitate immune evasion of MM cells by promoting cell proliferation through the IGF1-IGF1R axis and inhibiting T cells and other immune cells via the SIRPA-CD47 pathway. A risk prediction model based on G-MDSC gene signatures was constructed using RNA-seq and survival data from 713 MM patients, demonstrating high prognostic accuracy (AUC = 0.94) and validated by Kaplan-Meier analysis. Additionally, PTGS1 was identified as a key marker associated with high-risk groups, suggesting its potential as a therapeutic adjunct target to improve CAR-T treatment outcomes. Further in vitro experiments demonstrated that G-MDSCs may exert immunosuppressive functions through PTGS1 expression. Taken together, this study provides preliminary insights into the role of G-MDSCs in the MM TME and highlights potential therapeutic strategies to enhance CAR-T therapy efficacy, while acknowledging that larger and more diverse cohorts are required to substantiate these observations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e8ff33894cad405d661ae879b8aae448cec342e" target='_blank'>
              Functional Role of Granulocytic Myeloid-Derived Suppressor Cells in CAR-T Therapy: Insights from Single-Cell RNA Sequencing in Multiple Myeloma.
              </a>
            </td>
          <td>
            Chaoyu Zhang, Fang An
          </td>
          <td>2025-11-06</td>
          <td>Immunopharmacology and immunotoxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Simple Summary Chimeric Antigen Receptor (CAR)-T cell therapy has shown significant success in treating hematological cancers, but commercialized autologous CAR-T therapies face challenges such as high costs, manufacturing delays, complex standardization and the risk of tumor relapses due to single-antigen targeting. To address these issues, a novel allogeneic CAR-T therapy with broader target specificity was developed, optimizing its manufacturing process. Using CRISPR/Cas9, TCR and HLA class I complex expression were eliminated from donor T cells to reduce the risk of immune rejection and graft-versus-host disease. Additionally, NKG2D CAR, targeting eight ligands upregulated in both solid and hematological tumors, was lentivirally transduced. This study optimized CAR-T cell manufacture by testing various interleukin supplements (IL-2, IL-7/IL-15, IL-7/IL-15/IL-21). Results showed that IL-7/IL-15/IL-21 supplementation produced CAR-T cells with the most suitable characteristics in terms of genetic modification efficiency, cell proliferation, antitumor activity and memory profile. This new allogeneic NKG2D CAR-T therapy represents a promising universal treatment for a variety of cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8e4e75f43da33ddda8e85ac431c369c654f5ec0" target='_blank'>
              A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors
              </a>
            </td>
          <td>
            C. Aparicio, Mónica Queipo, Marina Belver, Francisco Espeso, Julia Serna-Pérez, Lucía Enríquez-Rodríguez, Carlos Acebal, Álvaro Martín-Muñoz, A. Valeri, A. Leivas, Paula Río, Daniel J. Powell, Rosa Lobo-Valentín, David Arrabal, Joaquín Martínez-López, Ana Sánchez, Miguel Á. de la Fuente, Margarita González-Vallinas
          </td>
          <td>2025-09-30</td>
          <td>Cancers</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="


 Extracellular vesicles (EVs) have emerged as critical mediators of immune processes. However, the involvement of immunocytes derived EVs in the pathogenesis of acute kidney injury (AKI) remains largely unclear. This study aims to profile EV subpopulations constituting the renal microenvironment via single EV analysis to delineate the role of critical immunocytes derived EVs in AKI.



 Single-vesicle proteomic analysis using a proximity barcoding assay (PBA) was applied to characterize renal EVs in a murine ischemia-reperfusion injury (IRI) model (35 minutes of unilateral ischemia, sacrifice after 1 day). Surface proteomics of individual EV were captured using DNA-labeled antibody conjugates, converting protein expression into unique DNA barcodes (Fig. 1). Differential proteomic and enrichment analyses revealed distinct EV subpopulations with specialized functions, validated through Western blotting, nanoparticle flow cytometry, and immunohistochemistry. Functional characterization of the most prominent EV subset was performed via immunomagnetic isolation, co-culture assays, flow cytometry, ELISA, and a reporter mouse model, which enabled in vivo EV tracking and elucidated their roles in AKI.



 Using cell-specific markers, we traced the origins of EVs in the IRI microenvironment and identified increasing immunocytes derived EVs, predominantly from M1 macrophages, followed by dendritic cells, neutrophils, T cells, and B cells. Tubular epithelial and endothelial cells were the primary sources of EVs among renal parenchymal cells. Matrix analysis revealed eight major EV subpopulations, with ITGAM/HAVCR1-dominant EVs being the most abundant (33.63%). Proteomic analysis uncovered 14 upregulated proteins, with ITGAM emerging as the key protein which linked to T cell cytotoxicity, leukocyte-mediated cytotoxicity, antigen presentation, and positive regulation of immune responses. These findings highlight the potential role of EV subset derived from ITGAM+ innaute immune cells.
 ITGAM+ EVs was then purified with immunomagnetic bead isolation which was consequently characterized with nanoscale flow cytometry, identifying macrophages (F4/80+, 60.82%), neutrophils (Ly6G+, 55.64%), and dendritic cells (CD11c+, 34.24%) as primary sources from innate immunocytes. Functional assays demonstrated that IRI kidney-derived ITGAM+ EVs enhanced CD8+ T cell proliferation, with increasing TNF-α and IFN-γ secretion and reduction of IL-10.
 Proteomic analysis revealed S100A9 as remarkably upregulated in IRI-derived ITGAM+ EVs, with immunoelectron microscopy confirming its surface localization. Blockade of S100A9 suppressed TNF-α and IFN-γ cytokine secretion. Interestingly, stimulation with ITGAM+EVs induced a significant upregulation of IFN-γ expression in CD8+ T cells compared to recombinant S100A9 protein. Using an IRI model with ITGAM-CD63-PA-GFP transgenic mice, we observed increased secretion of ITGAM+ PA-GFP+EVs colocalized with CD8+ T cells in renal lymphatic vessels, with augmented renal inflammation and CD8+ T cell activation after AKI.



 This study profiled immune microenvironment constituted with immunocytes derived EV via single EV analysis in AKI. ITGAM+ EVs derived from immunocytes promoted CD8T cell activation through the membrane protein S100A9, providing new insights into the immune process of AKI.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7836316ffafd26513e5a286f62a65a568f74c2b0" target='_blank'>
              #2210 Extracellular vesicles derived from ITGAM + innate immune cells augmented renal inflammation via activating CD8+ T cells in acute kidney injury
              </a>
            </td>
          <td>
            Yuqi Fu, Anran Shen, Yan Bao, Tao-Tao Tang, Bicheng Liu, Linli Lv
          </td>
          <td>2025-10-01</td>
          <td>Nephrology Dialysis Transplantation</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Abstract Background Dual immune checkpoint blockade (IO/IO) has significantly improved overall survival in renal cell carcinoma (RCC), but only ∼50% of patients initially respond to treatment. Understanding the mechanisms underlying primary response and resistance is critical to improving therapeutic outcomes. Methods We developed a novel mouse model of sarcomatoid RCC (sRCC) by targeting Vhl, Bap1, and Cdkn2a/b, recapitulating the genomic and histological features and tumor microenvironment of human sRCC. Mice were treated with anti-CTLA-4 antibody. Tumor-infiltrating immune populations were analyzed using single-cell RNA sequencing and flow cytometry to evaluate T cell subsets and cytotoxic function. Results Anti-CTLA-4 treatment led to Treg depletion and an increase in activated Th1 cells. Importantly, only responder mice exhibited a selective expansion of TCF1+ CD4+ T cells. This was accompanied by increased granzyme B and perforin expression in effector CD8+ T cells, indicating enhanced cytotoxic activity. In contrast, non-responder mice lacked this TCF1+ CD4+ population and associated cytotoxic CD8+ responses. Conclusions Our findings reveal that Treg-depleting anti-CTLA-4 therapy promotes anti-tumor immunity by expanding a TCF1+ CD4+ T cell population that orchestrates CD8+ T cell responses. This mechanism offers a novel insight into immune modulation in sRCC and identifies a potential target to improve immunotherapy efficacy in RCC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3aa635a80718bf4810ef5e37204ff599497c31dc" target='_blank'>
              47TCF1+ CD4+ T cells mediate response to anti-CTLA-4 therapy in a sarcomatoid RCC mouse model
              </a>
            </td>
          <td>
            Hui Jiang, Lynda Vuong, F. Kuo, Doris Zheng, Alex Penson, Jing Zhang, Shengyu Gao, Ankur Mascareno, Yingbei Chen, Yash S. Khandwala, Daniel Barbakoff, Andrea Lopez Sanmiguel, G. Luca Gusella, Ming Li, A. Hakimi
          </td>
          <td>2025-10-01</td>
          <td>The Oncologist</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Solid tumors often suppress antitumor immune responses by promoting various dysfunctional CD8+ T cell states, which limit the effectiveness of T-cell-based immunotherapy. However, the mechanisms that promote these states have not been fully characterized. It is demonstrated that spontaneous priming responses during tumor growth can produce memory T cell reservoirs that are conducive to poor proliferative responsiveness during boosting vaccination. Surprisingly, when type I interferon (IFN-I) signaling is impeded, boosting vaccination can elicit robust proliferative responses from tumor-primed memory T cells and promote tumor control. This is observed in multiple tumor types and target antigens. In contrast to conventional memory T cells, tumor-primed memory T cells are unique in their pre-encoded responsiveness to IFN-I and show enrichment of pathways pertaining to DNA repair and cell cycle arrest. Tumor-primed memory T cells up-regulate p21 expression and blockade of either p21 or IFN-I can alleviate this effect to improve their proliferative capacity during boosting vaccination. Characterization of tumor-primed memory T cells revealed transcriptional and phenotypic features of cellular senescence, where higher senescence severity correlated with higher responsiveness to IFNα/β receptor blockade. Overall, IFN-I hyperresponsiveness may be a unique feature of senescent tumor-primed memory T cells that can exacerbate their dysfunction during cancer vaccination.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb2455df0fef81e7cabdf5fd3952e0ae44f71bd" target='_blank'>
              Pre-Encoded IFN-I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors.
              </a>
            </td>
          <td>
            Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan
          </td>
          <td>2025-10-05</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Cytotoxic T lymphocytes eliminate infected or malignant cells, safeguarding surrounding tissues. Although experimental and systems-immunology studies have cataloged many molecular and cellular actors involved in an immune response, the design principles governing how the speed and magnitude of T-cell responses emerge from cellular decision-making remain elusive. Here, we recast the T-cell response as a feedback-controlled program, wherein the rates of activation, proliferation, differentiation and death are regulated through antigenic, pro- and anti-inflammatory cues. By exploring a broad class of feedback-controller designs as potential immune programs, we demonstrate how the speed and magnitude of T-cell responses emerge from optimizing signal-feedback to protect against diverse infection settings. We recover an inherent trade-off: infection clearance at the cost of immunopathology. We show how this trade-off is encoded into the logic of T-cell responses by hierarchical sensitivity to different immune signals. Notably, we find that designs that balance harm from acute infections and autoimmunity produce immune responses consistent with experimentally observed patterns of T-cell effector expansion in mice. Extending our model to immune-based T-cell therapies for cancer tumors, we identify a trade-off between the affinity for tumor antigens ("quality") and the abundance ("quantity") of infused T-cells necessary for effective treatment. Finally, we show how therapeutic efficacy can be improved by targeted genetic perturbations to T-cells. Our findings offer a unified control-logic for cytotoxic T-cell responses and point to specific regulatory programs that can be engineered for more robust T-cell therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fab45b4e077e814852ed2672d9e52555fdd36bdb" target='_blank'>
              Design principles of the cytotoxic CD8+ T-cell response
              </a>
            </td>
          <td>
            Obinna A. Ukogu, Zachary Montague, Grégoire Altan-Bonnet, Armita Nourmohammad
          </td>
          <td>2025-09-26</td>
          <td>ArXiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/476c643da3b7bab359ba00f9ad0d1145a5743d99" target='_blank'>
              Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages
              </a>
            </td>
          <td>
            Hongyu Cheng, Shenzhi Li, Hongjie Liu, Meiyi Yan, Jingxiang Wang, Jingping Huang, Shanshan Liu, Yifan Yang, Xinyu Cao, Pengfei Cui, Yuanna Cheng, Zhonghua Liu, Jie Wang, Xiaocheng Huang, Lin Wang, Lianhua Qin, Ruijuan Zheng, Carl G Feng, Qiang Zou, Yicheng Sun, Zhe Ji, Hua Yang, Baoxue Ge
          </td>
          <td>2025-10-10</td>
          <td>Nature Microbiology</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="Background Chimeric antigen receptor T cell (CAR-T) therapy targeting cluster of differentiation 19 (CD19) has shown promise in treating B-cell acute lymphoblastic leukemia (B-ALL), but the long-term efficacy of CD19-targeted CAR-T therapy remains limited. Programmed cell death protein 1 (PD-1), an inhibitory receptor on activated T cells, engages programmed death ligand 1 (PD-L1) in the tumor microenvironment, suppressing CAR-T cell function by impairing key signaling pathways. To address this limitation, we investigated the effect of short hairpin RNA (shRNA)-mediated PD-1 knockdown on alleviating CAR-T cell exhaustion, preserving memory phenotype, and enhancing the long-term efficacy of CD19-targeted CAR-T cells. Methods To overcome this limitation, we employed shRNA to achieve PD-1 knockdown in CD19-targeting CAR-T cells. Following screening multiple shRNA candidates, we assessed the cytotoxicity, cytokine secretion, and proliferation of PD-1 knockdown CAR-T cells. Their memory phenotype, exhaustion marker, and cytolytic function were further evaluated after repeated antigen stimulation. Therapeutic efficacy and safety were validated in NOD.Cg-PrkdCscid Il2rgtm1/Vst (NPG) mice. Results PD-1 knockdown significantly enhanced CAR-T cell cytotoxicity and persistence against PD-L1+ RAJI (human Burkitt’s lymphoma cell line) cells. After three rounds of antigen stimulation, PD-1 knockdown CAR-T cells sustained cytotoxic activity, retained a memory-like phenotype, and displayed attenuated exhaustion markers. In vivo, they prolonged survival without inducing cytokine release syndrome (CRS), indicating improved efficacy and safety. Conclusions PD-1 knockdown mitigates tumor-induced T-cell exhaustion and represents a promising strategy to enhance the durability and potency of CAR-T cell therapy in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7328d5fdc7d923649d26fe2e8b57365952938c16" target='_blank'>
              shRNA-based PD-1 suppression preserves memory phenotype and function of CD19-targeted CAR-T cell
              </a>
            </td>
          <td>
            Jiaxuan Zhao, Han Wu, Zhe Sun, Yeting Cui, Nan Liu, Yixuan Wang, Youyong Wang, Jiangzhou Shi, Tongcun Zhang
          </td>
          <td>2025-10-01</td>
          <td>Translational Cancer Research</td>
          <td>0</td>
          <td>5</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025'],
    y: [18],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>